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1 Introduction 
1.1 The Met receptor and its ligand hepatocyte growth 
factor 
Met (also: c-Met, HGFR) is a transmembrane protein that belongs to the family of 
receptor tyrosine kinases. It is translated as a 1,390 amino acid polypeptide that is 
cleaved into a 50 kDa alpha and a 145 kDa beta chain by furin and subsequently 
forms a disulphide-linked heterodimer (Figure 1-1). The N-terminal alpha chain is 
exposed extracellularly, while the beta chain forms an ectodomain, a 
transmembrane helix as well as a cytoplasmatic part. The first 519 extracellular 
amino acids span the alpha chain and 212 residues of the beta chain and 
represent the Sema domain. It forms a seven-bladed beta-propeller that is likely to 
mediate protein-protein interactions. This part is followed by a small cysteine-rich 
PSI domain and four immunoglobulin-like domains, which are supposed to 
function as spacers. The intracellular part includes the juxtamembrane and kinase 
domain as well as binding sites for downstream effector proteins (Niemann et al. 
2007; Niemann 2011).  
 
Figure 1-1: Domain structure of Met 
The Met receptor is produced as 1,390 amino acid precursor, which is processed at amino 
acid 308 by furin into an alpha and a beta chain to result in a disulphide-bound 
heterodimer. Amino acids 25-932 are exposed extracellularly. The Sema domain (for 
semaphorin) spans alpha and the first amino acids of the beta chain. From residue 519, 
there follow the PSI (for plexin, semaphorin, integrin) domain and four immunoglobulin-like 
(Ig1-4) domains. The transmembrane (TM) domain in located in the plasma membrane, 
while the juxtamembrane (JM), kinase, and effector binding (EB) domains are exposed to 
the intracellular space. (Figure modified, taken from (Niemann et al. 2007)).  
 
In the late 1980s, a mitotic factor for rat hepatocytes was discovered and named 
Hepatocyte Growth Factor (HGF). In parallel, Scatter Factor (SF), a protein 
triggering cellular motility was published. It turned out that both studies concerned 
Sema PSI  Ig1   Ig2    Ig3   Ig4  TM  JM            Kinase EB
25 308 519 932 1345 1390
Alpha chain Beta chain
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the same protein, which was then called HGF/SF. In the early 1990s, this factor 
was identified as the physiological ligand for the Met receptor (Birchmeier et al. 
2003; Nakamura et al. 2011). While HGF is expressed and secreted from 
mesenchymal cells, Met is located on the surface of epithelial cells. This paracrine 
activation of the receptor represents an important layer of regulation.  
HGF is expressed as a 728 amino acid single chain and is able to bind to Met, but 
not capable to stimulate the receptor. It is activated through cleavage into an alpha 
and a beta chain by the protease Hepatocyte Growth Factor Activator (HGFA). 
The cleaved and disulphide-linked heterodimer consists of an N-terminal hairpin 
loop (HL), four kringle domains (K1-4) formed by the alpha chain, and a serine 
protease-like domain (SPH) representing the beta chain (Figure 1-2). Two shorter 
splice variants exist, NK1 and NK2, which are agonistic and antagonistic to Met, 
respectively (Niemann 2011; Nakamura et al. 2011).  
 
Figure 1-2: Domain structure of HGF 
Hepatocyte growth factor is activated through proteolytic cleavage by HGFA. The resulting 
alpha chain forms an N-terminal hairpin loop (HL) and four subsequent kringle domains 
(K1-4). The beta chain exhibits a serine protease homology domain (SPH). Both chains 
are linked through a disulphide-bridge. Figure taken from (Trusolino, Bertotti, and 
Comoglio 2010). 
 
The Met receptor has developed very late in evolution and therefore, it is only 
found in vertebrates. Signaling effectors utilized by Met are conserved and can be 
found downstream of several receptor tyrosine kinases (Birchmeier et al. 2003).  
1.2 HGF/Met-induced signaling cascades 
During ligand-receptor interaction, HGF is predicted to bind to the extracellular 
Sema domain of Met with two different sites. A high affinity site is located N-
terminal in the HL-K1 fragment of HGF. The second one binds with lower affinity to 
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Met and is found in the SPH domain. Nevertheless, there is currently no complete 
crystal structure of the HGF/Met complex available (Niemann 2011).  
In response to HGF binding to its receptor, Met dimerizes and autophosphorylates 
at tyrosines pY1234 and pY1235 in the activation loop of the kinase domain. This 
induces further phosphorylations (pY1249, pY1256) in the C-terminal effector binding 
sequence. Once modified, the latter sites become able to recruit several 
downstream effectors (Organ and Tsao 2011). Those proteins mostly comprise 
SH2-domains, which mediate the interaction. For example, the kinase PI3K or the 
scaffold proteins GRB2 and GAB1 directly bind to Met. Noteworthy, the interaction 
between Met and multi-adapter GAB1 is special in vertebrates. While other 
receptors are utilizing GAB1 as part of their downstream network and interact with 
the adapter through GRB2, GAB1 can also directly bind to Met. Therefore, GAB1 
possesses a specific Met binding site (MBS). Due to this relationship, the adapter 
provides further binding sites for effectors like SHC, SHP2, PI3K, CRK, PLCγ1, 
and p120-Ras-GAP (Trusolino, Bertotti, and Comoglio 2010).  
The signaling downstream of the Met receptor is very complex. Several branches 
exist that trigger mitogenic, motogenic and morphological cellular responses. 
These responses involve the transcription of target genes, but also the direct 
regulation of cytoskeletal or adhesion proteins. It has to be emphasized that the 
signaling branches leading to these responses also interact with each other to 
produce directed and consistent outcomes. Furthermore, evoked reactions depend 
on the cell type and culture conditions (Birchmeier et al. 2003).  
According to Trusolino et al., 2010, there are four main pathways induced by the 
receptor (Figure 1-3). Firstly, Met activates the MAPK cascades through GRB2, 
SOS, and Ras. This pathway is also activated through SHC-2 dephosphorylating 
GAB1, which in turn causes p120-Ras-GAP to stimulate Ras, which then activates 
Raf. Once triggered, the MAP kinase families MEKK1-4, MEK1-7, ERK1-2 (alias 
MK01, MK03), JNK1-3, and p38α-δ can induce proliferation, migration, invasion, 
differentiation, or apoptosis. Secondly, the PI3K-AKT pathway can either stimulate 
protein synthesis and cellular growth through mTOR, or proliferation via inhibition 
of GSK3β. Furthermore, AKT suppresses apoptosis by inhibiting BAD and 
activating MDM2. Thirdly, Met phosphorylates STAT3, which dimerizes and 
translocates into the nucleus to activate the transcription of genes leading to 
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differentiation and proliferation. Finally, NFκB is released from the complex with 
IκB by IKK in response to Met activating the PI3K-AKT pathway. Transcription 
regulated by NFκB then triggers proliferation, survival or tubulogenesis (Trusolino, 
Bertotti, and Comoglio 2010).  
 
Figure 1-3: HGF-induced Met signaling pathways 
The cellular responses and the components involved are very diverse. Four main 
downstream pathways can be activated by Met according to (Trusolino, Bertotti, and 
Comoglio 2010). A) MAPK cascade that induces proliferation, migration, apoptosis, and 
differentiation. B) PI3K-AKT signaling, which causes cell growth, survival, and 
proliferation. C) STAT3 induces the transcription of proliferative and tubulogenetic genes. 
D) IKK and NFκB lead to the activation of genes triggering proliferation, survival, and 
tubulogenesis. 
 
How Met is able to activate different cascades specifically remains to be studied in 
detail. For example, only selected downstream effectors might be recruited at one 
time, because the receptor is unequally distributed on the cellular surface and 
would activate selected downstream effectors dependent on its spatial localization 
(Trusolino, Bertotti, and Comoglio 2010). Furthermore, due to steric reasons, only 
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one protein can attach to the effector binding site of Met. That would enable the 
receptor to differentially trigger downstream signaling branches (Birchmeier et al. 
2003).  
Additionally, the complex Met machinery has to be tightly regulated with regard to 
shutting down the signal. After HGF stimulation, Met gets also autophosphorylated 
at pY1003, which recruits the E3 ubiquitin ligase CBL and causes Met’s multi-
monoubiquitination (Peschard et al. 2001). CBL can also be activated indirectly 
through GRB2, which is in turn bound to pY1356 of Met. Following ubiquitination, 
Met is internalized through clathrin-dependent endocytosis. The early endosomes 
including Met are translocated to the perinuclear compartment and fused with 
sorting endosomes. This is followed either by receptor recycling or fusion with 
lysosomes to eliminate Met signaling by its degradation. When trafficking in 
endosomes, Met is still able to induce downstream signaling components like 
STAT3 that localizes in the perinuclear region. Despite ligand-induced 
degradation, Met can also be proteolytically cleaved by caspases during apoptosis 
and by ADAM10 to mediate receptor shedding. The proteoglycan Decorin can bind 
to the extracellular part of Met, but is unable to induce downstream cascades. 
However, it causes Met downregulation by endocytosis, comparable to HGF 
(Lefebvre et al. 2012).  
1.3 Met signaling is deregulated in cancer 
Cancer is characterized as a set of cells displaying a higher proliferation rate as 
the surrounding tissue without any time-restriction. Tumors originating from these 
cells have escaped the control of the organ and exhibit progressive self-
disorganization (Clark 1995).  
The causes of cancer are as diverse as their tissue origin and include 
environmental as well as hereditary factors (Ames, Swirsky, and Willettt 1995). 
During the transformation of healthy tissue into cancer cells, more than one 
genetic change is necessary to acquire the characteristic uncontrolled growing 
phenotype. Generally, several subsequent mutations cause this development 
(Solomon, Borrow, and Goddard 1991). On the one hand, proliferative signaling, 
replicative immortality, and angiogenesis, as well as invasion and genetic 
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instability are enhanced. On the other hand, growth suppression, apoptosis, and 
destruction through the immune system are inhibited (Hanahan and Weinberg 
2011).  
Although cancer development is due to genetic changes, the manifestation of 
these mutations takes place on the protein level. As a consequence, several 
cellular processes are deregulated in cancer. Notably, the Met receptor is among 
the affected proteins and even was first identified as proto-oncogene. It is 
deregulated in a number of different cancers types and its expression in tumors 
often correlates with poor prognosis (Birchmeier et al. 2003). For example, the 
receptor is overexpressed in musculoskeletal tumors and melanoma, and 
activated in small-cell lung cancer as well as renal papillary carcinoma by point 
mutations. Furthermore, fusion with protein TPR causes its deregulation in gastric 
cancer (Krause and Van Etten 2005). Met has also been found overexpressed in 
44-83% of prostate cancers (Van Leenders et al. 2002) and in 60% of patients with 
cervical cancer (Baykal et al. 2003). As Met is transcriptionally induced by 
inflammatory cytokines and pro-angiogenetic factors, it is likely that Met promotes 
cancer at a late state when the cells have already become malignant. This fact is 
further supported by its involvement in the activation of EMT as a requisite for 
invasion (Thiery 2002). In general, the receptor triggers proliferation, survival, and 
migration (Trusolino, Bertotti, and Comoglio 2010).  
Like its receptor, HGF is overexpressed in many cancers. Furthermore, proteases 
activating the growth factor are also upregulated, resulting in an increased amount 
of active HGF compared to healthy tissues (Trusolino, Bertotti, and Comoglio 
2010). Furthermore, the paracrine regulation of Met activity through HGF is lost in 
cancer cells, because the receptor is stimulated in an autocrine manner 
(Nakamura et al. 2011).  
1.4 Listeria monocytogenes exploits Met signaling by 
activation through internalin B 
Besides HGF, a further factor is able to bind and activate the Met receptor through 
its extracellular domain. This protein is called internalin B (InlB) and is located on 
the surface of Listeria monocytogenes. The latter is a facultative anaerobic rod-
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shaped bacterium, which is found ubiquitously in soil, water, food, and in the feces 
of humans and animals. It is pathogenic and able to live intracellularly. The 
bacterium causes listeriosis in immune-compromised humans, pregnant women 
and newborns as well as in other vertebrates like domesticated mammals. Usually, 
the pathogen is ingested via contaminated food, survives the gastric acid, and 
finally reaches the intestine. There, it is able to cross the intestinal barrier, invades 
neighboring cells, and spreads through the blood to lymph nodes and spleen. Most 
bacteria reach the liver where L. monocytogenes multiplies and can cause 
hepatitis. As the bacterium is able to also cross the blood-brain and the feto-
placental barrier, it can invade the tissues behind, which may lead to meningitis 
and miscarriage, respectively (Vazquez-Boland et al. 2001; Hamon, Bierne, and 
Cossart 2006).  
The intracellular life cycle of L. monocytogenes enables the organism to escape 
the host’s humoral immune system (Gouin et al. 2010). During evolution, the 
pathogen developed several virulence factors permitting the organism to invade 
and live in its host. On the one hand, the pathogen is able to survive phagocytosis 
by macrophages. Even more strikingly, it induces its internalization in usually non-
phagocytic cells like fibroblasts, hepatocytes, endothelial and epithelial cells. In a 
first step, L. monocytogenes adheres to host cells via surface proteins, which 
trigger the invasion of the bacterium through a zipper-like mechanism involving the 
clathrin-dependent endocytosis machinery (Figure 1-4) (Lefebvre et al. 2012; 
Ireton 2007; Cossart and Veiga 2008). Yet before the fusion of the phagosome 
with the lysosomal compartment, the pathogen escapes the vacuole via 
listeriolysin O (LLO) and the phospholipases PlcA and PlcB that lyse the 
membrane. The cytoplasmic Listeria cells are now free and start to proliferate. 
Furthermore, the bacterial protein ActA acts as a nucleation factor for F-actin. 
These filaments polymerize at one pole of the rod, forming a tail that enables 
Listeria to move through the cell. By chance, it is propelled to the cytoplasmic 
membrane from where it invades neighboring cells. This process is comparable to 
the initial internalization, except that now the bacterium is surrounded by two 
membranes. Utilizing the membrane lysing virulence factors LLO and particularly 
the Plcs, the pathogen once more escapes the phagosome to start a further 
infection cycle (Hamon, Bierne, and Cossart 2006; Vazquez-Boland et al. 2001).  
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Figure 1-4: Intracellular infection cycle of Listeria monocytogenes 
A) Adhesion and induced invasion of the pathogen is initiated by InlA or InlB. B) Listeria is 
incorporated in a phagosome. C) The bacterium is able to lyse the membrane of the 
vacuole with listeriolysin O and phospholipases PlcA and PlcB. Free intracellular Listeriae 
multiply and D) move through the cell by polymerizing actin at one pole with ActA. E) 
Neighboring host cells are invaded, resulting in the bacterium localized in a double-
membrane vacuole. F) Lysis of the membranes, particularly via PlcA and B, where the 
cycle restarts again. Figure taken from (Hamon, Bierne, and Cossart 2006).  
 
The crucial step for the intracellular life of L. monocytogenes is the adhesion to 
and invasion into its host cell. This is mediated by two proteins of the invasin 
family, namely internalin A (InlA) and B (InlB). While InlA binds to E-cadherin and 
facilitates the internalization into a small number of different cell types, InlB 
activates the Met receptor, triggering its endocytosis into a variety of cell types 
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(Hamon, Bierne, and Cossart 2006). Furthermore, InlB is sufficient to promote the 
entry of non-invasive bacteria and even of inert latex beads into mammalian cells 
(Braun, Ohayon, and Cossart 1998).  
InlB is a 630 amino acid residue surface-associated protein of L. monocytogenes 
that can also be released to the surrounding medium. Like all other members of 
the internalin family, it comprises an N-terminal internalin domain, which consists 
of a helical Cap domain, a leucine-rich repeat (LRR), and an interrepeat region 
(IR) (Figure 1-5). The first two parts, until residue 241, are sufficient to bind to the 
Met receptor. However, addition of the IR domain (InlB321) is required to activate 
the host receptor. Following the internalin domain, InlB consists of a poorly 
characterized B-repeat and three C-terminal GW domains, which are structurally 
related to SH3-domains that mediate protein-protein-interactions. The GW domain 
mediates binding to the bacterial surface, but is also able to interact with the 
mammalian surface proteins complement component receptor gC1qR and 
different Heparan Sulfate Proteoglycans (HSPGs) (Niemann 2011; Niemann et al. 
2007).  
 
Figure 1-5: Domain structure of internalin B 
Internalin B is an invasine of the internalin family consisting of 630 amino acids. It is 
composed of an internalin domain consisting of an N-terminal cap, a leucine-rich, and an 
interrepeat region. The protein also contains a B-repeat and three C-terminal GW 
domains. While cap and LRR are sufficient to bind the Met receptor, addition of the IR part 
(amino acids 1-321) successfully stimulates it. The GW domains link InlB to the bacterial 
surface and are able to bind to the host protein gC1qR and HSPGs. Figure taken from 
(Niemann et al. 2007). 
 
In conclusion, both external ligands of Met - HGF and InlB – exhibit no structure 
homologies and also bind to Met at different sites. Obviously, the cellular response 
to stimulation is clearly different, too. Thus, the question arises to what extent HGF 
and InlB trigger similar signaling pathways downstream of Met and are utilizing 
same components. Several studies provide hints to comparable signaling 
mechanisms. InlB activates the PI3K and the MAPK pathways, which are known to 
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be part of HGF-induced signal transduction. Nevertheless, InlB causes only 
transient Met autophosphorylation while HGF promotes a sustained activation. 
Furthermore, the MAPK cascade appears to be stronger activated in response to 
the bacterial protein (Hamon, Bierne, and Cossart 2006; Y. Shen et al. 2000). A 
proteome study investigating the InlB321-induced kinome also identified several 
similarly and differentially regulated signaling components compared to HGF/Met 
(Reinl et al. 2009).  
1.5 Signaling cascades and post-translational 
modifications 
Signaling pathways are induced by environmental changes or other extracellular 
stimuli. These are recognized by specific receptors that transduce the signal 
through the cell involving a diverse network of proteins, and finally results in 
specific cellular responses. It is believed that every eukaryotic cell utilizes 
comparable mechanisms in signal transduction, but the inputs and outputs are cell 
type-specific. How these signaling cascades and their cross-reaction are 
coordinated is poorly understood so far. As mentioned above, HGF and InlB 
induce Met-dependent signaling cascades involving numerous proteins. The 
different components not only recognize and transmit signals within one cell, but 
also amplify, multiply, and integrate them (Jordan, Landau, and Iyengar 2000; 
Keshet and Seger 2010). 
Signal transduction induced by Met is mainly mediated by phosphorylation 
cascades. As at least 30% of all proteins in a cell are phosphorylated at one time 
point, it is clearly a general and important regulating instrument (Hubbard and 
Cohen 1993). Phosphorylation is the transfer of the terminal phosphate group of 
ATP to the hydroxyl group of the amino acids serine, threonine and tyrosine. 
Arginine, histidine, aspartic and glutamic acid may also be modified; however, this 
occurs seldom in vertebrates and is more common in prokaryotes. 
Phosphorylation of these uncharged amino acids incorporates a negative charge 
into the modified protein sequence at neutral pH due to the charge of two oxygen 
atoms of the phosphate group (Figure 1-6 A). Thereby, the conformation of the 
protein is affected by electrostatic interactions and hydrogen bonds between the 
phosphate group and the neighboring residues. When the three-dimensional 
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structure of the protein is affected, phosphorylation may influence its activity, 
stability, and association with other proteins (Dissmeyer and Schnittger 2011; 
Manning 2005).  
Enzymes that are able to transfer a phosphate group from ATP to another protein 
are called kinases (Figure 1-6). With more than 500 members, it is one of the 
largest enzyme families encoded by the eukaryotic genome (Manning 2005). 
Dependent on their preferred amino acid substrates, they are classified as 
Ser/Thr- and Tyr-kinases. Most protein kinases are themselves targets for 
upstream kinases resulting in a consecutive chain of signaling molecules 
(Dissmeyer and Schnittger 2011). Because kinases are crucial for signal 
transduction and many of them have been implicated in different types of cancer, 
this group is now more and more targeted in cancer therapy. For example, 
Imatinib was the first kinase-targeting drug and has been shown to inhibit the 
oncogenic BCR-ABL in chronic myeloid leukemia (Krause and Van Etten 2005).  
Protein phosphatases also play an important role in signaling as they act as 
antagonists of kinases by removing phosphate groups from signaling components 
(Figure 1-6). In doing so, they interfere with induced cascades and diminish 
signaling. That is an important mechanism to tightly regulate the response to 
extracellular stimuli. As for kinases, two different groups exist, distinguished by 
their preferences in hydrolyzed residues. Serine/threonine-phosphatases act as 
large, multi-subunit complexes, which mediate dephosphorylation of a broad 
spectrum of substrates (Figure 1-6 B). About 30 different genes encoding catalytic 
subunits are known. With about 100 genes encoding Tyr-phosphatases, the group 
is much bigger and is comparable to that of the Tyr-kinases. In contrast to the 
protein kinases that share a common structure, phosphatases have developed 
separately and share no sequence homologies (Cohen 2004; Tonks 2006).  
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Figure 1-6: Protein phosphorylation and dephosphorylation in Met signaling 
A) Using the example of tyrosine modification, phosphorylation by protein kinases and 
dephosphorylation by protein phosphatases is illustrated. The phosphate group is taken 
from ATP, thereby producing ADP and a modified, polar amino acid residue that may 
influence the protein’s three-dimensional structure and function. Figure taken from (Seet 
et al. 2006). B) Balance between phosphorylation by kinases and dephosphorylation by 
phosphatases in Met signaling. Kinases amplify, multiply, and integrate the signal 
intracellularly. Substrate proteins may be transcription factors or cytoskeleton-associated 
proteins that, in response to HGF, regulate gene expression and morphologic alterations, 
respectively.  
 
One further class of transducers in Met signaling is the small GTPases, which 
catalyze the conversion of bound GTP to GDP while activating downstream 
components. They, in turn, are regulated by GAP proteins that stimulate their 
GTPase activity, and GEFs, which exchange bound GDP to GTP. Furthermore, 
adapter and scaffold proteins act downstream of Met. Although they are unable to 
transmit signals on their own, they provide multiple docking sites, which recruit 
several effector proteins at once in order to bring them in close contact. These 
A)
B)
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complexes assure fast, localized, and directed transduction reactions (Pawson 
and Nash 2000).  
Besides phosphorylation, about 300 other post-translational modifications are 
known, some of them also taking part in signaling. Furthermore, interaction of 
different types of PTMs in regulation of cellular processes is also possible (Seet et 
al. 2006). Activated Met, for example, gets phosphorylated at pY1003, which recruits 
ubiquitin ligase Cbl, followed by Met multimono-ubiquitination and degradation 
through the proteasomal pathway (Lefebvre et al. 2012; Peschard et al. 2001). 
Thus, the combination of phosphorylation and ubiquitination is one method to 
regulate RTK signaling.  
For the cell, the advantage of phosphorylation in signaling - compared to gene 
expression - is the immediate recognition and fast processing of a signal (Deribe, 
Pawson, and Dikic 2010). This mechanism enables the cell to adapt to changes in 
its environment in a short period of time. Thus, in order to identify and study early 
events triggered by HGF or InlB after Met-binding, monitoring the phosphorylation 
pattern of a cell is the method of choice.  
1.6 Proteomic strategies to characterize 
phosphorylation patterns 
In order to screen novel phosphoproteins, only proteome research based on mass 
spectrometry provides a broad overview of all modified proteins affected by an 
outside signal.  
2D gel electrophoresis (2D-GE) in combination with Matrix-Assisted Laser 
Desorption/ Ionization Mass Spectrometry (MALDI-MS) has long been the 
proteomic standard to decomplex a sample and identify proteins. Using staining 
methods for phosphorylated proteins like ProQ diamond or radio-labeling (32P), 
revealed several new modifications at once. However, these strategies lack the 
sensitivity for low-abundant proteins and slight changes in the often 
substoichiometric phosphorylation pattern, which is the case for signaling 
components. Thus, underrepresented phosphoproteins have to be enriched to 
improve resolution and a subsequently obtain higher amounts of identified 
phosphoproteins. Due to biochemical properties, which are more diverse on 
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protein level, this is easier when done on the level of peptides. Furthermore, only 
peptide sequencing reveals the exact localization of a phosphorylation site (Olsen 
et al. 2006; Kosako and Nagano 2011).  
In contrast, gel-free Liquid Chromatography-tandem Mass Spectrometry (LC-
MS/MS) in combination with effective phosphopeptide enrichment provides a 
robust high-throughput method to analyze the phosphoproteome even of a 
complex sample. Several approaches have been developed to purify 
phosphopeptides, including affinity-based methods as the most common ones 
(Figure 1-7). Antibodies against phosphorylated tyrosine have been shown to act 
very specific in immunoprecipitation (Rosenqvist, Ye, and Jensen 2011). 
Nevertheless, with a fraction below 1% in a mixture of phosphorylated peptides 
(Hunter and Sefton 1980; Olsen et al. 2006), phosphotyrosine is comparatively 
rare. Therefore, a general approach requires other methods that also capture 
serine and threonine phosphorylation. Affinity chromatography using metal oxides 
(MOAC), like TiO2 has been shown to be very efficient and specific for every 
phosphorylation type. Here, the option to change the charge of the phosphate 
group at different pHs is utilized. At low pH, phosphopeptide anions bind to the 
surface of TiO2, while they can be eluted at higher pH and neutral charge. 
However, this method is selective for mono-phosphorylated peptides (Larsen et al. 
2005). Because multiple phosphorylations play an important role in signaling – 
kinases for example have to be phosphorylated at two distinct nearby sites to get 
active – TiO2 is also not the method of choice for a phosphoproteome approach. 
Strong Cation eXchange chromatography (SCX) is often used in gel-free 
proteomic studies to reduce the complexity of a given sample. By increasing the 
salt concentration in the liquid phase, positively charged peptides that interact with 
the negatively charged resin are eluted depending on their isoelectric point. As 
phosphopeptides exhibit a negative charge, they are not retained on the column 
and elute in the first fractions. The advantage of SCX in phosphoproteomics is its 
application in experiments with large protein amounts. However, SCX is obviously 
not a specific method when used alone thus, it is often combined with other 
enrichment strategies (Grimsrud et al. 2010; Rosenqvist, Ye, and Jensen 2011). 
One of them is the Immobilized Metal Affinity Chromatography (IMAC), which 
takes advantage of positively charged metal ions binding to negative phosphate 
groups of peptides. Like for metal oxides, buffers with low and high pH affect the 
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binding or the elution of the peptides from the resin, respectively. IMAC is 
commonly carried out with Fe3+ or Ga3+ ions and purifies mono as well as multiply 
phosphorylated peptides. A disadvantage here is that it also binds to acidic 
peptides as they are negatively charged at low pH as well (Ndassa et al. 2006; 
Leitner, Sturm, and Lindner 2011; Villén and Gygi 2008).  
 
Figure 1-7: Commonly used phosphopeptide enrichment strategies 
IMAC via positively charged metal ions binds phosphate groups at low pH and releases 
them at higher pH. Phosphopeptides are eluted early in SCX, because they do not bind to 
the negatively charged column resin. Charged phosphate groups are retained on TiO2 at 
low pH. Antibodies against phosphorylated tyrosines specifically purify this type of 
modification. Figure taken from (Grimsrud et al. 2010). 
 
The enriched phosphorylated peptides are then measured by LC-MS/MS in order 
to determine the peptide sequence and the phosphorylation site. ElectroSpray 
Ionization (ESI) allows coupling to an upstream reverse phase chromatography, 
which provides a continuous flow of peptides for detection by MS. The peptide 
sequence is determined by a second MS after fragmentation of the mother ions. 
During this collision, the peptide backbone is split into fragments, which are 
detected by their characteristic masses. Furthermore, modifications appear as 
increased masses in the peptide spectrum. Phosphorylations cause a mass shift 
of 80 Da of the modified amino acid. While the phosphate group is mostly lost from 
serine and threonine during fragmentation, causing a mass shift of -98 (loss of 
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H3PO4), the modification of tyrosine is comparatively stable. Stepwise calculation 
of the mass differences between neighboring peaks in the peptide spectrum then 
yields the amino acid sequence of a peptide including its phosphorylation sites 
(Leitner, Sturm, and Lindner 2011; Boersema, Mohammed, and Heck 2009).  
1.7 Strategies for quantitative labeling 
A certain amount of phosphorylated proteins is present even in non-stimulated 
cells. This phosphorylation pattern is changed in response to a stimulus. Thus, in 
order to identify phosphorylations that are caused or abolished by stimulation, the 
patterns of the treated and the non-treated sample have to be compared by 
phosphoproteomics. Quantitative analysis provides a robust strategy to get reliable 
data from different samples on the basis of peptide ion intensities. Label-free 
approaches utilize either the evaluation of ion currents or spectral counting and 
are becoming more and more popular for comparative proteomic studies. 
Nevertheless, they remain to be validated in phosphoproteomics (Rosenqvist, Ye, 
and Jensen 2011).  
More commonly used are labeling strategies where several samples are marked, 
pooled and then measured together. Labeling with stable isotopes does not 
change the characteristics of a peptide, but slightly varies the mass. Approaches 
like ICAD rely on chemical tags with different masses. Those marked peptides 
elute in parallel from the LC, but display a mass shift in the peptide spectrum due 
to the isotope composition. This method of “light” and “heavy” peptides is also 
used in metabolic labeling. But in contrast to ICAD, no tags are applied, but amino 
acids consisting of different isotopes are directly incorporated during cell culture 
(SILAC, Stable Isotope LAbeling in Cell culture). SILAC is used frequently for 
phosphoproteomics approaches, because it provides comparable labeling from the 
beginning and therefore reduces technical variability. However, it is only applicable 
for samples for growing cells or organisms. In contrast to isotope-based strategies, 
isobaric labeling is not limited in sample number. For iTRAQ (isobaric Tags for 
Relative and Absolute Quantification), up to 8 different labels are available. This 
well-established method uses isobaric tags that are usually incorporated on the 
peptide level (Figure 1-8). These tags have the same masses, but during MS 
fragmentation dissociate into so-called balancer and reporter ions, with the latter 
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displaying different masses during MS/MS. The reporter ions are detected in the 
low mass range of the peptide spectrum. Most common are four labels that 
dissociate to fragment ions of 114, 115, 116, and 117 Da. Subsequently, the 
intensities of these fragment ions can be compared and the ratio of the peptide in 
all samples is calculated (Grimsrud et al. 2010; Schreiber et al. 2008; Timms and 
Cutillas 2010).  
 
Figure 1-8: Isobaric labeling strategy using iTRAQ 
Peptides are iTRAQ-labeled with tags having same masses and samples are combined 
afterwards. During MS/MS, tags are split into balancer groups and reporter ions with 
distinct masses. The reporters display the masses 114, 115, 116, and 117, which can be 
seen in the low mass range of a peptide spectrum. The intensities of the reporters then 
allow a comparative analysis of peptide amounts in different samples. Figure taken from 
(Schreiber et al. 2008) 
 
 
2 Aim of this work 
HGF/Met-induced signaling controls a variety of different cellular responses 
ranging from proliferation, migration, and survival to apoptosis or morphogenesis. 
Many studies have investigated the components downstream of Met and tried to 
separate them into several distinct pathways (Trusolino, Bertotti, and Comoglio 
2010; Organ and Tsao 2011; Rosário and Birchmeier 2003). However, currently 
only speculations exist as to how one growth factor binding to one receptor can 
produce several outputs and how this “decision” is regulated. The high rate of 
phosphorylation on proteins suggests a more complex view on signal transduction 
and processing, because a single modification may not always affect protein 
function, while a multi-phosphorylation can have a dramatic change of the 
protein’s behavior. That indicates that regulation of some signaling components is 
not controlled simply by one upstream protein, but rather by a combination of 
several factors. Obviously, downstream of multifunctional receptors like Met, there 
are signaling networks existing, which are highly interconnected. Signaling nodes 
are supposed to play important roles in the integration of stimuli and their 
processing to one clear, unmistakable cellular reaction out of a set of different 
possibilities. This thesis aimed to characterize Met signaling from a more 
integrative point of view using global “omics” technologies in combination with 
traditional biochemical methods.  
Proteomic approaches so far concentrated on the description of kinases or 
tyrosine phosphorylations involved in Met-induced signaling (Ma et al. 2007; 
Organ et al. 2011; Hammond et al. 2010; A. Guo et al. 2008). Here, the whole 
phosphoproteome after stimulation should be identified and characterized in the 
first 20 min after a stimulus. Using a time course of 3, 6, and 20 min should cover 
early as well as late events to increase the number of detected differentially 
regulated phosphoproteins in response to Met activation. Furthermore, it should 
allow characterizing the dynamics of regulated phosphorylation sites over time. 
The cell line DU145 was chosen because it is an accepted model for prostate 
cancer and Met is expressed at high levels. Additionally, it is known to respond to 
HGF stimulation with increased motility (Johnson, Hershberger, and Trump 2002; 
Humphrey et al. 1995).  
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Besides the global phosphorylation pattern affected by HGF, single components, 
which are potential signal integrators and their functions in Met signaling should be 
studied in detail. Those hubs are supposed to cause a significant cellular effect in 
response to HGF, revealing its regulation of crucial Met-induced pathways. 
Therefore, RNAi approaches in combination with gene expression arrays were 
designed that should clarify the role of these potential hubs in the processing of 
the HGF/Met signal into cellular reactions.  
As the first parts aimed for a better understanding of the complex signal networks 
triggered by HGF, the last part of this thesis should highlight the impact of Listeria 
monocytogenes virulence factor InlB on Met-dependent signaling. Binding of InlB 
to Met induces the uptake of the pathogenic bacterium through the endocytotic 
pathway within 10 minutes (Cossart and Veiga 2008). However, proximal signaling 
in the first 5 min after InlB-Met contact has not been analyzed so far by 
phosphoproteomics. The experiment was performed in HeLa S3 cells that have 
often been used as infection model for Listeria, because they do not express E-
cadherin, which binds to InlA (Shimabukuro et al. 2001).  
 
3 Materials and Methods 
3.1 Chemicals, reagents, and buffers 
Table 3-1: Materials and reagents 
Chemical Catalog number Company 
1,4-Dithiothreitol ≥99% (DTT) 20710 Serva 
2-Mercaptoethanol 444203 Calbiochem 
Acetonitrile (ACN) 9017 J.T.Baker 
Bovine serum albumin ≥98% (BSA) A7906 Sigma 
Formic acid (FA) 1.00264.0100 Merck 
Ammonia anhydrous ≥99.99% 294993 Sigma 
Ammonium dihydrogen phosphate (NH4H2PO4) 1126 Merck 
Ammonium phosphate (APS) A1292 Sigma 
Bromophenol blue  B0126 Sigma 
Chloroform 7386 J.T.Baker 
Complete Protease Inhibitor Cocktail 04693116001 Roche 
Coomassie Brilliant Blue G250 17524 Serva 
Diammonium sulfate ((NH4)2SO4) 3746.4 Roth 
Dipotassium hydrogen phosphate (K2HPO4) P749.2 Roth 
Disodium hydrogen phosphat (Na2HPO4) 1.06580.1000 Merck 
Dimethyl sulfoxide (DMSO) A994.2 Roth 
Iron(III) chloride (FeCl3) P742.1 Roth 
Acetic acid 3738.5 Roth 
Ethanol (EtOH) 8006 J.T.Baker 
HEPES Buffer ≥99.5% 9105.3 Roth 
Gallium nitrate (Ga(NO3)3) 289892 Aldrich 
Glycine ≥99% p.A. 3908.2 Roth 
Glycerole ~86% p.A. 4043.5 Roth 
Potassium chloride ≥99.5% p.A. (KCl) 6781.1 Roth 
Potassium dihydrogen phosphate (KH2PO4) 3904.1 Roth 
Magnesium chloride (MgCl2) 2189.1 Roth 
Skim milk powder 70166 Fluka 
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Methanol (MeOH) 8045 J.T.Baker 
Sodium chloride ≥99.5% (NaCl) 3957.1 Roth 
Sodium dodecyl sulfate (SDS) CN30.3 Roth 
Sodium fluoride 99.99 Suprapur® (NaF) 1610302 Merck 
Sodium orthovanadate ≥90% (Na3VO4) S6508 Sigma 
Phosphatase Inhibitor Cocktail 1 P2850 Sigma 
Phosphatase Inhibitor Cocktail 2 P5726 Sigma 
Orthophosphoric acid (H3PO4) 85% 9079.2 Roth 
Rotiphorese gel 30 (37.5:1), Acrylamide 3029.1 Roth 
Hydrochloric acid (HCl) 1.09060.1000 Merck 
TEMED 99% p.A. 2367.1 Roth 
Thiazolyl Blue Tetrazolium Bromide (MTT) M2128 Sigma 
Triethylammonium bicarbonate buffer for HPLC 
(TEAB) 
17902 Fluka 
Trifluoroacetic acid Uvasol (TFA) 1.08262.0100 Merck 
Triton X-100 T9284 Sigma 
TRIS ≥99.5% T1503 Sigma 
Tween 20 9127.1 Roth 
 
Table 3-2: Used buffers in this study 
Buffer Composition Concentration 
4x SDS sample 
buffer, pH 6.8 
TRIS 
Glycerine 
2-Mecaptoethanol 
SDS 
Bromophenol blue 
0.24 M 
40% (v/ v) 
12% (v/ v) 
0.27 M 
0.004% (w/ v) 
Blot buffer, pH 8.3 TRIS 
Glycerine 
SDS 
MeOH 
25 mM 
192 mM 
3.5 mM 
20% (v/ v) 
Coomassie silver H3PO4 
(NH4)2SO4 
MeOH 
10% (v/ v) 
10% (w/ v) 
20% (v/ v) 
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Coomassie BB G250 0.12% (w/ v) 
Digest buffer TEAB 
ACN 
Phosphatase Inhibitor Cocktail 1 
Phosphatase Inhibitor Cocktail 2 
50 mM 
10% (v/ v) 
1:100 
1:100 
Gel fixing solution EtOH 
Acetic acid 
30% (v/ v) 
10% (v/ v) 
IMAC elution buffer, 
pH 4.5 
NH4H2PO4 0.1 M 
IMAC wash buffer, 
pH 2.8 
MeOH 
ACN 
Acetic acid 
27% (v/ v) 
27% (v/ v) 
20% (v/ v) 
Lysis buffer, pH 7.5 HEPES 
NaCl 
MgCl2 
Complete Protease Inhibitor 
NaF 
Na3VO4 
Phosphatase Inhibitor Cocktail 1 
Phosphatase Inhibitor Cocktail 2 
Glycerine 
Triton X-100 
50 mM 
1 M 
10 mM 
1tablet/ 50 ml 
10 mM 
2.5 mM 
1:100 
1:100 
5% (v/ v) 
1% (v/ v) 
PBS, pH 7.4 NaCl 
KCl 
Na2HPO4 
KH2PO4 
137 mM 
2.7 mM 
10 mM 
2 mM 
RP elution buffer MeOH 
TFA 
60% (v/ v) 
0.5% (v/ v) 
RP wash buffer TFA 60% (v/ v) 
SCX buffer A FA 
CAN 
0.065% (v/ v) 
25% (v/ v) 
SCX buffer B FA 
ACN 
KCl 
0.065% (v/ v) 
25% (v/ v) 
0.5 M 
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SDS buffer A,  
pH 8.8 
TRIS 
SDS 
1.5 M 
14 mM 
SDS buffer B,  
pH 6.8 
TRIS 
SDS 
0.5 M 
14 mM 
SDS running buffer, 
pH 8.9 
Glycine 
TRIS 
SDS 
199 mM 
24 mM 
3.5 mM 
TBS-T TRIS 
NaCl 
Tween 20 
20 mM 
137 mM 
0.1% (v/ v) 
TBS-T/ NaCl TBS-T + 
NaCl 
 
0.5 M 
TBS-T/ Triton X-100 TBS-T +  
Triton X-100 
 
0.5% (v/ v) 
UPLC buffer A FA 0.1% (v/ v) 
UPLC buffer B FA 
ACN 
0.1% (v/ v) 
99.9% (v/ v) 
WB blocking 
solution 1 
TBS-T + 
Skim milk powder 
 
5% (w/ v) 
WB blocking 
solution 2 
TBS-T + 
BSA 
 
5% (w/ v) 
 
All used buffers and solutions were prepared with ddH2O water. To set the pH 
value, HCl, NaOH, ammonia, or acetic acid were used.  
3.2 Recombinant proteins 
Hepatocyte growth factor (HGF) and Internalin B (InlB) were kindly provided by Dr. 
Jörn Krauße and Dr. Joop van den Heuvel from the Molecular Structural Biology 
Department of the Helmholtz Center for Infection Research.  
HGF was recombinantly expressed in CHO insect cells in a 2.5 l fermenter. As the 
protein was secreted, the concentrated supernatant could directly be applied onto 
a heparin column where the protein was purified. Afterwards, it was activated by 
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digestion with hepatocyte growth factor activator (HGFA), bound to a strong cation 
exchange column, and eluted at about 750 mM NaCl in HEPES buffer. HGF was 
stored at 4 °C to maintain the conformation and activity of the protein.  
Internalin B full length (InlB) was recombinantly expressed in CHO cells with a 
GST-tag. The cells were pelleted, lysed by homogenization, and the supernatant 
was loaded onto a glutathione sepharose (GST) column. PreScission protease 
was added to cut off InlB, and the protein was eluted. To further purify the product, 
strong cation exchange chromatography was applied and the protein was eluted 
during an NaCl gradient. InlB was aliquoted and stored at -80°C to decrease 
protein degradation.  
To check purity of the recombinant proteins, SDS gels were run and stained with 
Coomassie blue. If the correct bands appeared on the gel, proteins were tested for 
activity as illustrated in section 3.3.2.  
3.3 Cell culture 
3.3.1 Splitting and storage of cells 
Table 3-3: Cell lines used in this study 
Cell line Origin Properties 
HeLa S3 Human cervix adenocarcinoma Epithelial, adherent 
DU145 Human prostate carcinoma Epithelial, adherent 
 
Standard medium HeLa S3: Dulbecco’s Modified Eagle’s Medium (Gibco DMEM, 
#31885, Invitrogen) was combined with 10% Fetal bovine serum (FBS Gold, 
#A15151, PAA Laboratories), 1x Pen/Strep (#15070-063, Invitrogen), 2 mM L-
Glutamine (#25030, Invitrogen).  
Minimal medium HeLa S3: Dulbecco’s Modified Eagle’s Medium (Gibco DMEM, 
#31885, Invitrogen) was combined with 1x Pen/Strep (#15070-063, Invitrogen).  
Standard medium DU145: Roswell Park Memorial Institute 1640 medium (Gibco 
RPMI, #21875, Invitrogen) was combined with 10% Fetal bovine serum (FBS 
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Gold, #A15151, PAA Laboratories), 1x Pen/Strep (#15070-063, Invitrogen), 2 mM 
L-Glutamine (#25030, Invitrogen).  
Minimal medium DU145: Roswell Park Memorial Institute 1640 medium (Gibco 
RPMI, #21875, Invitrogen) was combined with 1x Pen/Strep (#15070-063, 
Invitrogen). 
DU145 and HeLa S3 cells were cultivated to a confluence of 80-90% at 37 °C and 
7.5% CO2 in their medium, respectively. Before splitting, the cells were washed 
three times with PBS and removed from the culture dish with Trypsin-EDTA 
solution (#25300, Invitrogen). The reaction was stopped by adding standard 
medium. The cells were pelleted at 200 g for three minutes, resuspended in 
standard medium, and diluted from 1:20 to 1:100 in a new Petri dish with fresh 
medium.  
In order to store the human cells, their concentration was determined in a 
Neubauer counting chamber and the cells were diluted to a final concentration of 
2*106 cells/ ml in 1:1 standard medium with 10% DMSO in 1 ml aliquots. The cells 
were afterwards frozen at -80 °C and stored in liquid nitrogen. When needed one 
aliquot was thawed at 37 °C, washed with fresh medium and seeded in a 10 cm 
Petri dish.  
3.3.2 Preparation of human cells for experiments 
For functional testing of the recombinant HGF protein, 105 DU145 cells were 
seeded in 3 cm dishes in duplicates and cultured overnight in standard medium. 
The next day, cells were serum-starved with minimal medium for 24 h. Then, the 
first half was stimulated for 5 min with 0, 0.02, 0.2, 2, 20, or 200 nM HGF and 
harvested with 50 µl SDS sample buffer supplied with 1 µl Benzonase 
(#1.01695.001, Merck) by scraping on ice. The second half of the cells was 
stimulated for 20 h with the same concentrations. The HGF-induced motility was 
then monitored by microscopy with an Axiovert100 (Zeiss) and documented by 
taking pictures with a digital camera (DXM1200, Nikon).  
For the phosphoproteome experiments, three 15 cm dishes per sample were 
seeded with 3*106 cells and cultured overnight in standard medium. After 24 h of 
starvation in minimal medium, the cells were stimulated with 2 nM HGF for 3, 6, 20 
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min, or with 10 nM InlB for 5 min. The medium was drained off and the cells were 
harvested with 500 µl lysis buffer by scraping on ice. Lysis was carried out for 30 
min on ice and supported by vortexing and sonication in a water bath for 5 min.  
3.4 RNAi approaches 
3.4.1 Proliferation Assay 
For the proliferation assay of HeLa S3 cells in response to NEK9 knockdown and 
HGF, 1000 cells per well were seeded into a 96-well plate and transfected with 
both NEK9 siRNAs in combination or left untreated. All samples were starved with 
DMEM minimal medium for 24 h and then stimulated with 2 nM HGF for 6 d. Every 
24 h, cells were treated with 20µl of 5 mg/ ml MTT in PBS, which is reduced by 
living cells to the purple-colored formazan. After incubation for 2 h in the incubator, 
cells were washed with PBS and then incubated with isopropyl-HCl (0.13% HCl in 
isopropyl alcohol) while shaking, approximately for 10 -30 min, until the small 
crystals of the stain were dissolved. Afterwards, the absorbance was measured at 
595 nm with an Infinite M200 ELISA reader (Tecan).  
Table 3-4: Nek9 transfection solution for a 3 cm dish (3 ml volume) 
Reagent Catalog number Company Amount 
NEK9 siRNA 5 SI02622459 Qiagen 10 nM 
NEK9 siRNA 7 SI02660476 Qiagen 10 nM 
Or nonsense siRNA 1022076 Qiagen 10 nM 
HiPerFect 301705 Qiagen 12 µl 
DMEM minimal 
medium 
See 3.3.1 See 3.3.1 100 µl 
 
3.4.2 Gene expression arrays 
For NEK9 and HGF-dependent gene expression profiling, 8 plates with 3*105 
HeLa S3 cells per 10 cm petri dish were seeded and transfected either with 10 nM 
nonsense siRNA or NEK9 siRNAs 5 and 7 the next day. After 24 h, the medium 
was changed to DMEM minimal medium and cells were starved for additional 24 
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h. One half of the plates were afterwards treated with 2 nM HGF for 18 h, the 
others left untreated as a control. The experiment was performed in duplicates.  
Table 3-5: Samples for RNA array with Nek9 knockdown 
Samples Cell line Condition Treatment 
1 HeLa S3 Nonsense siRNA - 
2 HeLa S3 NEK9 siRNAs 5+7 - 
3 HeLa S3 Nonsense siRNA 2 nM HGF, 18 h 
4 HeLa S3 NEK9 siRNAs 5+7 2 nM HGF, 18 h 
5-8 second replicate 
 
For the EPHA2 gene expression array, 36 dishes each with 3*105 DU145 cells 
were seeded in 10 cm plates. In parallel, the transfection solutions with 100 nM 
nonsense siRNA, EphA2 siRNAs 5 or 7, respectively, were prepared and applied 
to the cells. After 1 d, cells were starved with RPMI minimal medium for 24 h and 
two-thirds of the plates were treated with 2 nM HGF for 1 h or 4 h. The experiment 
was performed in triplicates. 
For subsequent RNA isolation, cells were washed two times with ice-cold PBS and 
harvested with 350 µl RLT buffer (Qiagen, RNA extraction kit) by scraping on ice. 
RNA extraction and microarray analysis (Agilent.SingleColor.14850) was 
performed by the Array Facility of Dr. Robert Geffers at the HZI.  
Table 3-6: EphA2 transfection solution for a 10 cm dish (5 ml volume) 
Reagent Catalog number Company Amount 
EPHA2 siRNA 5 SI00300181 Qiagen 100 nM 
Or EPHA2 siRNA 7 SI02223508 Qiagen 100 nM 
Or Nonsense siRNA 1022076 Qiagen 100 nM 
HiPerFect 301705 Qiagen 25 µl 
RPMI minimal 
medium 
See 3.3.1 See 3.3.1 500 µl 
 
 
34 3 Materials and Methods 
Table 3-7: Samples for RNA array with EphA2 knockdown 
Samples Cell line Condition Treatment 
1 DU145 Wildtype - 
2 DU145 Nonsense siRNA - 
3 DU145 EPHA2 siRNAs 5 - 
4 DU145 EPHA2 siRNAs 7 - 
5 DU145 Wildtype 2 nM HGF, 1 h 
6 DU145 Nonsense siRNA 2 nM HGF, 1 h 
7 DU145 EPHA2 siRNAs 5 2 nM HGF, 1 h 
8 DU145 EPHA2 siRNAs 7 2 nM HGF, 1 h 
9 DU145 Wildtype 2 nM HGF, 4 h 
10 DU145 Nonsense siRNA 2 nM HGF, 4 h 
11 DU145 EPHA2 siRNAs 5 2 nM HGF, 4 h 
12 DU145 EPHA2 siRNAs 7 2 nM HGF, 4 h 
13-24 second replicate 
25-36 third replicate 
 
3.5 General biochemical Methods 
3.5.1 Determination of the protein concentration 
The protein concentration of cell lysates was determined according to Bradford 
(Bradford 1976). A small aliquot of the sample was diluted 1:10, 1:15, and 1:20 
with ddH2O, mixed with BioRad Protein Assay reagent (#5000006, Bio-Rad), and 
absorption was measured in triplicates by an Infinite M200 Elisa reader (Tecan) at 
595 nm. Several dilutions (0.1-1 mg/ml) of bovine serum albumin in ddH2O were 
used to create a calibration curve.  
3.5.2 SDS-PAGE 
Separation of protein samples according to molecular mass (Laemmli 1970) was 
performed in an SDS-PAGE system of Biometra (86*77*1 mm). Stacking and 
separating gels were prepared as described in Table 3-8 and polymerized at least 
overnight at 4 °C. In most cases, 10% SDS gels with 10 pockets were used. The 
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samples were mixed with 4x SDS sample buffer, boiled for 3 min at 95 °C, and 
centrifuged for 1 min at 13,000 rpm to pellet insoluble particles.  
Table 3-8: SDS gel preparation 
Solution Stacking gel 4.2% SDS Separating gel 10% SDS 
SDS buffer A - 2.5 ml 
SDS buffer B 2.5 ml - 
ddH2O 6.1 ml 4.2 ml 
Rotiphorese gel 30 1.4 ml 3.3 ml 
TEMED 30 µl 20 µl 
APS, 10% solution 60µl 50 µl 
  
10–20 µl sample per gel pocket was loaded on an SDS gel and run for about 90 
min at 120 V until Bromophenol Blue reached the bottom of the gel. PageRuler 
Prestained Protein Ladder (#26616, Fermentas) was used as molecular mass 
standard.  
3.5.3 Immunoblotting 
After gel electrophoresis, the proteins were transferred to a PVDF membrane 
(Immun-Blot PVDF Membrane, 0.2 µm, #162-0177, Bio-Rad). Therefore, the SDS 
gel, the membrane, and the Whatman paper were equilibrated in Blot buffer for 15 
min and the proteins were transferred at 55 mA and 25 V for 1 h by a Semi-dry 
transfer cell (Trans-Blot SD, #170-3940, Bio-Rad). After that, the membrane was 
saturated either with WB blocking solution 1, or, in case of phospho-specific 
antibodies, with WB blocking solution 2 for 1 h. The membrane was incubated with 
primary antibody in blocking solution overnight at 4 °C with gentle agitation, 
washed with TBS-T, TBS-T/NaCl, TBS-T/Triton X-100, and once again with TBS-
T. Afterwards, it was incubated with secondary antibody (1:2,000) in blocking 
solution for 1 h at room temperature. The membrane was washed three times with 
TBS-T. Detection was carried out by applying Lumi-Light Western Blot Substrate 
(#12015200001, Roche). Chemiluminescence was then detected by a CCD 
camera (Fujifilm LAS3000, Raytest).  
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Table 3-9: Applied antibodies 
Directed protein Reactivity Dilution Catalog number Company 
Actin Mouse 1:5,000 A5441 Sigma 
Actin Rabbit 1:5,000 A5060 Sigma 
EGFR Rabbit 1:1,000 4267 Cell Signaling 
GAPDH Mouse 1:2,000 MCA4740 ABD Serotec 
HSP90 Goat 1:1,000 AF3286 R&D Systems 
NEK9 Mouse 1.3,000 H00091754-A01 Abnova 
NEK9 Rabbit 1:5,000 (Roig et al. 2002)  
pEPHA2 (S897) Rabbit 1:1,000 CY1108 Cell Applications 
pERK1,2 
(T202/Y204) 
Mouse 1:1,000 9106 Cell Signaling 
pMet 
(Y1234/Y1235) 
Rabbit 1:1,000 3126 Cell Signaling 
 
3.5.4 Coomassie staining of SDS gels 
SDS gels were stained either directly after SDS-PAGE to estimate the amount of 
protein in cell lysates or after Western Blot to check the efficiency of the protein 
transfer to the blotting membrane. Therefore, gels were immersed in Gel fixing 
solution for at least 1 h and then stained overnight with Coomassie silver while 
shaking. To decrease background, gels were unstained by washing with H2O for 
several times. Afterwards, gels were scanned by a ScanMaker 9800XL (1108-03-
360072, Microtek) and saved as 16-bit grayscale pictures.  
3.6 Quantitative phosphoproteome analysis 
3.6.1 Protein precipitation 
Proteins from DU145 cells stimulated 0, 3, 6, and 20 min with HGF and those 
stimulated 0, and 5 min with InlB in HeLa S3 cells were precipitated according to 
Wessel and Flügge (Wessel and Flügge 1984). In short, one volume of the sample 
was mixed with four volumes of methanol and one volume of chloroform, and then 
three volumes of H2O were added. After vortexing and centrifugation, the protein 
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pellet, localized in the interphase, was washed with three volumes of Methanol 
and dried at room temperature. For each phosphoproteome sample 4 mg of 
protein were used.  
3.6.2 Tryptic digest 
For digesting of the proteins to peptides, Trypsin (sequence grade, bovine, 
#V511A, Promega) had to be activated in 100 µl Trypsin resuspension solution 
(#V542A, Promega) for 15 min at 37 °C. Next, the protein pellet was resuspended 
in 1.5 ml of digestion buffer by sonication and 40 µg Trypsin (corresponding to 200 
µl) were added. The tryptic digest was performed overnight at 37 °C.  
3.6.3 Purification of peptides via Bakerbond columns 
For purification of the peptides C18 reverse phase (RP) chromatography was 
utilized. LiChroprep RP-18 (25-40 µm, #1.09303.0100, Merck) resin was mixed 
with RP elution buffer and pipetted to a Bakerbond column (#7121-01, J.T. Baker) 
to a filling level of 3-5 mm. The resin was equilibrated three times with 600 µl 
elution buffer and three times with wash buffer by gently blowing nitrogen through 
the column. After that, the samples were acidified with 10% TFA and loaded ten 
times. By adding three times RP wash puffer, the peptides on the column were 
desalted. For elution, 600 µl RP elution buffer was applied to the resin, peptides 
were collected below and the eluted fraction was dried in a centrifugal evaporator.  
3.6.4 Isolation of phosphopeptides 
For phosphoproteome analyses the phosphopeptides have to be enriched by 
Immobilized Metal Affinity Chromatography (IMAC) as they are underrepresented 
in cell lysates and non-phosphopeptides also disturb the ionization during mass 
spectrometric measurements. Using the Ga-IDA Phosphopeptide Enrichment Kit 
(#89853, Thermo-Pierce, not available anymore), which is based on Ga3+ ions 
binding to phosphate groups, it was possible to purify phosphopeptides from whole 
cell lysates. Therefore, the peptides were resuspended in 50 µl IMAC wash buffer, 
mixed with the swell gel of the kit, which contains the Ga resin, and incubated 
overnight at 4 °C. The next day, the resin was transferred into the supplied 
centrifugation columns and washed five times with 100 µl IMAC wash buffer to 
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flush out the non-phosphopeptides. To elute phosphopeptides, the resin was 
incubated 5 min with IMAC elution buffer and centrifuged afterwards. This was 
repeated four times to dissolve all phosphorylated peptides from Ga-resin. The 
flow-through was collected as well and used for a subsequent IMAC. This 
procedure was repeated until no phosphopeptides were enriched anymore. All 
dried samples were stored at -80 °C.  
3.6.5 iTRAQ labeling of phosphorylated peptides 
Before labeling of the peptides they first have to be purified by RP chromatography 
with Bakerbond columns as described above. The labeling was done with iTRAQ® 
Reagents Multiplex Kit (#4352135, AB Sciex) according to the manufacturer’s 
advices. In short, purified peptides were resuspended in 40 µl Dissolution Buffer. 
The four labels with different reporters available in the kit (114.1, 115.1, 116.1, 
117.1) were reconstituted in 70 µl ethanol and transferred to the sample. The 
incubation was done for 2 h at room temperature in the dark. Once the peptides 
were labeled, all samples of one experiment were pooled together and dried.  
Table 3-10: iTRAQ Labeling scheme 
Experiment Sample Label 
HGF time course 0 min 114.1 
 3 min 115.1 
 6 min 116.1 
 20 min 117.1 
InlB stimulation 0 min 115.1 
 5 min 117.1 
 
3.6.6 Fractionation of phosphopeptides 
The peptides were purified once again by RP chromatography with Bakerbond 
columns as described above. After that, fractionation by Strong Cation eXchange 
chromatography (SCX) was performed to decomplex the samples for mass 
spectrometry and to further purify phosphopeptides from acidic peptides. 
Therefore, 45 µl SCX buffer A was added to the peptides, the samples were 
ultracentrifuged (Sorvall Discovery MS120E, Hitachi, rotor S100AT3-308) for 20 
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min at 50,000 rpm and the supernatant was transferred into an Ettan-microLC 
system. The peptides were separated on a Mono S PC1.6/ 5 column (#17-0672-
01, GE Healthcare) by a linear gradient (0–35% SCX buffer B, 15 min, 150 µl/ min 
flow rate). One fraction per minute was collected, in total 30 fractions were 
analyzed. The identification of peptide-containing fractions was supported by 
measuring the absorbance at 214 nm.  
3.6.7 Purification of peptides using pipette tips 
After fractionation the amount of phosphopeptides in each fraction is very low, 
however, for mass spectrometry, the samples need to be desalted again. 
Therefore, purification was done with RP resin containing pipette tips (ZipTip 
Pipette Tips 0.6 µl, # ZTC18S008, Millipore). As for the Bakerbond columns, the 
resin was first washed five times with RP elution buffer, then five times with RP 
wash buffer, and the sample was loaded ten times by gently pipetting the solutions 
up and down. Washing was done ten times; finally, the peptides were eluted in 30 
µl RP elution buffer. The eluted phosphopeptides were then dried and stored at -
80 °C until they were measured by mass spectrometry.  
3.6.8 Mass spectrometry analysis 
The purified samples were resuspended in 10 µl RP wash buffer, floating particles 
were pelleted by ultracentrifugation at 50,000 xg for 15 min and the 
phosphopeptides were applied to an Ultimate 3000 RSLCnano system (Thermo) 
with a C18 precolumn (Acclaim PepMap100 C18 nano-Trap Column, #164535, 
Thermo) for washing with UPLC buffer A. The separation took place on the 
analytic column (Acclaim PepMap RSLC, #164536, Thermo) with UPLC buffer B 
and a flow rate of 350 nl / ml with a 30–120 min gradient. The connected mass 
spectrometer was an Orbitrap Velos (Thermo), which was operated with Xcalibur 
(version 2.1, Thermo). The measurement parameters included dynamic exclusion 
(Table 3-11).  
 
 
40 3 Materials and Methods 
Table 3-11: Parameters for dynamic exclusion 
Parameter Setting 
Repeat count 2 
Repeat duration 20 sec 
Exclusion duration 120 sec 
Exclusion mass width By mass 
- Low 1.1 
- High 1.6 
Exclusion list size 500 
Early expiration Enabled 
Count 3 
S/ N threshold 2.0 
 
3.6.9 Identification of proteins by database search 
The resulting spectra from mass spectrometry (MS) provide the masses of the 
mother ions and after a further fragmentation step (MS/MS) show the fragment 
ions of the mother ions. These were sent against Mascot (version 2.3, Matrix 
Science), a database consisting of theoretically calculated masses, and were 
matched with the current UniProt database. The parameters chosen for the 
identification of the peptides and their corresponding proteins are shown in Table 
3-12. Furthermore, Mascot is also able to identify phosphorylation sites. Those of 
the significantly regulated phosphopeptides were later checked manually together 
with Dr. Manfred Nimtz.  
Table 3-12: Parameters for identification of peptides/ proteins 
Parameter Setting 
Taxonomy Homo sapiens (human) 
Database SwissProt 
Fixed modifications CarboxyMethyl (C) 
Variable modifications iTRAQ4plex (K), iTRAQ4plex (N-term.), 
iTRAQ4plex (Y), Oxidation (M), Phospho (ST), 
Phospho (Y)  
Enzyme Trypsin 
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Max. missed cleavages 2 
Peptide charge 2+ and 3+ 
Peptide tol. +/ - 5 ppm 
Data format Sequest (.DTA) 
Decoy database Enabled 
Monoisotopic Enabled 
MS/ MS search Enabled 
MS/ MS tol. +/ - 0.02 Da 
Instrument ESI-FTICR 
 
3.6.10 Analysis of regulated peptides 
The normalization of the samples was carried out with Prof. Dr. Frank Klawonn. 
For quantitative analysis of the different samples, the peptides were labeled with 
iTRAQ. The labels’ reporters can be found in the peptide spectra in the low mass 
range. The intensities of the reporters were then used to compare the amount of 
the associated peptide between the samples. ITRAQassist, an in-house 
bioinformatics software (Hundertmark et al., 2009; Reinl et al., 2009) calculated 
regulation factors of the peptides on the basis of Mascot result files (dat-file). 
Firstly, the program corrected for the contamination of the labels’ isotopes, 
secondly, estimated the instrument’s specific background noise, and finally 
calculated the most probable Regulation Factor (RF) for a peptide group. The 
parameters were set to a minimum peptide score of 20, the regulation base was 
114.1 (unstimulated control), only unique peptides were considered and peptide 
view was selected. The results were then exported into an Excel sheet and also as 
Likelihood plots. These curves illustrate the reliability of the calculated RFs, which 
is demonstrated by the Interval of Robustness (IoR).  
To separate identified phosphopeptides from non-modified ones, the iTRAQassist 
results were loaded into MassCluster (version 1.2.3., in-house bioinformatics 
software), which then resulted in an Excel sheet showing only the 
phosphopeptides and their RFs in log2 scale.  
This table was further processed together with Prof. Dr. Frank Klawonn to 
calculate significantly regulated phosphopeptides by multiple testing. Therefore, it 
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was assumed that regulation factors follow a normal distribution and that the 
significantly regulated peptides should exceed a theoretical calculated threshold 
within all experiments of the triplicate. The probability of a significant regulation 
was represented by a p-value above 95%, which corresponded to a log2 regulation 
factor of about 0.6.  
3.6.11 Applied further software 
To visualize all identified proteins and their peptide spectra, Mascot results were 
directly imported into Scaffold Q+ (version 3-00-01).  
UniProt (www.uniprot.org) was used for annotation of single proteins, synonyms, 
functions, and interaction partners. For deeper literature studies PubMed 
(www.ncbi.nlm.nih.gov/pubmed) was searched.  
As iTRAQassist and MassCluster provide only Protein Identifiers, but not UniProt 
Accession Numbers, StrAP 1.0 (www.downloadplex.com/Scripts/Matlab/ 
Development-Tools/strap-clustering-data-streams-with-affinity_445041.html) was 
used for fetching those numbers. The program also added GO Annotations and is 
able to visualize data.  
Java Treeview was utilized to illustrate regulated peptides or genes as a heatmap. 
To get an overview of identified and regulated peptides, the belonging proteins 
were loaded into DAVID Bioinformatics Resources 6.7 (Database for Annotation, 
Visualization and Integrated Discovery, www.david.abcc.ncifcrf.gov). This online 
tool clusters and visualizes proteins by functional annotation (GO Annotation) or 
by pathways (KEGG pathway maps).  
An alternative tool for pathway mapping and gathering protein information is 
GeneGo (www.genego.com). This commercial database also provides network 
building from experimental data and prediction of modulated transcriptions factors 
for example.  
The expression of proteins in cell lines and tissues was queried with BioGPS 
(www.biogps.org).  
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Whether an identified phosphorylation site is known and functionally characterized 
was checked in several phosphorylation databases. The most complete and well-
arranged ones were PhosphoNet (Kinexus, www.phosphonet.ca) and 
PhosphoSitePlus (Cell Signaling, www.phosphosite.org). PHOSIDA 
(www.phosida.com) and Phospho.ELM (www.phospho.elm.eu.org) were also 
utilized.  
 
4 Results 
Growth factor receptor signaling is a dynamic process, which is mediated by 
protein-protein interactions that depend on post-translational modifications. The 
transfer of phosphate groups amongst others between proteins influences their 
activity, interaction and localization and thus is an important mechanism for signal 
transduction and the regulation of cellular responses. However, analysis of the 
phosphoproteome by mass spectrometry requires an efficient enrichment method 
for phosphopeptides, as they are underrepresented in whole cell extracts 
(Hubbard and Cohen 1993).  
Using state-of-the-art phosphoproteomics, this study was supposed to 
characterize HGF/Met signaling in a time-dependent manner to better understand 
the coordination of induced physiological processes, e.g. during wound healing 
and embryogenesis. As the cascades are also strongly activated in cancer and the 
experiments were performed in a cancer cell line, the approach might also reveal 
activities that take place during tumor growth and metastasis. How this 
physiological signaling is influenced by a pathogen during infection was examined 
in the second part of this work. As an example, the impact of the bacterium Listeria 
monocytogenes was determined by stimulation of cells with the pathogenic 
surface-located invasion protein InlB that is also able to activate Met (Hamon, 
Bierne, and Cossart 2006; Reinl et al. 2009).  
4.1 Establishment of the phosphoproteome workflow 
Several different phosphosproteome workflows have been described in the current 
literature. Most of them utilize SCX and subsequent metal ion chromatography for 
enrichment of phosphopeptides in combination with SILAC (Macek, Mann, and 
Olsen 2009; Rosenqvist, Ye, and Jensen 2011). As iTRAQ labeling and 
subsequent quantitative analysis supported by iTRAQassist were already 
established in this group (Hundertmark et al. 2009; Reinl et al. 2009) and future 
studies might include primary patient material, iTRAQ was chosen as the preferred 
labeling strategy. In order to improve the yield of identified phosphopeptides and to 
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cover all significant downstream pathways, several parts of the workflow had to be 
optimized.  
First of all, the cell line DU145 was chosen for the HGF/Met study, because it is an 
accepted prostate cancer model and Met is expressed in high amounts to 
guarantee significant Met signaling. Furthermore, the cells show increased motility 
after HGF-stimulation, which could easily be used as control for a physiological 
response (Johnson, Hershberger, and Trump 2002; Humphrey et al. 1995).  
An effective workflow for phosphoproteome isolation and characterization had to 
be established next. The aim was to identify as many phosphopeptides as 
possible, equivalent to current reports where thousands of sites have been 
published from one phosphoproteomic study (P. H. Huang 2011). Figure 4-1 
illustrates the experimental strategy to investigate Met signaling in DU145 cells. 
The cells were starved for 24 h, followed by cell lysis and tryptic digestion of 
different amounts of protein. In the next step, phosphorylated peptides were 
enriched by IMAC. For sequencing, phosphopeptides were analyzed by LC-
MS/MS. Corresponding proteins and their phosphorylation sites were then 
identified supported by the database Uniprot.  
Within distinct pre-experiments, one parameter each was varied in order to 
improve efficiency of the described workflow. First of all, two IMAC strategies were 
compared, because isolation of phosphopeptides by IMAC is the most crucial step. 
Secondly, the initial amount of protein was increased in order to check for 
limitations. Finally, phosphopeptides after 1-dimensional IMAC separation were 
compared to those additionally fractionated in a 2-dimensional workflow using 
IMAC and SCX.  
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Figure 4-1: Experimental strategy for pre-experiments for the optimization of 
phosphopeptide enrichment 
Human DU145 cells were stimulated with serum and lysed to extract proteins. For mass 
spectrometry, the samples were digested to peptides. Phosphopeptides were enriched by 
IMAC followed by fractionation via SCX. LC-MS/MS and database search were then 
performed to identify proteins and phosphorylation sites.  
 
Specific phosphopeptide enrichment is the crucial step in the whole workflow. 
IMAC can be prepared with different types of metal ions and every material is 
known to have characteristic binding preferences (Mann et al. 2002). This 
experiment was designed to check whether IMAC via Fe3+ or Ga3+ ions produced 
a comparable number of phosphorylated peptides and whether a combination of 
both can improve selectivity or yield. To reduce experimental effort, only 2 mg of 
protein were utilized. It turned out that about 125 phosphopeptides were enriched 
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Stimulation of Met pathway
Precipitation of proteins
Tryptic digest into peptides
Enrichment of phosphopeptides
LC-MS/MS
Fractionation of 
phosphopeptides
Ga3+ Fe3+Ga3+ and Fe3+
Eluted phosphopeptides
Identification of proteins 
and phosphorylation sites
4.1 Establishment of the phosphoproteome workflow 47 
by both methods but Ga-IMAC isolated additionally almost 5-fold more 
phosphorylated peptides than Fe-IMAC with only 28 (Figure 4-2). Figure 4-2B 
shows the number of enriched peptides when the flow-through of Ga-IMAC is 
applied onto a Fe3+ column. In this case, no further phosphopeptides could be 
enriched by Fe-IMAC in comparison to the Ga-IMAC elution. These data illustrated 
clearly that IMAC with Ga3+ ions alone represented the method of choice for all 
further experiments.  
 
Figure 4-2: Comparison of different IMAC materials 
A) Peptides from DU145 cells were either enriched by Ga- or by Fe-IMAC, and identified 
by LC-MS/MS. B) Phosphopeptides were first purified with Ga-IMAC, the eluate was 
measured by mass spectrometry, and the flow through was applied to Fe-IMAC. The 
number of identified unique phosphopeptides by each enrichment method is shown.  
 
Next, the amount of protein required to produce a maximum number of 
phosphopeptides through this workflow was determined. For that, the protein 
quantity from serum-stimulated DU145 cells was varied from 300 µg to 4,000 µg 
and the resulting number of phosphopeptides after digestion, Ga-IMAC and LC-
MS/MS was determined. While only 78 unique phosphopeptides were identified 
from 300 µg protein, the quantity increased more than 8-fold to 668 for 4,000 µg 
(Figure 4-3). Thus, increasing the amount of protein produced a greater number of 
identified phosphopeptides by LC-MS/MS and there was no negative effect of 
higher protein concentrations observable. In the main experiments, iTRAQ was 
planned as 4-plex labeling for a time course analysis. Therefore, all four samples 
would be combined before LC-MS/MS measurement and it was assumed that the 
number of phosphopeptides would further increase, because 16 mg of protein 
extract were used in total. The limit of 4 mg for each sample was chosen to 
Ga Fe
133 125 28
Ga Fe after Ga
258 0 0
A B
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maintain experimental practicability, as this amount already requires the 
preparation of 3 – 4 large petri dishes (diameter: 15 cm).  
 
Figure 4-3: Determination of relation of protein amount to phosphopeptide recovery 
Indicated amounts of protein were digested, phosphopeptides were enriched by Ga-IMAC, 
and analyzed by LC-MS/MS. Shown are the identified unique phosphopeptides of each 
sample.  
 
So far, pre-experiments examined the efficiency of the workflow by improving 1-
dimensional separation techniques. However, only the largest peptide ions in a 
sample are chosen for further identification during LC-MS/MS, which results in a 
low identification rate of ions with lesser intensity. Therefore, an additional 
separation of phosphopeptides via strong cation exchange chromatography (SCX) 
was tested next to improve the resolution of the phosphopeptides during LC-
MS/MS. Ga-IMAC enriched phosphopeptides were separated on a SCX column to 
gain 2-dimensional-resolved peptides. One fraction per minute was collected 
during a 15 min salt gradient and the eluted peptides were monitored by 
absorption at 214 nm (Figure 4-4). The gradient (yellow curve) started during 
fraction 15, had a plateau between fractions 25-30 at 40% SCX buffer B, and 
increased then to 100% SCX buffer B at fraction 40. The absorption (blue curve) of 
fraction 17 displayed the most prominent peak, while fractions 18 to 25 and 35 to 
42 also showed noteworthy absorbance, indicating peptide-containing fractions.  
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Figure 4-4: SCX chromatogram 
IMAC-enriched phosphopeptides were labeled with iTRAQ, pooled and fractionated by 
SCX. The orange curve shows the increasing concentration of SCX buffer B during the 
gradient. The blue curve corresponds to milli absorbance units (mAU) of the eluted 
peptides detected at 214 nm.  
 
Following, the ratio of phosphopeptides to non-phosphopeptides after SCX was 
calculated. Figure 4-5 shows the amount of identified peptides per SCX fraction. 
Non-phosphorylated peptides mainly eluted from fractions 18 to 25 corresponding 
to the detected absorbance in the SCX chromatogram. In contrast, phosphorylated 
peptides eluted earlier, namely from 8 to 27 with a maximum in fraction 16. This 
characteristic distribution of modified and non-modified peptides illustrated the 
potential of SCX in further separating phosphopeptides from non-modified ones. 
Therefore, only the first phosphopeptides-containing fractions 1 to 22 were 
analyzed by LC-MS/MS in this study in order to reduce the number of unmodified 
peptides in the further analyses.  
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Figure 4-5: Distribution of phosphopeptides and non-phosphopeptides in SCX fractions 
The total amount of LC-MS/MS-identified unique peptides for each fraction (6-35 
analyzed) is shown. Light blue bars correspond to non-phosphopeptides, while the blue 
ones represent identified phosphopeptides. For further analyses the resulting raw-files 
were merged.  
 
Furthermore, the number of phosphopeptides resulting from 2-dimensional Ga-
IMAC and SCX were compared to those, from samples not further fractionated. 
Indeed, SCX increased the number of identified unique phosphopeptides more 
than 2-fold up to approximately 1,400 (Figure 4-6). However, the number of 
fractions collected is limited by the time these samples need for measurement by 
LC-MS/MS as one fraction already takes about 150 min to be analyzed.  
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Figure 4-6: SCX increased the number of identified phosphopeptides 
Phosphopeptides from digested proteins were purified by Ga-IMAC and identified by LC-
MS/MS. Additional SCX fractionation after IMAC produced more identified unique 
phosphopeptides.  
 
Screening the resulting list of phosphorylated proteins revealed that many 
essential signaling components were identified by this method. For example, 
mitogenic protein kinases like NEK9 and some CDKs as well as survival-regulating 
kinases like ABL-2 were detected by their phosphorylated peptides. The 
motogenic response was shown by the phosphorylation of several PAKs and 
some activating proteins of the small GTPases like RHG29 and RHG32. Several 
of the antagonists of kinases in signaling, the protein phosphatases PP4R2 and 
PTN12, were also identified. Furthermore, the transcription factors BCLF1, TCF20, 
and TF3C1 were observed. All of these mentioned proteins have in common that 
they belong to the low abundance proteins (Beck et al. 2011). Thus, this workflow 
was sensitive enough to even detect phosphorylations of proteins that show a 
small copy number per cell.  
Taken together, the established workflow was able to extract a high amount of 
phosphopeptides out of 4 mg protein, enriched by Ga-IMAC and SCX. 
Remarkably, it provided access to many signaling components, and is therefore a 
suitable and sensitive method for the analysis of Met-dependent signaling.  
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4.2 Characterization of the physiological HGF/Met 
signaling 
4.2.1 HGF-activated Met signaling and scattering of DU145 cells 
Hepatocyte growth factor (HGF) was used to stimulate Met signaling in DU145 
cells. It was recombinantly expressed in CHO cells and purified by the Molecular 
Structural Biology Department of the HZI. To ascertain the purity and functionality 
of the protein, three different tests were performed. First, a small aliquot was 
applied on an SDS gel to check for contaminations with other proteins. Second, 
DU145 cells were stimulated with different concentrations of HGF and the 
phosphorylation response of known pathway components was investigated by 
immunoblotting. Finally, DU145 cells were stimulated with the different 
concentrations of HGF and monitored for increased motility.  
As described above, HGF was separated on an SDS gel with reducing sample 
buffer. As shown in Figure 4-7, elution fractions from SCX purification produced 
two bands of about 50 and a double band at 30 kDa, corresponding to the alpha 
and beta chains of the heterodimeric protein. A small portion of undigested pre-
HGF was detected as a light band of 80 kDa. As this precursor only occurred in a 
low concentration, it was supposed to not influence the stimulation. The most 
concentrated HGF-containing fractions 5-10 were pooled and stored at 4°C until 
usage.  
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Figure 4-7: Control of purified HGF 
HGF was recombinantly expressed in CHO insect cells and purified by affinity 
chromatography. Aliquots of the SCX fractions 1-14 were applied to an SDS gel, and 
stained with Coomassie brilliant blue. M: Precision Plus protein standard.  
 
Two further approaches with different HGF concentrations (0, 0.02, 0.2, 2, 20, 200 
nM) were carried out to determine the minimal concentration required for triggering 
Met signaling. The first experiment was designed as activity test for known 
phosphorylation sites downstream of Met. Therefore, cells were stimulated for 5 
min with different concentrations of the growth factor and then analyzed for the 
presence of phospho-Met (pT1234/pY1235), phospho-ERK1 (MK03, pT202/pY204) and 
phospho-ERK2 (MK01, pT185/pY187) with specific antibodies. As illustrated in 
Figure 4-8, the Met receptor as well as the MAP kinases ERK1 and ERK2 were 
activated at 0.2 nM HGF and higher. These results proved the ability of the 
recombinant HGF to stimulate a significant phosphorylation response in the Met 
pathway.  
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Figure 4-8: Activation of the Met pathway by HGF stimulation 
DU145 cells were stimulated for 5 min with indicated concentrations of HGF. Samples 
were analyzed by Western blotting with antibodies against phospho-Met (pY1234/pY1235) 
and phospho-ERK1 (pT202/pY204) and phospho-ERK2 (pT185/pY187). GAPDH served as 
control.  
 
Additionally, the ability of HGF to induce Met-dependent cell scattering (Humphrey 
et al. 1995) was tested. DU145 cells were stimulated with the same concentrations 
of HGF as for the phospho-specific immunoblot and monitored under a 
microscope after 24 h. Without HGF, DU145 cells grew in clusters, adherent to the 
surface of the dish. Stimulation with increasing concentrations of the growth factor 
up to 0.2 nM HGF resulted in increased motility (Figure 4-9, first row). Above 0.2 
nM, the scattering of cells decreased again, but no negative effects could be 
observed by microscopy (Figure 4-9, second row).  
Taken together, a concentration of 0.2 nM HGF is sufficient to trigger Met-induced 
signaling and for inducing a motoric response of DU145 cells. To ensure a reliable 
stimulation of the cells in the main experiments and because no negative effect 
was determined above, a HGF concentration of 2 nM HGF was chosen for further 
studies.  
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Figure 4-9: Activation of HGF-induced cell scattering 
100-fold magnification of DU145 cells stimulated for 24 h with indicated concentrations of 
HGF. Images were taken with a digital camera under a transmitted light microscope (see 
3.3.2).  
 
4.2.2 The HGF/Met-induced phosphoproteome 
Following the purity and functional activity of the HGF protein used for stimulation, 
main studies analyzing the HGF-induced phosphoproteome were performed. 
Therefore, activation of known pathway components after the chosen time points 
was checked first by immunoblotting with phospho-specific antibodies. Afterwards, 
all identified phosphopeptides were investigated concerning their functional 
classification as well as their composition of modified amino acids. Quantitative 
analysis of the different samples was performed subsequently. 
In order to investigate HGF/Met signaling, the cell line DU145 was selected, 
because it provides an accepted model system for Met and cancer studies 
(Johnson, Hershberger, and Trump 2002). As the peak of Met activation is at 5 
min and that of the MAP kinases at 15 min (Ozen et al. 2012), time points 3, 6, 
and 20 min were chosen for stimulation with HGF. A fourth sample, consisting of 
non-stimulated DU145 cells, served as a control. This time course ensured 
covering of very early as wells as sustained or late signaling events.  
0 nM HGF 0.02 nM HGF 0.2 nM HGF
2 nM HGF 20 nM HGF 200 nM HGF
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The workflow for these experiments was mainly as for the pre-experiments. 
Instead of serum, HGF was used for stimulation. In order to monitor the 
phosphorylation pattern over a time course, cells were stimulated for the three 
indicated time points and compared to non-stimulated cells. Furthermore, the 
samples were labeled with the four iTRAQ reagents in contrast to the non-tagged 
samples of the pre-experiments.  
DU145 cells were stimulated for 0, 3, 6, and 20 min with 2 nM HGF-HEPES in 
RPMI minimal medium. Stimulation was controlled using immunoblots, and the 
same amount of HEPES buffer in medium were applied to cells in parallel 
samples. Afterwards, the cells were harvested and lysed for phosphoproteome 
analyses. One aliquot of each sample was analyzed by immunoblotting for 
presence of phospho-Met (pT1234/pY1235), and phospho-ERK1 and 2 (alias MK03, 
MK01, pT202/pY204, pT185/pY187). As shown in Figure 4-10, cells treated with only 
buffer showed no phosphorylation of either Met or ERK1 and ERK2. Light bands 
could be found for phospho-Met, though, but it is rather typical background of the 
antibody. That is also true for the 0 min time point of the HGF-stimulated sample, 
which was also treated with buffer and displayed a light band for Met. Importantly, 
after 3 min with HGF, Met was activated at pY1234/pY1235, and the phosphorylation 
of the MAP kinases ERK1/2 was also induced after 3 to 20 min. These 
observations proved the successful stimulation of the HGF samples, which could 
afterwards be further processed to enrich phosphopeptides.  
 
Figure 4-10: Stimulation control for phosphoproteome analyses 
DU145 cells, either treated with HGF or with buffer in RPMI medium, were harvested, 
lysed and an aliquot was applied to SDS-PAGE and immunoblotted against phospho-Met 
(pT1234/pY1235) and phospho-ERK1, 2 (alias MK03, MK01, pT202/pY204, pT185/pY187). Actin 
served as loading control.  
Actin
pERK1,2
pMet
0min      3min      6min      20min 0min     3min  6min      20min
2 nM HGF in RPMI Buffer in RPMI
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After LC-MS/MS, peptide sequences were obtained from the distance between 
peaks in the resulting fragment ion spectra (three examples are depicted in Figure 
4-11). The mass difference between two peaks corresponds to the mass of the 
amino acids. In the same way, other modifications, like phosphorylations, could be 
detected. As the phosphate ion (PO4
3-) has a molecular weight of 80 Da, this 
modification causes a mass shift of the modified amino acid. However, serine and 
threonine phosphorylations are often eliminated during fragmentation, resulting in 
a 98 kDa loss of phosphoric acid (H3PO4). The remaining products are dehydro-
alanine for serine and dehydro-aminobutyric acid for threonine, with a specific 
mass of 69 Da and 83 Da, respectively. Tyrosine phosphorylations, however, are 
more stable due to the robust aromatic ring structure of the tyrosine side chain and 
can be confirmed via the characteristic immonium ion with a specific mass of 216 
Da. Thus, these characteristics enable the identification of the phosphorylation site 
within a peptide sequence.  
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Figure 4-11: Fragment ion spectra of phosphorylated peptides 
The mass difference between two peaks corresponds to the mass of one specific amino 
acid. If one is phosphorylated, it can be detected by a 80 Da shift. In the case of S/T 
phosphorylation, the elimination of phosphoric acid (-98 kDa) is frequently observed. In 
contrast, Y phosphorylation is very stable and does not eliminate phosphoric acid. 
Sequences are calculated from both sides: b ions (forwards, red) and y ions (backwards, 
blue). iTRAQ reporters can be found in the low mass range of the spectra. For 
identification, spectra were compared to theoretical computed ones of known protein 
sequences in the database UniProt. Examples for each of the three phosphorylation types 
at serine (A) pSSTVTEAPIAVVTSR of NEK9), threonine (B) 
EAGLELGPPAAQLpTPPPAPVGLR of RAVR1), and tyrosine (C) VDpYVVVDQQK of 
GAB1) are shown.  
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Summarizing all three biological and technical replicates, phosphoproteomics 
identified 7,996 different phosphopeptides corresponding to 2,592 proteins. These 
proteins were analyzed supported by StrAP to obtain Gene Ontology data (GO 
annotations, Figure 4-12) to get a global functional overview of the identified 
phosphorylated proteins. For 2,260 of the 2,592 proteins, localization information 
was available. With about 1,300 members, the most prominent portion of proteins 
was annotated in the nucleus. The second largest group localized in the 
cytoplasm. Additionally, more than 500 proteins were identified from different 
organelles like peroxisomes, mitochondria, endosomes, and ER. Of course, highly 
abundant ribosomal as well as cytoskeleton-associated proteins were also found 
in the phosphoproteome. Thus, the localization of the identified proteins reflected a 
representative distribution of proteins within the different cellular compartments. As 
signal transduction takes place mainly from the plasmamembrane to the 
cytoplasma into the nucleus and these groups were the three largest, this provided 
excellent conditions to analyze the Met signaling.  
2,153 phosphoproteins identified in this study were clustered according to their 
molecular function (Figure 4-12B). For 1,952 of them, interaction with other cellular 
component was known (“binding”) and 200 to 700 were described to have catalytic 
activity (“enzyme regulator activity”, “catalytic activity”). However, 75 were 
assigned to be part of signal transduction processes (“molecular transducer 
activity”). Thus, the majority were signal effectors, demonstrating the importance of 
this class of proteins.  
2,009 proteins of the dataset were assigned to biological processes (Figure 
4-12C). 227 play a role during development that is also affected by Met signaling. 
Importantly, 135 were already known to “respond to a stimulus” and might 
therefore be signal transducers or substrates of Met signaling. However, this 
number of proteins is very low compared to the response known for signaling 
processes and illustrates the lack of knowledge of proteins involved in signaling 
cascades like those induced by HGF/Met.  
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Figure 4-12: GO annotations of identified phosphoproteins 
All identified phosphoproteins were loaded into the software StrAP and annotated 
automatically by Gene Ontology. For cellular localization 2,260 of 2,592 identified proteins 
were annotated, for molecular function 2,153, and for biological process 2009 proteins.  
 
In addition to the functional overview of purified phosphoproteins, the 
characteristics of the corresponding peptides were further examined. As every 
serine, threonine, and tyrosine can be phosphorylated, peptides happen to carry 
multiple modifications at once. The majority, with more than 85% of identified 
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peptides, was phosphorylated at one site, while 13.9% carried two, and 0.4% even 
three phosphate groups (Figure 4-13). Several phosphorylation sites in close 
proximily to each other increase the effect on structural rearrangements of the 
proteins and offer more possibilities to regulate the protein through several layers 
in case of signal integration. The distribution of phosphorylated amino acids was 
very disparate. As only 0.9% was tyrosine, and 15.5% threonine phosphorylation, 
the most prominent proportion by far was modified serine with 83.6%. This ratio is 
consistent with other phosphoproteome studies (Olsen et al. 2006; Hunter and 
Sefton 1980) and validates the ability of this workflow based on Ga-IMAC to purify 
all three common types in human cells representatively.  
 
Figure 4-13: Composition of phosphopeptides 
A) All 7996 identified phosphopeptides were sorted according to their phosphorylation 
state. Single, double, and triple phosphorylations occurred in this study. B) The proportion 
of serine, threonine, and tyrosine phosphorylations of the identified peptides is shown.  
 
Normalization of the phosphopeptide regulation data was carried out to ascertain 
the comparability of the samples. For each of the three independent experiments 
and time points one boxplot was generated to check and compare the distribution 
of regulation factors in comparison to the non-treated control (Figure 4-14). All 
boxes located in the range of -0.3 to 0.3, with the median around 0. The 20 min-
sample of experiment 1 showed the broadest box, while experiment 2 after 6 min 
revealed the smallest one. Nevertheless, all boxes were located in the unregulated 
range between -0.5 and 0.5. Few extreme values occurred in different samples, 
but taken together, all boxplots exhibit similar patterns concerning their regulation 
factor distribution, which ensures that the samples were comparable.  
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Figure 4-14: Boxplot of samples after normalization 
Regulation factors for every experiment (E1-E3) and time point were normalized and their 
distribution was illustrated by boxplots. The line in the middle of the box represents the 
median, the box includes 50% of the data, and antennae show the 1.5-fold range of the 
box. Dots represent extreme regulation factors. The range between the two external dots 
corresponds to 100% of all identified regulation factors for one sample.  
 
4.2.3 Quantitative analysis of time-resolved HGF/Met signaling 
So far, the whole identified phosphoproteome after HGF stimulation was regarded. 
In the next step, quantitative analysis was performed with the non-stimulated 
sample as control to calculate regulated phosphopeptides in response to HGF. 
Furthermore, the regulated peptides were not only separated into up and 
downregulated, but were also clustered more detailed according their 
phosphorylation dynamics over the time course.  
Of 8,000 phosphopeptides detected in three replicates, 2,311 were identified 
reproducibly in all three replicates. Only these were taken into account for the 
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extraction of significantly regulated phosphopeptides from the regulation factors 
calculated from the iTRAQ reporter ion intensities.  
For quantitative comparison of the different samples of the HGF time course, the 
peptides had been labeled with the iTRAQ reagent. During MS/MS, the four 
iTRAQ reporters were split from its associated peptide and detected in the low 
mass range at 114, 115, 116, and 117. The relative intensities of the iTRAQ ions 
represent the amount of the corresponding peptide in one sample compared to the 
control. This analysis was supported by the in-house bioinformatics tool 
iTRAQassist. Figure 4-15 shows one peptide spectrum of the Met adapter protein 
GAB1 including all four iTRAQ reporters in the low mass range as an example. 
Based on the reporter intensities, less peptide occurred in the control, while it 
increased until 6 min HGF stimulation and decreased after 20 min. Supported by 
the software iTRAQassist, the intensities of all identified peptides were processed 
and the corresponding regulation factors were calculated.  
 
Figure 4-15: Regulation analysis with iTRAQ 
The intensities of the iTRAQ reporters reflect the ratio of peptides in the different samples. 
Spectrum of the peptide VDpYVVVDQQK of the adapter protein GAB1 is shown here. The 
low mass range between 113 and 118 Da is enlarged to illustrate iTRAQ reporters of the 
samples. 114.1: unstimulated control, 115.1: 3 min HGF, 116.1: 6 min HGF, 117.1: 20 min 
HGF.  
 
For the calculation of significantly regulated phosphopeptides, a normal 
distribution was supposed and multiple testing was utilized. Based on that, a 
theoretical threshold was calculated, which should be exceeded at one time point 
in all three replicates. Those peptides considered significantly regulated exhibited 
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a p-value below 0.05 and correlated with a log2 RF threshold of at least +/-0.5 in all 
three replicates, which is consistent with other proteome studies using iTRAQ. 
Furthermore, regulated peptides were additionally validated by checking their 
MS/MS spectra and their Interval of Robustness (calculated by iTRAQassist, 
section 3.6.10), which measures the reliability of a given regulation factor.  
According to these criteria, 95 phosphopeptides were found to be significantly 
regulated at least at one time point of HGF stimulation (Figure 4-16, and appendix 
Table 8-1). These peptides corresponded to 80 proteins. Interestingly, 82 
phosphopeptides exhibited a positive regulation, in contrast to only 13 peptides 
being downregulated. Furthermore, 19 phosphopeptides were regulated after 3 
min, 36 after 6 min, and even 81 after 20 min, demonstrating the broadening of the 
signal network over time. The heatmap clearly depicts the diverse regulation 
patterns of the phosphorylated peptides. While some phosphopeptides were 
regulated throughout, others displayed significant regulation only at one or two 
time points. Furthermore, the regulation factors of one peptide often slightly 
differed from each other within the triplicate. This clearly illustrated the fast and 
transient characteristic of these modifications, which resulted in shifted 
phosphorylation dynamics. 
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Figure 4-16: Heatmap of all HGF-regulated phosphopeptides 
Regulation factors of significantly regulated peptides were illustrated as heatmap with 
Java Treeview. Peptides are shown in rows and the samples in columns. The color code 
illustrates regulation factors in log2 scale. Red boxes indicate upregulated, green 
downregulated, black non-regulated, and grey missing values. P-Site: phosphorylation 
site.  
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Each regulated peptide in every replicate exhibited a characteristic regulation 
behavior over the three different time points. Nevertheless, the phosphopeptides 
could be clustered according to their dynamics. Supposing 4 regulation factors per 
peptide (one for 0, 3, 6, 20 min each), clustering was performed depending on the 
order of absolute values of the regulation factors. This resulted in 24 possible 
clusters. For example, a peptide phosphorylated gradually over time exhibited the 
order 1<2<3<4 (in short: ord1234), with the lowest value after 0 min, and the 
highest after 20 min. In contrast, a phosphopeptide increasing until 6 min and then 
decreasing until 20 min might have the order 1243 and so forth. Importantly, those 
peptides being clustered together displayed a similar phosphorylation behavior 
and thus, were regulated in the same manner in response to HGF. Similar 
regulation therefore indicated the participation in the same biological process and 
might also hint at the regulation by the same upstream kinase subset.  
Of the 24 possible clusters, the four orders 2341, 2431, 3412, and 4213 were not 
reflected by any regulated phosphopeptide in this study. This is not surprising 
since these dynamics are very inconsistent over time. As some of the remaining 
20 clusters showed very similar regulation dynamics , these were further combined 
in a second step. As indicated by the representative schemes 1-4 in Figure 4-17 
and Figure 4-18, phosphorylations were regulated either early, or late, constant, 
oscillating, or in between. This second “clustering” was only supposed to clarify the 
distinct phosphorylation dynamics and sometimes is ambiguous as several options 
may be possible (Figure 4-17, Figure 4-18). An overview of which phosphorylation 
sites was integrated in which cluster is illustrated in Table 8-2 and Table 8-3 in the 
appendix.  
Most strikingly, more than 50% of the regulated peptides concentrated in the 3 
clusters ord1234 (Figure 4-17 F), ord1243 (Figure 4-18 A), and ord2134 (Figure 
4-17 G). Thus, the three large clusters seem to be common phosphorylation 
dynamics of peptides in response to HGF.  
Furthermore, peptides regulated early were almost exclusively upregulated and 
also stayed regulated over time. Thus, the majority of early responders was sorted 
into the cluster with constant behavior (Figure 4-18 A+B), while 7 phosphopeptides 
(Figure 4-17 A-C) were only upregulated after 3 min. Among the group of 
phosphopeptides only regulated early were all three peptides of the functionally 
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uncharacterized protein NCK5L modified at pS473. The sites pY659 of the Met 
adapter GAB1, pY204 of the kinase MK03, and pS458 of the membrane-bound 
adapter CD2AP were upregulated with a maximum after 3 min HGF, but still 
stayed slightly regulated until 20 min (Figure 4-17 D). In contrast, gradually 
upregulated phosphorylation sites included pS1124 of Rac1-GAP RHG05, pS137 of 
the actin-membrane linker PAXI, and pS1000 of the cytoskeleton-associated protein 
NAV1. Additionally, pS448 of the E3 ubiquitin ligase NED4L, pS609/pS613 of the 
uncharacterized protein K0802, and pS897 of the receptor tyrosine kinase EPHA2 
were sorted into this group of late upregulated responders (Figure 4-17 F-H). In 
comparison, late downregulated phosphopeptides were pS2449, as well as pS284 
and pS941 on cytoskeleton-associated proteins APC, JAM1 and MAP4, 
respectively (Figure 4-17 I-J).  
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Figure 4-17: Phosphopeptides regulated early and late in response to HGF 
Regulated phosphopeptides were clustered according to their rate of regulation over time. 
Phosphopeptides with maximal regulation after 3 min (early) and after 20 min (late) are 
illustrated. Clusters were generated corresponding to the orders A) ord4132, B) ord3142, 
C) ord4312, D) ord1432, E) ord2413, F) ord1234, G) ord2134, H) ord2314, I) ord4321, J) 
ord4123 ,where the first value reflects the lowermost and the last represents the topmost 
regulation in the time course. The clusters 1-4) are representatives for each group of 
regulated phosphopeptides and mark the time point of maximal regulation. Connecting the 
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values of one phosphopeptide was only used for better illustrating the dynamics. Of 
course, it is not known what happened to the phosphopeptides between the time points. 
See Table 8-2 in the appendix for information, which phosphorylation site was integrated 
in which cluster.  
 
Three phosphopeptide clusters exhibited sites that were upregulated almost 
immediately after HGF stimulation and maintained there until 20 min (Figure 4-18 
A-C). Among them were pT185/pY187 and pT202/pY204 of the MAP kinases MK01 
and MK03, respectively, as well as pT246 of the AKT1 substrate AKTS1. 
Furthermore, pS1146 of the nuclear protein WIZ and pS2116 of the nuclear pore 
complex protein TPR were clustered together. Furthermore, the constant 
upregulated phosphopeptides included also the sites pS541 and pS1089 of the 
uncharacterized proteins CS021 and DEN4C.  
On the contrary, the next group of phosphorylation sites was not constantly 
regulated, but showed oscillating modification (Figure 4-18 D-F). Among the 
upregulated sites after 3 and 20 min were pS839 of the E2 ubiquitin conjugase 
UBE2O and pT306 of the adhesion protein ZYX. Furthermore, the sites pS132/pS137 
and pS672 of the uncharacterized proteins DEN4C and NOC2L also showed this 
dynamics. However, phosphorylation sites that were regulated inconstantly 
included pS95 of the transcriptional regulator CBX3 and pS768 of the 
deubiquitinating enzyme VCIP1 (Figure 4-18 G).  
Additionally, phosphopeptides that were significantly regulated only after 6 min 
were almost not identified. Nevertheless, all three peptides of the signaling protein 
BCL9L modified at pS21 exhibited this dynamics (Figure 4-18 H-J).  
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Figure 4-18: Phosphopeptides with other dynamics in response to HGF 
Cluster of regulated phosphopeptides with different dynamics than early and late 
response. Shown are phosphopeptides regulated constantly over the time points, 
oscilliating and those with a maximum after 6 min. Clusters were generated corresponding 
to the orders A) ord1243, B) ord1423, C) ord2143, D) ord1342, E) ord1324, F) ord3124, 
G) ord4231, H) ord3421, I) ord3241, J) ord3214, where the first figure reflects the 
lowermost and the last represents the topmost regulation in the time course. The clusters 
1-4) are representatives for each group of regulated phosphopeptides and mark the time 
point of maximal regulation. Table 8-3 in the appendix shows, which phosphorylation site 
was integrated in which cluster. 
 
While most of the 95 phosphopeptides were only regulated at one or two time 
points, some peptides were significantly regulated throughout. Examples among 
the 9 allover regulated phosphorylation sites were known components like 
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pT185/pY187 of MK01, but also novel like pT246 of AKTS1, pS2233 of FLNC, and 
pT2116 of TPR. The permanent regulation indicates that they are particular 
important signaling components downstream of HGF/Met.  
All differentially regulated phosphopeptides comprised 101 phosphorylation sites 
as some peptides exhibited double phosphorylations. Comparing the regulated 
phosphorylation sites with the current phosphorylation databases 
PhosphoSitePlus and PhosphoNet uncovered that the majority of sites were 
known but not functionally characterized. However, the sites pS720 of AKAP2, and 
pS343 of CMIP were not listed in the databases and are thus novel identifications 
(Figure 4-19).  
 
Figure 4-19: Regulation dynamics of novel phosphorylation sites 
Screening all regulated phosphorylation sites in the databases PhosphoSitePlus and 
PhosphoNet revealed these two sites of AKAP2 and CMIP as novel. The graphs A) and 
B), illustrate their phosphorylation dynamics in response to 3, 6, and 20 min of HGF. Each 
curve corresponds to the phosphopeptide identified in one of the three replicates (E1-E3). 
 
In contrast, for 9 regulated phosphorylation sites, further information was available 
in the databases (Table 4-1). For example, pT/pY double phosphorylations of the 
MAP kinases MK01 and MK03 increase their enzymatic activity. The site Y659 of 
the adapter protein GAB1 is known to trigger cell proliferation in response to 
growth factors. Furthermore, the novel component AKTS1 was phosphorylated at 
T246 that is known to be caused by AKT1, one of the key players in growth factor 
signaling. All these components confirmed the activation of the HGF/Met cascade.  
Additionally, the physiological effects of signaling could also be monitored by the 
differential modification of several novel Met pathway candidates. For example, 
pS25 of STMN1 is responsible for rearrangements of the cytoskeleton during cell 
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cycle progression. Furthermore, pS886 of ARHG2 recruits the protein to 
microtubules where it is able to activate Rho GTPases. SGK1 phosphorylates S448 
of the E3 ubiquitin ligase NED4L and thus, changes its binding preferences from 
inhibiting SCNNA to 14-3-3 proteins. It is also known that pS284 of the tight junction 
protein JAM1 alters its cellular localization. Phosphorylation of pS897 of the EPHA2 
receptor by AKT1 influences cell motility.  
 
Table 4-1: Regulated phosphorylation sites with known function 
HGF-regulated phosphorylation sites were matched with entries in the databases 
PhosphositePlus and Phospho.NET. For those listed here, further functional 
characterization was provided. P-Site: phosphorylation site. Regulation direction for every 
time point is indicated by arrows.  
Protein P-Site Regulation 
(3, 6, 20 min) 
Upstream 
Kinase 
Function / effect  
of P-Site 
AKTS1 T246 ↑↑↑ AKT1 Interaction with 14-3-
3β 
MK01 T185/Y187 ↑↑↑ MEK1, JAK2 Activity, signal 
transduction 
MK03 T202/Y204 ↑↑↑ MEK1+2, JAK2 Activity, signal 
transduction 
GAB1 Y659 ↑↑→ EGFR, InsR Cell cycle regulation 
NED4L S448 →↑↑ SGK1 Activates SCNNA 
STMN1 T25 →↑↑ CDK1, PKCB Cytoskeleton 
reorganization 
ARHG2 S886 →→↑ PAK1 Relocalization of 14-3-
3 to microtubules 
EPHA2 S897 →→↑ AKT1 Motility regulation 
JAM1 S284 →→↓ PKCA Relocalization 
 
Proteins that exhibited regulated phosphorylation sites were further analyzed by 
GeneGo to get an overview of the HGF-affected processes. Mapping the 
experimental data onto canonical pathway maps revealed mainly cascades 
triggering cell adhesion, development, and cytoskeleton reorganization. Only 6 of 
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the 80 identified phosphoproteins could be integrated, because the majority was 
not present on the canonical pathway maps.  
However, functional data was available for 71 differentially phosphorylated 
proteins. These were classified according to their task in signaling or as substrates 
to uncover affected mechanisms in the cell. The first group comprised the 
signaling molecules. As part of these, the serine/threonine protein kinases MK01 
and MK03, and the receptor tyrosine kinase EPHA2 have been identified. As 
protein phosphatases, MTMR3 and tyrosine phosphatase PTN12 were found. The 
regulated dataset also included the signaling adapter proteins GAB1, AHNK, 
AKP13, and P85B. Signaling via small GTPases was also influenced by HGF 
stimulation. The GAPs RHG05, RGPH1, and RB3GP, as well as the GEFs 
ARHG2, ARHGI, and PSD3 displayed significantly regulated phosphopeptides. 
The deubiquitinating enzymes also take part in signaling and were represented by 
one regulated phosphorylation site of VCIP1. The second group consisted of 
signaling substrates. The transcription factor ELYS was found to be 
phosphorylated after HGF treatment. The function of the site is unknown, but it is 
likely that this phosphorylation influences the protein’s transcription activity in 
response to HGF. Other differentially phosphorylated nuclear proteins have also 
an effect on transcriptional progression (e.g. PCIF1, BCL9L, CBX3) or support the 
cytoplasma-nucleus transport (e.g. TPR). Other acceptors of signaling are proteins 
that, once phosphorylated, directly affect cellular processes. For example, 
adhesion-associated proteins like AFAD, ZYX, and JAM1 appeared to be modified 
here. Cytoskeletal proteins like FLNC, PLEC, TENS3, PAXI, PALLD, APC, and 
CD2AP are likely to be involved in HGF-mediated migration or proliferation as well 
as receptor internalization. In the dataset, ubiquitin ligases were regulated via 
phosphorylation, which mediates degradation and thus stops signaling via 
ubiquitin-labeled proteins. Here, E3 ubiquitin ligase NED4L, and E2 ubiquitin 
conjugase UBE2O were found with one regulated phosphorylation site each.  
4.2.4 The role of EPHA2 in HGF/Met signaling 
The EPH receptor family is the largest group in tyrosine kinase-mediated signaling 
(Bush and Soriano 2012). The family member EPHA2 can be activated by its 
ligands Ephrin A1, A2, A3, A4, A5, and A6 and is involved in angiogenesis, 
74 4 Results 
branching morphogenesis, and epithelial proliferation. Deregulated EPHA2 is 
known for many cancer types, both, as tumor inhibitor, and accelerator, which is 
supposed to be mediated by the presence and absence of its ligand (Miao and 
Wang 2012; Pasquale 2008).  
Interestingly, the site pS897 of EPHA2 was identified in this study by 
phosphoproteomics to be regulated after HGF stimulation (Figure 4-20). The 
phosphorylation of this site increased gradually in the first 20 min after HGF. As 
EPHA2 is also regulated ligand-independently, this phosphorylation confirmed a 
receptor crosstalk between Met and EPHA2. Therefore, the receptor tyrosine 
kinase became an interesting candidate for studying the role of EPHA2 in Met-
dependent signaling. 
 
Figure 4-20: Phosphorylation dynamics of pS897 of EPHA2 in response to HGF 
Phosphoproteomics revealed a modified and gradually increasing phosphorylation of this 
site of the receptor tyrosine kinase EPHA2 in the first 20 min after HGF/Met-activation. 
Curves E1- E3 represent the three replicates.  
 
First of all, EPHA2 knockdown was established and different siRNAs were tested 
for adequate efficiency. Afterwards, gene expression dependent on HGF 
stimulation in DU145 wildtype cells was investigated in order to check for proof-of-
concept data. Finally, the influence of EPHA2 knockdown on HGF-stimulated gene 
expression was studied in detail. Therefore, genes affected by the EPHA2 
knockdown were compared to the HGF/Met transcription response in wildtype 
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cells in order to determine important HGF/Met-regulated genes that are controlled 
by EPHA2.  
In order to investigate a potential EPHA2-dependent Met response, EPHA2 
knockdown was established in DU145 cells, and gene expression was compared 
to the wildtype. In order to exclude off-target effects of the siRNA, two different 
sequences were used separately to create the knockdown; one binding to the 5’ 
region (siRNA5) and the second one aiming at the 3’ end (siRNA7) of the EPHA2 
mRNA. Furthermore, a nonsense siRNA control was added as fourth sample to 
exclude site effects due to the transfection reagents besides the siRNAs. All four 
samples were stimulated with HGF and were compared to their unstimulated 
counterparts. Moreover, two different time points for the stimulation with HGF were 
selected to cover immediate as well as later gene expression and compared to the 
unstimulated control. After 1 h, first transcripts of HGF/Met signaling were 
supposed that could provide information of induced upstream pathways. The 
transcripts of regulators of the cellular response were thought to be produced after 
4 h of HGF stimulation. Thus, in total, 12 different samples were analyzed by a 
microarray in triplicate.  
Before considering the gene expression, an immunoblot against activated Met and 
the EPHA2 protein in all samples was performed as a control. Afterwards, genes 
regulated by HGF in the wildtype were determined to check the HGF/Met 
response for known targets and ensure a physiological effect of stimulation. Only 
after all these necessary controls were considered, the actual influence of EPHA2 
knockdown on the HGF/Met-induced gene expression was analyzed.  
As described above, aliquots of the samples for the microarray were first analyzed 
by immunoblot to ensure an efficient EPHA2 knockdown by each of the siRNAs 
and a sufficient stimulation of Met by HGF stimulation. Figure 4-21 A shows this 
immunoblot of all samples analyzed in the microarray. Met’s activation loop was 
phosphorylated on pY1234/pT1235 after 1 h HGF stimulation, and still slightly after 4 
h. Importantly, Met was not affected by the EPHA2 knockdown. Furthermore, 
EPHA2 was detected equally in the wildtype and nonsense samples, while the 
protein concentration was lower in the siRNA-treated samples. Noteworthy, 
knockdown by siRNA7 was more efficient than by siRNA5. Quantification of the 
EPHA2 bands of the immunoblot clearly demonstrated a reduction of EPHA2 
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protein in the samples treated with siRNA (Figure 4-21 B). The amount of EPHA2 
protein was decreased down to 60% through siRNA5 and to 33% through siRNA7 
compared to the wildtype. Thus, knockdown mediated by siRNA7 was almost 2-
fold more efficient than that of siRNA5.  
 
Figure 4-21: EPHA2 knockdown efficiency in microarray samples 
A) Immunoblot against phospho-Met (pY1234/pT1235) and EPHA2 showing Met activation 
and EPHA2 knockdown efficiency in samples used for the microarray. DU145 cells were 
treated with nonsense (NS) RNA, EPHA2 siRNA5 (si5), or EPHA2 siRNA7 (si7) and were 
stimulated for 1 h and 4 h with 2 nM HGF. These samples were compared to non-
stimulated cells, which serve as a control. B) Quantification of the EPHA2 protein 
intensities calculated from the EPHA2 bands on the immunoblot. Shown is the mean of 
the three samples each (for - HGF, 1 h HGF, 4 h HGF). The histogram proves the 
successful knockdown of EPHA2 and illustrates the different EPHA2 knockdown 
efficiencies by the two siRNAs.  
 
Using an Agilent chip, expression of more than 41,000 genes from three 
biologically independent experiments were compared. The nonsense siRNA 
control exhibited comparable behavior as the wildtype, ensuring no side effects of 
the transfection besides the siRNAs. Therefore, siRNA-treated samples could be 
compared directly to the wildtype. Only genes regulated in all three replicates 
more than 2-fold were considered. The usual threshold of 5-fold for gene 
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expression analyses could not be applied here, because it resulted in a very low 
amount of regulated genes. This might be due to the comparatively early time 
points for the analysis of transcripts in this experiment (compared to NEK9 study, 
section 4.2.5).  
First, genes regulated in the DU145 wildtype during HGF stimulation compared to 
non-stimulated cells were considered to reveal proof-of-concept data. After 1 h 
HGF, 656 genes were affected, and 1,072 after 4 h. Each list was evaluated with 
the help of GeneGo to detect genes that are known to be influenced by HGF/Met 
and therefore serve as proof-of-concept. Genes corresponding to transcription 
factors EGR1, EGR3, FOSB, and JUNB as well as the receptor LDLR were clearly 
upregulated at the first time point. Later, genes of integrin ITA2 and transcriptional 
regulator SOX9 were also induced. No further genes as these 7 were found that 
were regulated in the wildtype and are listed in GeneGo to be known as targets of 
HGF and Met. This is perhaps due to the fact that data in GeneGo also refers to 
other cell lines or even different organisms. However, there were no genes in the 
dataset disagreeing with former data, by either being regulated in the opposite 
direction as described, or being unregulated but should be regulated according to 
literature. Additionally, GeneGo (using the tool “Which are the key transcription 
factors and target genes in my data”) supported the identification of transcription 
factors that led to the expression of genes regulated in this dataset. Noteworthy, 9 
of 31 known transcription factors for HGF and Met were retrieved - amongst them 
prominent ones like JUN, MYC, and STAT3, but also cell-cycle regulating E2F1 
and developmental factor SOX9. These results proved the activation of the 
HGF/Met-dependent gene expression machinery.  
To answer the question whether there is an EPHA2-dependent Met signaling after 
HGF stimulation, growth factor regulated genes of DU145 wildtype were compared 
to those regulated by HGF in EPHA2-knockdown cells (Figure 4-22). Therefore, 
only genes behaving the same in the two knockdown samples siRNA5 and 
siRNA7 in response to HGF stimulation were considered. The knockdown through 
siRNA7 was more efficient (Figure 4-21) than that of siRNA5. Therefore, genes 
were considered as regulated if they exhibited a fold change more than 2-fold in 
the siRNA7 sample, compared to the wildtype, and were regulated in the siRNA5 
sample at least in the same direction.  
78 4 Results 
 
Figure 4-22: Strategy to uncover EPHA2-dependent effect on HGF/Met-response 
First, genes regulated by HGF in the wildtype were extracted. Second, genes affected in 
both EPHA2 siRNAs (5 and 7) by HGF were calculated and those regulated similarly (see: 
=) were selected. Finally, ratios between regulation values of wildtype (WT) and EPHA2 
knockdown (KD) were computed to identify genes that are regulated by EPHA2 in 
response to HGF. Because the knockdown of siRNA7 was more efficient, this was 
preferentially considered. As a regulation threshold, a fold change of +/-2 was considered 
each time. This procedure was done for both time points: after 1 h and 4 h of HGF 
stimulation.  
 
70 genes behaved differently in wildtype and both types of EPHA2 knockdown 
cells in response to HGF (Figure 4-23). After 1 h of stimulation, 44 genes were 
affected, with a majority of 91% being upregulated in the knockdown. 
Correspondingly, after 4 h, 31 genes were affected of which 74% were 
upregulated. Conversely, this indicates for the wildtype that most gene expression 
is usually inhibited or decreased by EPHA2 in DU145 cells during HGF 
stimulation.  
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Figure 4-23: Heatmap of EPHA2-regulated genes during HGF stimulation 
Two different siRNAS against EPHA2 were used for EPHA2 knockdown. Genes regulated 
by HGF in DU145 wildtype and knockdown cells were compared. The fold change 
between these two values is illustrated as boxes, respectively. A) 44 genes regulated in 
the EPHA2 knockdown compared to WT after 1 h HGF. B) 31 genes regulated in EPHA2-
knockdown with WT as basis after 4 h HGF. C) Legend for fold change regulation factors. 
Upregulated values are red, while downregulated are green. Si5: EPHA2-siRNA5, si7: 
EPHA2-siRNA7, WT: wildtype DU145.  
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To figure out, which genes in the important HGF/Met response are affected by 
EPHA2, the 70 genes differentially regulated in knockdown and wildtype were 
matched with genes top-regulated in the wildtype. Importantly, 13 of the 70 genes 
were highly regulated in the wildtype and appear to be particularly under the 
control of EPHA2 (Figure 4-24).  
After 1 h HGF stimulation, 7 regulated genes were affected by EPHA2 knockdown 
during HGF stimulation. All of them are so called “immediate-early genes” (IEGs) 
and they were upregulated in the wildtype in response to stimulation, but even 
more in the EPHA2 knockdown (Figure 4-24 A). Only two of them, namely EGR1 
and Fos, are known transcriptional targets of HGF/Met. IEGs usually respond to 
different kinds of signals by rapid and transient induction. Many of them - like here 
egr1-4 and fos - are encoding transcription factors. Their transcription is usually 
very low but they get activated within minutes after transcription (Tullai et al. 2007; 
Sukhatme 1990).  
In comparison, after 4 h HGF stimulation, only 3 genes are up- and 4 
downregulated in an HGF- and EPHA2-dependent manner (Figure 4-24 B). EGR4 
is still activated, though not as strong as after 1 h. Furthermore, the potassium 
channel KCNK12 is highly upregulated in the wildtype, while in EPHA2 knockdown 
it is only slightly affected. This protein has not been implicated in growth factor 
receptor signaling so far. NPY5R (neuropeptide Y receptor Y5) is downregulated 
in the wildtype and upregulated in the EPHA2 knockdown, which means that 
EPHA2 strongly limits its expression in DU145 cells in response to HGF. 
Furthermore, SPSB4 is more upregulated in wildtype than in the EPHA2 
knockdown and the protein is able to bind Met (Wang et al. 2005).  
Three further regulated genes, c12orf67, c5orf58, and c14orf105, and their 
corresponding protein products CL067, CE058, and CN105 have not been 
described functionally so far. The first two are upregulated about 8-fold in the 
wildtype, but only 3-fold in the EPHA2 knockdown. The latter one is downregulated 
8-fold in the wildtype, but only 3-fold in the EPHA2 knockdown samples. 
Obviously, those proteins are expressed in response to HGF and are influenced 
by the EPHA2 knockdown.  
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Figure 4-24: Regulation profiles of EPHA2- and HGF-dependent genes 
Illustrated genes are part of the main HGF expression response in the wildtype and are at 
least 2-fold influenced by EPHA2. Fold changes are encoded by colored boxes of a 
heatmap, where red is upregulated and green is downregulated. A) shows 7 regulated 
genes after 1 h HGF stimulation and B) the affected genes after 4 h HGF. The color code 
of the boxes is illustrated below heatmaps. WT: DU145 wildtype; KD: EPHA2 knockdown, 
realized with two different siRNAs: 5 und 7.  
 
4.2.5 The kinase Nek9 in HGF/Met signaling 
The protein kinase NEK9 belongs to the NIMA family of cell cycle regulators (Roig 
et al. 2002). Previous work identified NEK9 as part of the Met-dependent signaling 
as it was phosphorylated at pT333 after 4 min of InlB stimulation (Reinl et al. 2009). 
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Since HGF/Met triggers proliferation and NEK9 was known to be a mitotic kinase, 
a role of NEK9 in physiological signaling was apparent.  
Indeed, in this study, the site pT333 of NEK9 was regulated after HGF stimulation 
(Figure 4-25). The phosphorylation was identified in only one of three replicates 
(E3), probably due to the absence of a kinase-specific enrichment step in this 
phosphoproteome workflow in contrast to Reinl et al., 2009. Nevertheless, pT333 of 
NEK9 was identified clearly with a peptide score of 57 and exhibited a maximum 
regulation factor of 1.3 in log2 scale after 6 min HGF.  
 
Figure 4-25: Dynamic regulation of pT333 of the kinase NEK9 after HGF stimulation 
The log2 regulation factors of NEK9 pT
333 after HGF stimulation for 3, 6, and 20 min of 
DU145 cells is illustrated for replicate 3 (E3). The phosphopeptide was not found in 
replicates 1 and 2 (E1, E2).  
 
As Met regulates proliferation and NEK9 plays a role in mitosis, a liekly function of 
the kinase NEK9 in the HGF/Met response should be investigated. Therefore, 
different siRNAs against NEK9 were tested to establish an efficient NEK9 
knockdown. After that, the effect of the NEK9 knockdown during HGF stimulation 
was characterized by proliferation and motility assays. In order to investigate its 
influence on the transcription of HGF/Met target genes, gene expression analysis 
was performed next. Proof-of-concept data of HGF-affected genes in the HeLa S3 
wildtype were tested first to confirm physiological response. Afterwards, genes 
regulated by NEK9 knockdown during HGF stimulation were calculated to 
investigate the role of NEK9 in HGF/Met-induced gene regulation.  
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In order to test siRNAs for their NEK9 knockdown efficiency, two different 
sequences against the NEK9 mRNA were used either separate or in combination. 
While the siRNA5 binds to the middle region of the NEK9 mRNA, the siRNA7 aims 
at the first third of the 5’ end. The resulting knockdown was monitored by 
immunoblotting against NEK9. Figure 4-26 shows the immunoblot against Nek9 in 
the Hela S3 wildtype and in the siRNA-treated samples. While a clear band was 
visible in the wildtype cells, the separate siRNAs provided a NEK9 knockdown of 
about 80% each. However, the knockdown efficiency was further increased by the 
combination of both siRNAs to over 90%. In order to ensure efficient NEK9 
knockdown, all characterization studies on NEK9 were therefore performed with 
both siRNAs in combination and compared to the wildtype.  
 
Figure 4-26: Knockdown efficiency of NEK9 siRNAs 
HeLa S3 cells were treated with siRNA5 and 7, separate and combined, against NEK9 in 
order to test knockdown efficiency. The expression of NEK9 was compared with the 
wildtype 72 h after transfection and actin served as loading control.  
 
As mentioned above, NEK9 was annotated as a mitotic kinase. Therefore, a 
proliferation assay (MTT assay) was performed in a cell line that was known to 
respond HGF/Met rather with proliferation than with scattering as DU145 does. 
Thus, HeLa S3 cells were transfected with the two siRNAs against NEK9 in 
combination and were compared to non-transfected cells. The subsequent 
proliferation was documented over 6 days in response to HGF stimulation in 
comparison to non-stimulated cells. During the first 72 h, no significant proliferation 
could be observed for all samples (Figure 4-27). After 96 h and 120 h, all cells had 
increased in number as indicated by a higher absorbance at 595 nm due to a 
larger amount of formazan produced by living cells. HGF stimulation in wildtype 
and NEK9 knockdown samples had a positive effect on proliferation, although non-
WT     siRNA5   siRNA7   siRNA5+7
NEK9
Actin
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stimulated cells also exhibited a small increase in number. Even though the effect 
of HGF was similar in wildtype and knockdown cells, the total amount of cells in 
the NEK9 knockdown was overall 50% smaller. This could be due to increased cell 
death after transfection with siRNA against NEK9. Taken together, NEK9 
knockdown did not affect the responsiveness of HeLa S3 cells in proliferating after 
HGF stimulation.  
 
Figure 4-27: Influence of NEK9 on proliferation of Hela S3 cells in response to HGF 
The effect of NEK9 knockdown via two siRNAs and stimulation with 2 nM HGF was 
monitored over 168 h. Absorption of living cells was detected by staining with MTT and 
subsequent measurement at 595 nm. WT: wildtype Hela S3; NEK9: NEK9 knockdown 
cells; combination of two siRNAs used for efficient knockdown.  
 
To further examine the role of NEK9 in HGF/Met signaling, HeLa S3 and DU145 
cells transfected with the two NEK9 siRNAs were tested on their migration 
behavior in response to HGF. Wildtype DU145 cells without HGF formed compact 
clusters on the surface of the petri dish (Figure 4-28). Treatment with either NEK9 
or nonsense siRNA revealed less cell-cell contacts. This phenotype was possibly 
caused by dying of several cells in the clusters throughout the treatment. Once 
stimulated for 18 h with HGF, all samples exhibited a scattered phenotype as 
expected for the motile DU145 cell line. A difference regarding motility between 
wildtype and NEK9 knockdown was not detected for DU145 cells. 
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Figure 4-28: Effect of NEK9 knockdown on DU145 cells 
DU145 wildtype, NEK9 knockdown, and nonsense-treated cells were stimulated for 18 h 
with 2 nM HGF and screened for morphological changes in comparison to the non-
stimulated control.  
 
Without stimulation, wildtype HeLa S3 cells grew in close clusters (Figure 4-29). 
As for DU145, some cells died during siRNA treatment, resulting in less compact 
clusters. Wildtype and nonsense-treated cells behaved similar after 18 h of HGF 
stimulation. Surprisingly, HeLa cells with NEK9 knockdown and HGF in 
combination displayed an impressive scatter phenotype. The cell-cell contacts 
have been abrogated, and the cells were released from the clusters. Furthermore, 
the cells spread in every direction, thereby changing their globular morphology into 
a stretched ellipsoid shape with long, thin filopodia in the front and rear. Usually, 
this cell line is proliferating after HGF/Met-induction and is not known to respond 
growth factor stimulation with scattering. Therefore, this monitored motile 
phenotype of HeLa S3 cells with NEK9 knockdown is novel and very remarkable.  
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Figure 4-29: Effect of NEK9 knockdown on HeLa S3 cells 
NEK9 or nonsense siRNA transfected and wildtype HeLa S3 cells were stimulated with 2 
nM HGF. After 18 h, they were screened for phenotypic alterations by monitoring the cells 
under a microscope.  
 
Based on the previous observation that NEK9 knockdown dramatically effects 
motility of HeLa S3 cells, a gene expression array with these cells was performed 
to investigate whether NEK9 participates in gene regulation or directly controls 
signaling components to result in such an intense phenotypic alteration. For that, 
wildtype HeLa S3 cells were compared to cells treated with the two NEK9 siRNAs 
in combination. Furthermore, a nonsense siRNA was added as third sample to 
exclude side effects of the transfection reagent. Each sample was either 
stimulated for 18 h with HGF or left unstimulated. In total, two replicates were 
performed in order to ensure reproducibility.  
First of all, gene expression data of the two replicates should be compared and 
only those genes regulated in the same direction were considered. Next, proof-of-
concept data from the HeLa S3 wildtype with and without HGF should be 
investigated and confirmed. Only after that, the effect of NEK9 knockdown on the 
HGF/Met-dependent gene expression after HGF stimulation was analyzed.  
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In total, more than 41,000 different genes were analyzed on a gene expression 
chip. After deletion of outliers and those genes exhibiting strong variances within 
the replicates, 3,334 genes remained for further analyzes. As the nonsense siRNA 
sample showed comparable gene expression as the HeLa S3 wildtype, the latter 
one was used as regulation basis. A minimum fold change of ≥5 in comparison to 
the unstimulated wildtype was assumed as significant regulation, resulting in 336 
genes fulfilling these criteria.  
First of all, genes in the HeLa S3 wildtype affected by HGF were investigated. 
Only 56 were downregulated, while 280 were upregulated. Affected genes 
included proof-of-concept data as the transcriptional regulator EGR1, which 
activates genes responsible for mitogenesis and differentiation. The cell adhesion 
proteins ITA2 and LAMC2 are also known to be transcriptional targets of HGF/Met 
signaling and influence cell-cell contacts as well as migration. The determination of 
transcriptions factors that lead to the expression of HGF-regulated genes in the 
HeLa S3 wildtype was supported by GeneGo. Indeed, 47 key transcription factors 
were identified that control the transcription of the regulated genes in this study. Of 
them, 11 (of 28 established) were known for HGF/Met signaling, among them 
FOS, FOSB, JUN, and GATA-4.  
Analysis of the dependency of the NEK9 knockdown during HGF stimulation that 
caused the altered phenotype was performed in two steps. First, the fold changes 
of genes between the wildtype with and without HGF as well as the NEK9 
knockdown with and without HGF were calculated. Second, the fold change 
between these two values was computed (analogous to the EPHA2 array, Figure 
4-22). The regulated genes were affected by NEK9 during HGF stimulation. 170 
genes were considered, of which 48 exhibited no regulation between wildtype and 
knockdown. Of the remaining 122 genes, 73 were up- and 49 downregulated 
through NEK9 dependent on HGF. Most affected genes were collagen degrading 
protein MMP-3, the purine receptor P2RY8, functionally unknown LRC36, nuclear 
pore protein NAV3, and the ubiquitin ligase TRI63 - all about 20 fold upregulated in 
the NEK9 knockdown.  
Searching for altered gene expression, which could be responsible for the 
observed migration, the list of 122 was sorted by function. Indeed, 22 genes were 
found associated with motility and migration in pathways provided by GeneGo 
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(Table 4-2). For example, FLRT3 causes dynamin-dependent internalization of c-
cadherin resulting in decreased cell contacts. Matrix metallopeptidases MMP1 and 
MMP3 as well as PAI1 cleave the extracellular matrix. Furthermore, EGR1 induces 
the transcription factor SNAI1, which regulates genes involved in motility. Also 
genes coding for cytoskeletal proteins were affected by the NEK9 knockdown. The 
tubulin TBAL3, linker protein DYST, and actin-modulator SYP2L were upregulated. 
PLEK2 is involved in the formation of lamellipodia and was also found 
upregulated. Additionally, genes for small GTPases or their regulators were also 
affected by the NEK9 knockdown in HeLa S3 cells. Notably, the gene coding for 
RAC2 was upregulated more than 10-fold. RAPGEF3 activates the GTPase RAP 
and triggers motility through this pathway. IL8 stimulates cascades involving RAC 
and RHO as well as PI3K to enhance cellular movement. In contrast, genes 
expressing proteins for cellular adhesion were negatively affected by NEK9 
knockdown. Downregulated ID2 inhibits e-cadherin expression and CLN1 
eliminates cell adhesion. Furthermore, the gene coding for a 2ABB, which is 
involved in cell cycle progression, was downregulated. In contrast, upregulated 
genes of RGS2 and CDN1A are known to inhibit proliferation.  
 
Table 4-2: NEK9- and HGF-regulated genes associated with motility. 
22 genes occur in GeneGo pathways related to motility and migration and were found 
among 122 genes differentially regulated in NEK9 knockdown cells in comparison to the 
wildtype depending on HGF stimulation. WT: wildtype HeLa S3 cells; KD: NEK9 
knockdown HeLa S3 cells. 
Gene Protein name Fold Change 
(WT +/- HGF) vs. 
(KD +/- HGF) 
NEK9 knockdown effect 
mmp3 Matrix Metallopeptidase 3 28.0 Cleaves ECM 
p2ry8 Purinergic receptor 8 27.3 Receptor family triggers motility 
coha1 Collagen type17, alpha 1 13.7 Regulates MAPK-induced 
migration 
mmp1 Matrix Metallopeptidase 1 12.4 Cleaves ECM 
Inhba Inhibin/activin, beta A 
chain 
11.2 Activates MAPK-induced 
migration 
rac2 Ras-related C3 botulinum 
toxin substrate 2 
10.5 Cytoskeletal reorganization 
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gpr56 G protein coupled 
receptor 56 
9.1 Regulates migration 
flrt3 Fibronectin leucine rich 
transmembrane protein 3 
7.8 C-cadherin internalization 
cdn1a Cyclin-dependent kinase 
inhibitor 1A 
7.0 Inhibits cyclin-CDK complexes, 
cell cycle 
rapgef3 Rap guanine nucleotide 
exchange factor 3 
4.9 Cytoskeletal reorganization 
egr1 Early growth response 1 4.0 Activates SNAI1 
syp2l Synaptopodin 2-like 3.6 Cytoskeletal reorganization 
pgh2 Prostaglandin-
endoperoxide synthase 2 
3.3. Affects migration 
tbal3 Tubulin, alpha-like 3 3.2 Cytoskeletal reorganization 
plek2 Pleckstrin 2 2.8 Formation of lamellipodia 
dyst Dystonin 2.4 Cytoskeletal reorganization 
rgs2 Regulator of G protein 
signaling 2 
2.4 Inhibitor of proliferation 
il8 Interleukin 8 2.1 Cytoskeletal reorganization 
pai1 Serpin peptidase 
inhibitor, clade E 
2.0 Disrupts cell contacts 
id2 Inhibitor of DNA-binding 
2 
-2.4 Inhibits e-cadherin expression 
2abb Protein phosphatase 2, 
subunit B 
-3.1 Affects cyclin through GSK3β 
cln1 Claudin 1 -8.4 Eliminates cell adhesion 
 
4.3 The effect of Listeria InlB on Met signaling 
4.3.1 The phosphoproteome triggered by InlB/Met 
The growth factor HGF is the only physiological ligand known, which binds and 
activates Met, inducing cascades for proliferation, migration, and survival. 
Nevertheless, internalin B of the pathogenic bacterium Listeria monocytogenes is 
also able to externally bind and stimulate the Met receptor.  
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To compare induced pathways of HGF and InlB in this study, phosphoproteomics 
was applied to cells stimulated with the bacterial surface protein. Human cervix 
cancer line HeLa S3 is the common model for infection studies and was used in 
these experiments. In contrast to the HGF-study, only one time point was selected 
to reduce time and effort. A maximum stimulation of known pathway components 
was supposed to happen during the first minutes (Reinl et al. 2009).  
First of all, the purity and activity of the InlB protein was tested by gel 
electrophoresis and immunoblot against known signaling proteins of the Met 
pathway. After that, the phosphoproteome of InlB-stimulated HeLa S 3 cells was 
investigated. Regulated phosphopeptides after 5 min InlB stimulation were 
calculated next. These were compared to phosphopeptides affected by HGF (from 
section 4.2.3) to determine the influence of the pathogenic protein on the 
physiological signaling.  
SCX elution fractions of InlB recombinantly expressed InlB in CHO cells were 
loaded on a SDS gel to control the purity of the protein. All lanes showed a thick 
band at 70 kDa which corresponds to the InlB chain (Figure 4-30). Fractions 1-7, 
and 12-14 exhibited three slightly smaller bands, perhaps variants of the protein 
with different glycosylation patterns. Additionally, most fractions contained a faint 
band at 20 kDa. For the stimulation experiments, InlB of fraction 10 was used, 
because it was one of the purest.  
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Figure 4-30: Elution fractions of recombinantly expressed InlB 
The protein was expressed in CHO cells and purified. Elution fractions of the SCX were 
applied to an SDS gel to control purity. Protein of fraction 10 was chosen for further 
experiments.  
 
Second, the activity of the protein was checked testing whether it was able to 
induce Met-dependent signaling. To determine an InlB concentration which is 
sufficient to induce signaling cascades downstream of Met, HeLa S3 cells were 
treated with 7 and 10 nM InlB. Three different stimulation times (2, 6, 20 min) were 
compared to identify the time point with maximal stimulation.  
According to the loading control HSP90, all samples contained equal amounts of 
protein (Figure 4-31). In non-stimulated controls (lanes 1, 2) no signal was 
detected with phospho-specific antibodies against pY1234/pY1235 of Met as well as 
pT185/pY187 and pT202/pY204, of MK01 (ERK2) and MK03 (ERK1), respectively. In 
contrast, every time point and every concentration of InlB caused the 
phosphorylation of MK01 and MK03. Met phosphorylation was also induced by 
InlB, particularly at 10 nM after 2 and 6 min. Based on these results, stimulation 
with 10 nM InlB for 5 min was selected for the phosphoproteome study.  
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Figure 4-31: InlB is able to stimulate Met-pathway 
HeLa S3 cells were stimulated as indicated with InlB or MES buffer and activation of Met 
as well as MK01 (ERK2), MK03 (ERK1) was evaluated with phospho-specific antibodies. 
Heat shock protein 90 (HSP90) was utilized as loading control. 
 
Human cervix cancer line HeLa S3 was stimulated for 5 min with L. 
monocytogenes surface protein InlB and compared to the non-treated control. 
Following stimulation and harvest, aliquots of cell lysates were immunoblotted to 
check for the stimulation of Met-pathway components via phospho-specific 
antibodies. Loading control GAPDH exhibited similar bands, proving equal 
amounts of proteins applied per sample (Figure 4-32). Activation sites 
pY1234/pY1235 of Met was found to be phosphorylated after 5 min InlB as well as 
double sites of the MAP kinases ERK1 (MK03) and ERK2 (MK01).  
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Figure 4-32: Stimulation control for phosphoproteomics 
Aliquots of the stimulated cell lysates for phosphoproteomics were applied to 
immunoblotting. With phospho-specific antibodies against pY1234/pY1235 of Met as well as 
pT202/pY204 and pT185/pY187 of ERK1 (MK03) and ERK2 (MK01), respectively, the 
activation of the Met cascade was tested. GAPDH served as loading control.  
 
Phosphoproteomics of the two samples carried out as duplex iTRAQ labeling with 
three replicates each, identified 2,784 phosphopeptides belonging to 1,299 
phosphorylated proteins. The data were processed as shown and described in 
detail for the HGF/Met phosphoproteome. In this approach, 387 phosphopeptides 
were detected in all three experiments and 28 of them were considered as 
significantly regulated after 5 min InlB-treatment.  
Regulated phosphopeptides were illustrated in a heatmap (Figure 4-33) and 
further information is illustrated in the appendix (Table 8-4). The 20 upregulated 
peptides were marked again by red boxes, while the green boxes indicated the 8 
downregulated phosphopeptides. As for the HGF phosphoproteome, regulation 
directions within the triplicate were the same, but the regulation factors varied due 
to the fast phosphorylation dynamics. The activation sites pT185/pY187 and 
pT202/pY204 of the MAP kinases MK01 and MK03 were upregulated clearly. The 
adapter protein AHNK exhibited several upregulated phosphorylations. Further, 
the site pS801 of the motor protein KIF4A, which plays a role in cytokinesis, was 
modified as well. The kinase PKN2 was phosphorylated at pS583 after 5 min with 
InlB. Notably, the site pT693 of the growth factor receptor EGFR was found to be 
upregulated, revealing potential receptor crosstalk between Met and EGFR in 
response to InlB. Phosphorylation sites for Met were not detected, perhaps due to 
5min   0min
10 nM InlB
pMet
pERK1,2
GAPDH
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a lack of kinase enrichment. OSTF1, a protein probably involved in signaling was 
found to be dephosphorylated at pS213 in response to InlB. The site pS134 of the 
p53- and NF-k-interacting protein IASPP was downregulated as well. Surprisingly, 
a protein involved in immune response, namely TRAD1, was also affected by InlB-
stimulation by downregulation of pS415.  
As previously mentioned, InlB is supposed to activate signaling cascades 
comparable to HGF. Therefore, proteins corresponding to the 28 regulated 
peptides were checked for known functions in Met signaling. The majority of these 
has not been published and is therefore detected in this context for the first time. 
The proteins MK01, MK03, and EGFR were already described as part of this 
cascade and thus constitute proof-of-concept. The first two are among the most 
well-known signal transducers in Met-dependent signaling (Birchmeier et al. 2003) 
and even served as stimulation control for HGF and InlB in this study. The EGF 
receptor is closely related to Met and shares several downstream components. 
Furthermore, it has been shown to occur in complexes with Met, at least in cancer 
cells (Mueller et al. 2010). Met was first identified as an oncogenic fusion protein 
together with TPR, resulting from a chromosomal rearrangement. This construct 
forms dimers through TPR located in the cytoplasm and leads to continuous and 
ligand-independent Met dysregulated signaling in affected cells (Peschard and 
Park 2007). Here, TPR was identified with two upregulated phosphorylation sites.  
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Figure 4-33: Phosphopeptides regulated after 5 min stimulation with InlB. 
Heatmap of significantly regulated phosphopeptides after InlB treatment. Green boxes 
illustrate downregulations, while red boxes stand for upregulated peptides. Values of 
regulation factors are shown in log2 scale. P-Site: phosphorylation site.  
 
All regulated phosphorylation sites were already described in human cells, except 
for pS406 of the palmitoyltransferase ZDHC5. This site is only predicted from 
mouse in the databases PhosphoSitePlus and PhosphoNet. Phosphoproteomics 
revealed this modification to be upregulated after 5 min of InlB stimulation (Figure 
4-34).  
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Figure 4-34: Regulation of the novel phosphorylation site pS406 of ZDHC5 
Phosphorylation sites regulated in response to InlB were looked up in the current 
databases PhosphoSitePlus and PhosphoNet. All sites were found, besides pS406 of 
palmitoyltransferase ZDHC5. This novel modification of unknown function was 
upregulated in all three replicates (E1-E3).  
 
Further functional information was available for only 5 of the 28 phosphopeptides 
regulated after InlB-stimulation,. The protein kinases MK01 and MK03 with their 
phosphorylation sites at pT185/pY187 and pT202/pY204 are key players of several 
signaling cascades. They are activated through the identified double modifications 
caused by MP2K1 (MEK1), MP2K2 (MEK2), and JAK2. MK01 and MK01 are also 
able to phosphorylate pS1044 of LIFR, which inhibits this protein. EGFR was 
phosphorylated at pT693 by the MAP kinases leading to its internalization. 
Furthermore, modification of pS82 of heat shock protein HSPB1 causes the 
dissociation of chaperone complexes and triggers cytoskeletal rearrangements by 
binding to TPM1. Several kinases are able to phosphorylate this site, which also 
inhibits interaction of HSPB1 with TRAF6 and AKT1.  
4.3.2 Influence of Listeria monocytogenes’ InlB on physiological 
Met signaling 
The growth factor HGF and the L. monocytogenes surface protein InlB both bind 
to and activate the Met receptor, triggering comparable signaling cascades on the 
kinase level (Reinl et al. 2009). Nevertheless, they produce different kinds of 
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cellular responses: While HGF stimulates proliferation, migration, and survival, 
InlB induces the bacterium’s uptake into the host cell. In this study, HGF- and InlB-
regulated phosphopeptides have been identified and characterized (see 4.2.3 and 
4.3), and thus can be compared in order to find similarities and differences in 
these phosphoproteomes.  
Comparable to the kinase data, the majority of regulated phosphorylation sites 
were not known to play a role in Met signaling before. Besides that, 25 
phosphopeptides were regulated after HGF and were detected after InlB 
stimulation, but were not regulated in the InlB dataset. However, it has to be taken 
into account that for InlB only the 5 min time point was analyzed. Thus, all late 
responders in HGF signaling were not considered when matching both datasets. 
That resulted in 11 phosphopeptides, which were only regulated by HGF, but were 
detected after InlB stimulation (Table 4-3). Several proteins possessing HGF-
regulated sites seemed to be involved in progression of the cell cycle. While 
TP53B is a transcriptional regulator, which induces mitosis, NUFP2 changes its 
localization in a cell cycle-dependent manner, indicating an associated function. 
RIR2 is a regulator of Wnt-signaling, taking part in several processes, including 
mitosis and establishing cell polarity. Furthermore, the regulated site pS20 is 
phosphorylated by CDK1 and CDK2 that are key players of the cell cycle. Other 
proteins with regulated phosphorylation sites only after HGF stimulation influence 
cytoskeleton reorganization, which is necessary for cell division or migration. Rho-
GEF ARHG2 regulates signaling via small GTPases, which activate 
rearrangements of the cytoskeleton. TENS3 and LIMA1 are responsible for 
reformation and polymerization of actin fibers. The protein NIBL1, however, is 
supposed to suppress apoptosis. 
In conclusion, phosphopeptides regulated only in the HGF dataset correspond to 
proteins involved in the physiological response of Met signaling like mitosis, 
migration, and survival.  
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Table 4-3: Phosphorylation sites regulated only by HGF after 3 and 6 min 
Listed sites were regulated after 3 or 6 min of HGF stimulation, but displayed no response 
in the InlB dataset. Protein functions were retrieved from the Uniprot database. Arrows 
illustrate the regulation direction of the phosphorylation site after 3 and 6 min HGF 
treatment. The 20 min time point was not taken into account for this comparison, because 
InlB was only stimulated for 5 min. 
Protein P-Site Regulation 
(3, 6min) 
Protein function 
NUFP2 pT571 ↑↑ Relocalization during cell cycle 
SH3B4 pS244 ↑↑ Transferrin receptor internalization 
TENS3 pS776 ↑↑ Reorganization cytoskeleton 
TPR pT2116 ↑↑ Nuclear pore, protein import 
RTN4 pS107 ↑↔ Regulation in development 
ARHG2 pS886 ↔↑ Rho-GEF 
LIMA1 pS686 ↔↑ Formation of actin fibers 
NIBL1 pS678/pS679 ↔↑ Anti-apoptosis signal 
OXR1 pS202 ↔↑ Oxygen stress response 
RIR2 pS20 ↔↑ Inhibits Wnt-signaling 
TP53B pS1114 ↔↑ Transcription, Mitosis 
 
On the other hand, 13 phosphopeptides were regulated after InlB, but not HGF 
stimulation, although they had been detected there (Table 4-4). The adapter 
protein LMO7 exhibited modified sites in response to InlB as well as the 
transcriptional regulators NELFE and MORC2. Compared to HGF, the involvement 
of these components implicates at least a slightly altered signaling after contact 
with this isolated pathogenic factor. Interestingly, three proteins of TRAF6-NFκB-
signaling appeared differentially phosphorylated in this dataset. The heat shock 
protein HSPB1 was modified at pS82, which inhibits interaction with the signaling 
adapter TRAF6. Second, pS134 of phosphatase IASPP was downregulated. The 
protein interacts with the transcription factor p53, but also negatively regulates 
NFκB. A phosphorylation site of TRAD1, a protein involved in the negative 
feedback in immune response, was downregulated in response to InlB.  
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Table 4-4: Phosphorylation sites regulated only by InlB 
Illustrated phosphorylation sites were regulated only in response to InlB after 5 min and 
were not affected in the HGF-dataset. The regulation direction of the phosphorylation site 
is indicated by arrows. Functional protein information was retrieved from the Uniprot 
database.  
Protein P-Site Regulation 
(5 min) 
Protein function / effect 
AHNK pS210 ↑ Adapter in development 
HSPB1 pS82 ↑ Heat shock, actin reorganization 
LR16A pS1094 ↑ Actin polymerization 
NELFE pS115 ↑ Transcription  
SC22B pS137 ↑ Vesicle trafficking 
SH24A pS315 ↑ Inhibits proliferation 
CCD86 pS91 ↓ Unknown 
IASPP pS134 ↓ Interaction with p53, NFκB 
IF4G2 pT508 ↓ Translation 
LMO7 pS925 ↓ Adapter protein 
MORC2 pS743 ↓ Inhibits transcription 
RL1D1 pT358 ↓ Unknown 
TRAD1 pS415 ↓ Inhibits immune response 
 
In contrast, 5 of 28 phosphorylation sites affected by InlB were significantly 
regulated in both datasets. 19 further sites were significantly regulated after HGF 
stimulation and were affected by InlB, although not significantly. Thus, 24 
phosphorylation sites on 21 proteins were similar in both signaling cascades, 
indicating – at least in part - comparable downstream components for both ligands. 
Among those regulated sites were the activation sites of the MAP kinases MK01 
and MK03, as well as pT246 of the AKT1 target protein AKTS1 and pS262 of the 
PI3K subunit P85B. Furthermore, phosphorylation sites pS893 and pS137 of the 
actin-associated proteins PALLD and PAXI and pT587 of the phosphatase PTN12 
were also regulated by both ligands. In conclusion, the pathogen-derived protein 
InlB activates also signaling cascades induced by HGF/Met, although it is 
structurally unrelated and binds to different regions on the Met receptor.  
 
5 Discussion 
Intracellular signal transduction processes utilize phosphorylation to transmit and 
process information. Addition of a phosphate group to serine, threonine, or 
tyrosine affects the protein’s interactions, activity, stability or localization. Kinases 
transduce those signals from one to another, thereby spreading, enhancing, or 
integrating them within minutes. The mechanism is antagonized and tightly 
regulated by phosphatases, which dephosphorylate their substrates. The flexibility 
and rapidity of this processes enables cells to respond immediately to 
environmental changes by regulating target gene expression or protein activity 
(Jordan, Landau, and Iyengar 2000). One of the most important signaling 
pathways for embryogenesis and wound healing, but also during cancer 
progression, was investigated in this study. Signaling by the Met receptor was 
either stimulated by binding of the growth factor HGF or of the surface-located 
invasin InlB of Listeria monocytogenes, which triggers the pathogen’s invasion 
(Birchmeier et al. 2003; Ireton 2007). Although the downstream signaling 
cascades of Met have been studied for two decades, recent proteomic approaches 
allow for a comprehensive overview and a more precise characterization of 
involved proteins and substrates.  
5.1 Successful strategy to uncover the 
phosphoproteome from cell lines 
Traditional 2D gel electrophoresis in combination with phospho-staining can be 
utilized to identify phosphorylated proteins. However, in a current study using 2D 
gels stained with Pro-Q Diamond to identify regulated phosphoproteins in 
response to wounding in maize leaves, the limitations of the technique became 
obvious. The authors identified 270 proteins in total, of which 41 were regulated 
and could be identified by MALDI-MS. Nearly all proteins were already known in 
this context before and phosphorylation sites were not determined (Lewandowska-
Gnatowska et al. 2011). As most signaling molecules like kinases and transcription 
factors are among the low abundance proteins, there is a need for an efficient 
phosphoproteome enrichment strategy. Ruan and co-workers recently proved that 
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purification of phosphoproteins previous to two-dimensional difference gel 
electrophoresis (2D-DIGE) improves the sensitivity for signaling proteins. They 
were able to identify 28 phosphoproteins differentially regulated in response to 
EGF in CNE2 cells, but the method used by them did also not provide information 
about the location of the phosphorylation sites (Ruan et al. 2011). Thus, in order to 
additionally localize phosphorylation sites, this work utilized LC-MS/MS, where 
peptide sequencing is performed in the second MS. Indeed, phosphopeptide 
enrichment by affinity chromatography using metal ions (IMAC) followed by strong 
cation exchange chromatography (SCX) and LC-MS/MS as established in this 
study successfully enriched and identified more than 3,000 phosphopeptides in the 
preliminary studies including those of low-expressed signaling components. 
Furthermore the technique provided reliable phosphorylation site information for all 
identified proteins.  
Initial experiments in this study were designed to establish a robust and effective 
workflow to characterize the Met-induced phosphoproteome. Results showed that 
Ga3+-based IMAC purified phosphopeptides more efficiently than IMAC using Fe3+-
ions. Furthermore, applying the Ga-IMAC flow-through onto Fe3+-resin did not 
result in additional enriched peptides. Thus, Ga-based IMAC was sufficient to 
purify phosphopeptides from a complex cell lysate. Increasing the amount of 
protein from cell lysate resulted in a larger number of identified peptides. Notably, 
no negative effect was observed concerning binding characteristics of the Ga-
resin. Of course, the binding sites for phosphopeptides on the IMAC material were 
limited, but could be expanded by using larger amounts of Ga3+. The limiting factor 
was rather the amount of cells prepared for the experiment, as 4 mg of protein 
required already more than 107 cells for each sample. IMAC binds acidic peptides 
as well, because they also interact with positively charged metal ions at low pH as 
phosphopeptides do. Therefore, enriched peptides were fractionated via SCX, 
where the resin interacts with cations, while phosphorylated peptides are not 
retained during elution. The ability of SCX to further separate phosphorylated from 
non-modified peptides was clearly demonstrated by their distinct distributions in 
the eluted SCX fractions. However, not all currently available phosphopeptide 
enrichment strategies were compared in the pre-experiments due to time 
limitations. Olsen and co-workers for example were successful using SCX followed 
by TiO2 (Olsen et al. 2006), which was not examined here.  
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In the first main study, the phosphoproteome isolated after HGF stimulation over a 
time course consisted of about 7,996 different phosphopeptides from three 
independent experiments. Comparable studies investigating tyrosine receptor 
signaling resulted in similar peptide amounts, reflecting the efficiency of the utilized 
workflow. For example, the mentioned TiO2 approach by Olsen et al. resulted in 
10,000 phosphopeptides after 5 and 10 min EGF stimulation of HeLa cells. In 
comparison, strategies with anti-phosphotyrosine antibodies revealed up to about 
250 tyrosine phosphorylation sites when cell lines were stimulated by HGF 
(Hammond et al. 2010; Organ et al. 2011). The recent publication of Organ has to 
be compared to the results of this study, because it is highly equivalent. They 
screened the colorectal cancer cell model DLD1 to analyze the cellular response 
after 10 and 60 min HGF stimulation. Utilizing phosphotyrosine-specific antibodies, 
they identified 266 phosphorylation sites on 168 proteins and performed regulation 
analysis with label-free quantification (Organ et al. 2011). However, the authors 
achieved access to only tyrosine phosphorylations that represent 1-2% of a 
complex phosphoproteome.  
Furthermore, the ratio of the phosphorylated amino acids (pS:pT:pY) 84:15:1 in 
this work was analogous to data from other phosphoproteome studies. Olsen et al. 
published 86:12:2 for the distribution of phosphorylated serine, threonine, and 
tyrosine, and Hunter found 90:10:0.05 by radioactive-labeling with 32P (Hunter and 
Sefton 1980), reflecting the comparability of this enrichment workflow with other 
methods.  
In contrast, the phosphoproteome after InlB stimulation only yielded 2,784 
modified peptides in total. The striking difference to the HGF-dataset might be 
caused by several factors. Firstly, only 8 mg instead of 16 mg of protein were 
applied to the workflow due to iTRAQ duplex labeling of two instead of four 
samples in comparison. During the first MS run only peptide ions with certain 
intensity are further processed and sequenced to decrease the false discovery 
rate. Therefore, it is likely that a smaller amount of peptides resulted in a lower 
number of identified peptides in total. Furthermore, no phosphopeptides were 
detected as regulated after more than 5 min InlB which decreases the total amount 
of identifications compared to the HGF time course. Nevertheless, biological 
reasons could also play a role. HGF might be able to induce a broader response 
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resulting in more phosphorylated proteins. Furthermore, the threshold for inducing 
downstream pathways could vary depending on the concentration of the ligand. In 
the stimulation control, phosphorylation of Met as well as MK01 and MK03 (alias 
ERK2 and ERK1) was monitored only in a qualitative manner; therefore no 
quantitative comparison of the activation of these proteins by the different ligands 
is available from this work. Thus, it is possible that an increase of the 
concentration of InlB might have caused an analogous stimulation, resulting in a 
comparable amount of identified phosphopeptides. However, the most likely 
reason for the differences between the two datasets are the unlike amounts of 
peptides applied to mass spectrometry and the resulting ion shadding by highly 
abundant peptides.  
Time-resolved analyses of RTK signaling allow covering of several intermediate 
states during the process of signal transduction. In order to quantitatively compare 
these states with each other or with the non-stimulated condition, the samples 
were labeled. Here, iTRAQ was used for tagging, because it has been 
successfully used in several investigations of Met (T. Guo et al. 2010; Reinl et al. 
2009) or RTK signaling (Lim et al. 2009; Zhang et al. 2010; Zhang et al. 2005). 
The strategy provided relative quantification data based on the regulation factors 
of HGF-activated samples compared to the non-stimulated control. As the 
distribution of regulation factors in all samples after normalization was comparable, 
the triplicate was performed without any major sources of error. However, cell lines 
were used to extract proteins, which could have been compared also with SILAC. 
In this case, inter-experimental variations might have been almost completely 
abolished because of the earlier labeling on the level of intact cells. Biological 
variances between cells, however, still cannot be eliminated by either technique. 
Furthermore, results of this work established a robust and comparable workflow 
using iTRAQ labeling. Additionally, the workflow can now be easily adapted to 
clinical human tissue samples, where SILAC labeling is not possible.  
Phosphorylation events were monitored during the first 20 min after stimulation, 
because the modification cascade is fast. For example, Met was phosphorylated 
after 1 min (Y. Shen et al. 2000), while the MAP kinases MK01 and MK03 were 
shown to be activated after 5 min (Wells et al. 2005) or even earlier (see Figure 
4-10). Generally, no significant change in the concentration of proteins identified 
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during this time span can be expected. As first transcripts occur after 30 min at the 
earliest, protein synthesis is usually much slower than phosphorylation. Thus, it 
can be assumed that no increase in protein amount might influence the 
upregulation of a phosphopeptide. The contrary mechanism, decreasing the 
amount of protein through degradation, will also take some time and can be 
expected to play a minor role after 3 and 6 min, when a downregulation of a 
phosphopeptide is monitored. Nevertheless, Goormachtigh et al. investigated the 
degradation time of GAB1 in HeLa cells and demonstrated that already after 15 
min HGF stimulation there is a decrease of the protein’s amount in the cell. 
However, this was not the case for Met and the MAP kinases, which did not show 
degradation within the first 2 h after stimulation (Goormachtigh et al. 2011). 
Therefore, it has to be taken into account that phosphopeptide downregulation 
might be due to a decreased protein amount and not due to a regulation of the 
phosphorylation site. In this case, additional immunoblots against the whole 
protein have to be performed to ascertain no change in the protein level. In 
contrast, for all other regulated sites, no influence of the corresponding protein 
concentration should be expected.  
Taken together, the established strategy was able to identify, quantify and 
compare thousands of phosphopeptides from the cell lines DU145 and HeLa S3 
after stimulation with HGF or InlB. With this, the HGF study was one of the most 
extensive investigations of RTK signaling and the largest of the HGF/Met-induced 
phosphoproteome so far. Although fewer phosphopeptides were found for the 
InlB-induced signaling, this work was the first phosphoproteomic study that 
investigated the host response after stimulation with a specific pathogenic effector 
molecule.  
5.2 Activation of known HGF/Met pathway components 
The majority of previous approaches to analyse HGF/Met signaling have not been 
global, but instead concentrated on single proteins or complexes that could play a 
role in this context. Main pathway components were identified using hypothesis-
driven and targeted traditional biochemical methods against a limited amount of 
candidate proteins that have been implicated in certain phenotypes involving Met. 
For example, the Ras-Raf-MEK-ERK cascade has been known to trigger motility, 
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was therefore screened by phospho-immunoblots during Met activation and 
confirmed as part of the downstream network (Jeffers et al. 1998). Additionally, 
one of the first interaction partners of Met, PI3K, was identified by co-
immunoprecipitation with the receptor after HGF stimulation (Graziani et al. 1991). 
Nowadays, these techniques are still important to characterize a protein or its 
interactions, but signaling cascades are rather screened by proteomic approaches. 
This enables researchers to get a comprehensive overview and provides many 
potential pathway components from one experiment. In this study, 80 proteins 
were identified as part of this pathway by their regulated phosphorylation sites in 
response to HGF stimulation. Notably, among them were 6 known proteins of the 
HGF/Met pathway that were integrated into the established signaling network.  
5.2.1 The GAB1-MAPK-PAXI cascade 
The essential and direct Met adapter GAB1 was phosphorylated on pY659 with a 
maximum in the first 6 minutes. The phosphorylation site is known to be modified 
by several growth factor receptors and leads to the activation of the MAPK 
cascade (Onishi-Haraikawa et al. 2001; Ingham et al. 1998). Members of this 
cascade, namely MK01 and MK03, were identified in this by their known activating 
double phosphorylations on tyrosine and threonine. Those were significantly 
upregulated in response to HGF with a maximum after 6 min. Furthermore, as one 
target of MK01, PAXI exhibited increased phosphorylation after 6 and 20 min. 
Although, the site pS137 on PAXI is not functionally characterized so far, it is likely 
that the MAP kinase modifies this site in response to HGF. PAXI is a protein 
localized in the focal adhesions and is supposed to play a role in cell migration 
(Schaller 2001). The GAB1-MAPK-PAXI cascade is a perfect example of a signal 
being transmitted stepwisely through the cell in the first 20 min of HGF stimulation 
(Figure 5-1). This pathway might regulate cellular motility in response to activated 
Met. 
106 5 Discussion 
 
Figure 5-1: GAB1-MAPK-PAXI signaling cascade 
In response to HGF stimulation, the indicated phosphorylations sites of the known Met 
pathway members GAB1, MK01, and PAXI were upregulated one after another within the 
first 20 min. When activated, the adhesion protein PAXI regulates migration.  
 
5.2.2 The PI3K-AKT1 axis 
GAB1 acts as adapter for the kinase PI3K, which is also able to bind to Met 
directly. Binding of PI3K to Met is mediated via its SH2 domain-containing p85 
subunit (Ponzetto et al. 1994) that was identified by phosphoproteomics in this 
study. P85B is the adapter unit of the kinase complex that transmits the signal 
from Met to AKT1 thereby triggering several distinct pathways leading to 
proliferation and protection from apoptosis (Rosário and Birchmeier 2003). The 
site pS262 was found upregulated after 20 min of HGF stimulation, but is not 
functionally characterized yet. As PI3K belongs to the proximal Met signaling, an 
activating phosphorylation might occur earlier than that. Thus, the function of this 
site could be inhibitory in order to stop PI3K-AKT1 signaling.  
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Small GTPases like RAC1 and CDC42 mediate HGF/Met-induced migration 
(Wells et al. 2005). Although these proteins could not been identified in this study 
because they are not controlled by phosphorylation, another known regulator of 
cell motility that interacts with GTPase signaling was detected by its 
phosphorylation site. The Adenomatous Polyposis Coli (APC) protein accumulates 
in lamellipodia and membrane ruffles in HeLa cells stimulated by HGF. Under 
these conditions, it co-localizes with the Rho-GEF SPT13 and the phosphatase 
complex scaffold protein NEB2, which both are required for migration in response 
to HGF (Sagara et al. 2009). SPT13 again activates RAC1 and CDC42 in a PI3K-
AKT1-dependent manner. Binding of APC to SPT13 increases its GEF activity 
thereby enhancing this pathway (Kawasaki et al. 2007). As the phosphorylation 
site on APC was downregulated after 20 min of HGF stimulation, the modification 
might affect the interaction with SPT13 and thus, regulate the migratory pathway.  
5.2.3 Where are the proof-of-concept data? 
Of course, more than these proteins are known as members of Met signaling, but 
obviously have not been identified here. To consider the reasons, one should keep 
in mind that, phosphorylation of the components was monitored at only three time 
points. Additionally, peptides that reacted differently in one experiment were 
ignored due to the stringent statistic parameters applied during quantitative 
analysis. Furthermore, those hypothetically regulated before, in between, or after 
the chosen time points could not be detected either. As phosphorylations are 
highly dynamic, this time course is only able to provide snapshots of the 
phosphorylation pattern at the investigated moments after HGF stimulation. 
Incidentally, this is also true for the phosphorylation dynamics monitored for each 
significantly regulated peptide. How one site is modified off-time points cannot be 
said. Therefore, the lines in the presented figures (see section 4.2.3) connecting 
the regulation values in the phosphorylation dynamics of the exemplified peptides 
are a simplification and rather serve as a better illustration. In order to circumvent 
this problem, many more time points have to be chosen resulting in a dramatic 
increase in experimental complexity and sample number. Furthermore, the 
quantification strategy would need to be redesigned according to the high amount 
of samples.  
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Other known Met downstream proteins might not be identified due to the 
enrichment method. Proteins that function as substrates are more likely to be 
detected, because phosphorylations on these signal acceptors might be more 
sustained compared to the highly dynamic regulation of kinases for example. 
These transducers are among the low abundant proteins and might still be 
underrepresented in the phosphoproteome due to a lower concentration of their 
phosphorylation sites. Finally, known signaling components of Met signaling have 
been detected in a large number of different cell types ranging from cancer tissues 
to cell lines. It is obvious that every cell type might express or use different sets of 
proteins involved in Met signaling. That is a problem when comparing 
experimental data with the literature or databases. For example, GeneGo 
interactions collected in the database originate from studies performed in different 
cell lines or even distinct organisms. Thus, in a phosphoproteome approach like 
this, which was done in one cell line, it cannot be expected that all known 
interactions can be matched to the experimental data.  
In conclusion, only 6 of 80 proteins that exhibited regulated phosphorylation sites 
after HGF stimulation are currently known components of the Met downstream 
signaling. Notably, that means vice versa that the majority of proteins differentially 
modified in response to the stimulus has not been described in this context so far. 
This fact clearly demonstrates how incomplete the knowledge of the HGF/Met 
pathway components was prior to this study, although it has been investigated for 
a long time.  
5.3 Characterization of novel pathway components and 
substrates of HGF/Met signaling 
40 of 74 proteins that have not been described before in HGF/Met signaling are 
likely to have a function in this pathway (marked with ** in Table 8-1 in the 
appendix), because they were differentially phosphorylated in response to HGF 
stimulation and are known to interact with established pathway members or they 
participate in cellular rearrangements known for Met (Figure 5-2). These 
candidates of Met signaling were additionally compared to the publication of Organ 
et al., as they performed the only other phosphoproteomics screen on HGF/Met 
signaling so far (Organ et al. 2011).  
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Figure 5-2: Novel proteins in the Met pathway 
Dark blue protein names mark the novel HGF/Met signaling substrates identified by 
phosphoproteomics in this work and which are described in the subsection below. 
Established proteins of the pathway are illustrated by light blue ovals, with those identified 
here marked in dark blue. The known components are not completely depicted to improve 
clarity. Only those exhibiting interactions with novel proteins are mentioned.  
 
5.3.1 Signaling molecules 
One of the main signaling components of HGF/Met is the kinase AKT1 that was 
not regulated here. However, its substrate AKTS1 was detected with the 
upregulated site pT246 that is known to be modified by AKT1. AKTS1 interacts with 
mTOR in a complex called mTORC1 that triggers protein synthesis (Sancak et al. 
2007). As mTOR is a target of Met signaling through the PI3/AKT1 axis (Trusolino, 
Bertotti, and Comoglio 2010), AKTS1 is likely to be involved in this pathway as 
well.  
Furthermore, another target of AKT1 was gradually phosphorylated in response to 
HGF. The receptor tyrosine kinase EPHA2 was modified at S897, a site that was 
previously described by Miao and co-workers. They discovered this 
phosphorylation and monitored the migration of PC-3M and U373 cells in 
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response to different growth factors. When the cells were co-stimulated with the 
EPHA2 ligand Ephrin A1 (EFNA1), migration was abolished as well as the 
phosphorylation at pS897 (Miao et al. 2009). Therefore, EPHA2 might be involved 
in HGF-induced cell motility. Additionally, three tyrosine-modifications on EPHA2 
were identified by Organ and co-workers that were upregulated after 60 min HGF 
stimulation (Organ et al. 2011). Thus, EPHA2 is an interesting novel candidate in 
Met signaling. The role of EPHA2 in the HGF/Met pathway was therefore analyzed 
further in this study and is discussed in detail in the following chapter (see section 
5.4).  
PI3K and AKT1 also mediate signaling via small GTPases that trigger cell motility. 
These proteins were not identified by phosphoproteomics, because they are 
regulated by binding to GTP and GDP and not by phosphorylation sites. However, 
7 of their regulators - GEFs and GAPs – were differentially modified in response to 
HGF. ARHGI and ARHG2 interact with Rac1 (Niu et al. 2003; Ren et al. 1998), 
which is one of the most prominent proteins in Met signaling and belongs to the 
Rho family of small GTPases. The regulated site pS886 is known to be 
phosphorylated by PAK1, which recruits 14-3-3 proteins to the microtubules 
(Zenke et al. 2004). Furthermore, AKP13 acts also as a GEF for Rho family 
members (Diviani, Soderling, and Scott 2001), while RHG05 functions as GAP for 
these proteins (Burbelo et al. 1995). They all were identified by a phosphorylation 
site upregulated after 6 or 20 min HGF.  
As the example of GAB1 illustrates (see section 5.2.1), scaffold proteins play a 
major role in signaling by supporting the formation of protein complexes. The 
adapter AHNK and the anchor protein AKAP2 are two such scaffolds that may 
take part in HGF/Met signaling. They are phosphorylated with a maximum after 20 
min of HGF stimulation, indicating rather a secondary role in the cellular response 
than an important function during signal transduction.  
Furthermore, the phosphatase PTN12 was phosphorylated on T587 after 20 min 
HGF. As this protein removes phosphorylations on tyrosine kinases, the regulation 
might be a negative feedback loop of HGF/Met signaling.  
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5.3.2 Transcription factors and nuclear proteins 
After Met activation, the signal is also transmitted into the nucleus where gene 
expression is modified by activation or inhibition of different transcription factors. 
The translocation is accomplished by components of the nuclear pore complex 
(NPC) that shuttles its substrates into the nucleus. TPR and ELYS are 
nucleoporins that were phosphorylated in response to HGF. ELYS was first 
proposed as transcription factor in mice and was shown later to be responsible for 
postmitotic NPC assembly in HeLa and Xenopus cells (Franz et al. 2007). TPR 
has been characterized as MK01 substrate and nuclear shuttle (Vomastek et al. 
2008). In this thesis, an uncharacterized phosphorylation site on TPR was 
upregulated at every time point after HGF stimulation. Therefore, TPR is likely to 
play an important role in HGF/Met-induced translocation of the signal into the 
nucleus (Figure 5-3).  
 
Figure 5-3: TPR is responsible for MK01 translocation into the nucleus 
After HGF stimulation, the MAP kinase MK01 is activated by double phosphorylation and 
dimerizes in the cytosol. MK01 phosphorylates the protein TPR of the nuclear pore 
complex (NPC), which induces MK01’s translocation into the nucleus.  
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5.3.3 Crosstalk with Wnt signaling 
In response to HGF stimulation, three proteins involved in Wnt signaling were 
differentially phosphorylated. Wnt signaling is induced by receptors of the Frizzled 
(FDC) family and is characterized by inhibition of GSK3β and APC resulting in 
elevated levels of β-catenin (CTNNB1). CTNNB1 again is induced to interact with 
BCL9L that together promote the transcription of Wnt target genes through a 
complex involving LEO1. Subsequent gene expression promotes the production of 
proteins involved in development and cancer invasion (Akiyama 2000; Chaudhary 
et al. 2007; Brembeck et al. 2004). As GSK3β and APC are also described in Met 
signaling (Papkoff and Aikawa 1998; Sagara et al. 2009), a crosstalk between both 
pathways is obvious and was previously proposed (Boccaccio and Comoglio 2006; 
Papkoff and Aikawa 1998; Huang et al. 2012). A crosstalk is further supported by 
the observed phosphorylations on the three proteins APC, BCL9L and LEO1 after 
HGF stimulation in this phosphoproteome analysis.  
5.3.4 Cell adhesion and motility apparatus 
Among other processes, HGF/Met controls cellular movement of DU145 cells that 
is accompanied by regulation of the cytoskeleton and cell adhesion (Humphrey et 
al. 1995; Organ and Tsao 2011). During HGF stimulation of DU145 cells, linkage 
protein E-cadherin is lost from cell-cell junctions, which allows migration (Wells et 
al. 2005). Furthermore, E-cadherin interacts with nectin that has been shown to 
regulate E-cadherin endocytosis. This process involves afadin (AFAD), another 
adherence junction protein that links nectin to the actin cytoskeleton (Hoshino et 
al. 2005). In this study, AFAD was phosphorylated on serine in response to HGF, 
indicating a role for AFAD in Met-mediated dissociation of cell-cell adhesion. 
TENS3, a focal adhesion protein, was phosphorylated on serine after 6 and 20 min 
HGF. Although it is not known in Met signaling, it has been implicated in the EGF 
response in MDA-MB-468 epithelial cells. After stimulation, it also gets 
phosphorylated and occurs in a complex with FAK1 and BCAR1, which are both 
implicated in cell migration (Cui, Liao, and Lo 2004). As Met and EGFR utilize 
comparable downstream cascades and TENS3 is modified by both pathways, it is 
likely that the protein is part of Met signaling and might regulate migration there. 
This is also supported by the finding of Organ and co-workers, who identified this 
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site as upregulated after 10 and 60 min HGF as well (Organ et al. 2011). Other 
junction proteins like LIMA1, ZYX, and JAM1 were also differentially modified after 
growth factor stimulation and might therefore have a function in the 
downregulation of cell adhesion. The regulated site pS284 of JAM1 is 
phosphorylated by PKCA and causes clustering of the protein to cell-cell 
adhesions (Ozaki et al. 2000). Interestingly, Organ also identified a tyrosine 
phosphorylation on JAM1 that is only 4 amino acids apart from the serine 
modification that was regulated in this study. Once the cellular junctions have been 
abolished, the cells are able to move freely. The movement is mediated by 
stretching and contraction of the cytoskeleton. Several proteins unknown in 
HGF/Met signaling but regulating the cell’s motility apparatus were identified by 
phosphoproteomics in this work. One example is MAP1B that binds to 
microtubules and enhances their dynamic stability. Further evidence for the protein 
being part of the Met response is its phosphorylation by GSK3β (Goold, Owen, 
and Gordon-Weeks 1999) and its involvement in the migration of neurons 
(González-Billault et al. 2005). Palladin (PALLD) is an actin-associated protein that 
binds to a large set of other actin-interacting proteins like VASP and PROF1 
(Dixon et al. 2008). Furthermore, it has been described as direct target of the 
kinase AKT1 and contributes to motility of breast cancer cell lines (Chin and Toker 
2010). Here, it was identified by its upregulated serine phosphorylation after 20 
min HGF stimulation and might therefore play a role as regulator of Met-induced 
motility. Other potentially novel cytoskeleton-associated proteins acting in Met 
signaling are FLNC, CD2AP, NAV1, STMN1, and MAP4.  
5.3.5 Crosstalk with the ubiquitin system 
The phosphorylation and ubiquitination systems act hand in hand as is known for 
example in Met signaling during receptor degradation and recycling. While 
activating (E1), conjugating (E2), and ligating enzymes (E3) are required for 
ubiquitination, the reverse process is mediated by deubiquinating enzymes 
(DUBs). Just like for phosphorylation, ubiquitination is tightly controlled by 
balancing these enzymatic activities. In addition to determining a protein’s fate, 
this modification also contributes to signaling pathways by regulating protein 
activity, interaction, and localization. Ubiquitin ligases are often activated by 
phosphorylation (Grabbe, Husnjak, and Dikic 2011). In contrast, modification of 
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DUBs is known for some examples, but mostly the effects are unknown (Reyes-
Turcu, Ventii, and Wilkinson 2009).  
Here, three members of the ubiquitin apparatus were differentially phosphorylated 
after prolonged HGF stimulation (20 min). The E2 enzyme UBE2O is an 
exceptionally large conjugase that transfers ubiquitin to its substrates without any 
involvement of an E3 ligase (Van Wijk and Timmers 2010). The detected 
phosphorylation site on pS839 was also identified after 15 min EGF stimulation 
(Cantin et al. 2008), but is not functionally described yet. Nevertheless, it seems to 
be a conserved modification site in GFR signaling. The second enzyme of the 
ubiquitin system identified here is the E3 ubiquitin ligase NED4L. The regulated 
site pS448 is known to inhibit interaction with ENaC, a channel protein, which 
stabilizes and promotes Na2+ transport (Snyder et al. 2004). No direct link between 
HGF/Met signaling and sodium channels is published, but the MAPK cascade is 
supposed to downregulate the channel’s activity. Furthermore, stimulation of cystic 
fibrosis airway cells with HGF resulted in a reduction of the Na2+ transport (B. Q. 
Shen, Widdicomb, and Mrsny 1999). The third protein differentially phosphorylated 
in response to HGF is the DUB VCIP1. In a RNAi approach targeting several 
DUBs, it was identified as 1 of 12 members that affect HGF-mediated scattering of 
A549 cells (Buus et al. 2009) and might therefore be a crucial component in Met-
induced motility.  
In conclusion, the majority of proteins that were identified here as differentially 
phosphorylated in response to HGF were not known to take part in Met signaling 
before. However, in accordance with their described function, they are likely to 
play a role as signal transducers or effectors. Comparison with the 
phosphotyrosine approach of Organ revealed only one shared phosphorylation 
site among the novel HGF/Met candidates (Organ et al. 2011). Thus, their study 
should not be regarded as competitive, but rather as complementary, because 
they found more than 150 new tyrosine phosphorylations.  
There were 10 uncharacterized proteins that exhibited differential phosphorylation 
sites after HGF stimulation. Due to a lack of information about their function, 
structure and interactions, they could not be integrated into any cascade 
downstream of Met. However, this fact even increases the possibility for these 
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proteins to be novel components of HGF/Met signaling, because they might not 
have been discovered so far.  
More than half of the proteins affected by HGF could not be integrated into 
canonical pathways. One reason is that many proteins are not well-characterized 
concerning their function or involvement in pathways. Additionally, pathway maps 
provided by specialized databases like GeneGo are highly conservative to improve 
clarity. While this is an advantage for getting a first overview of a certain pathway, 
an illustration is not able to reflect the actual complexity of signaling networks.  
5.3.6 Benefits and limitations of time-resolved studies 
In this study, phosphorylations were analyzed during the first 20 min after HGF 
stimulation. Because this modification is highly transient and is adjusted within 
seconds, monitoring several time points improves the number of identified 
phosphopeptides. Only coverage of many time points during signaling will provide 
a comprehensive overview of involved proteins. However, the sample number is of 
course limited by practicability of the experiment and the type of labeling utilized. 
Importantly, time-resolved analyses do not only increase the number of potential 
signal components, but also provide quantitative information about changes of the 
phosphopeptides from one time point to another. This phosphorylation dynamics 
was monitored in the HGF study after 3, 6, and 20 min of stimulation. For all 
regulated peptides, the change of regulation factors over time was determined. 
Clustering according to these dynamics uncovered peptides regulated in the same 
manner and allowed drawing conclusions on effected regulatory networks (see 
previous sections 5.2 and 5.3). However, the heatmaps illustrating regulated 
phosphopeptides already indicated a problem with this transient modification. The 
reproducibility of the values of regulation factors within the three replicates was 
sufficient to draw conclusions, but it differed from one experiment to another. This 
might be affected by slightly different stimulation times and by experimental 
variation during processing of the samples. However, it might also be affected by 
slightly different stimulation times. Phosphorylation reactions are considered as 
fast and thus, seconds might influence the sum of identified phosphopeptides at a 
certain time point. Furthermore, variation between biological samples concerning 
the speed or magnitude of signal processing may also cause this discrepancy. 
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These effects obviously result in three different phosphorylation patterns for the 
triplicate that are shifted, for example, by some seconds on the time-scale.  
Supported by Prof. Frank Klawonn, a promising strategy was set up to calculate a 
temporal correction factor for the triplicate (Klawonn et al. 2012). So far, the 
attempt was only computed for the proof-of-concept data. Nevertheless, this 
strategy is a new chance to reduce intra-experimental variations. Biological 
variation and individual cell responsiveness may also cause the observed variation 
and are therefore difficult to factor in. As the strategy was not applied to the whole 
dataset, it had no effect on the quantitative analyses.  
5.4 The EPHA2 receptor regulates HGF/Met gene 
expression 
Met utilizes a large network of downstream proteins to process the HGF signal and 
produce the required cellular effects. Notably, the network seems to include 
another membrane-bound receptor that usually exhibits an own signaling when 
triggered by its extracellular ligands. The EPHA2 receptor can be activated by 
membrane-bound Ephrin A family ligands and is involved in axon guidance during 
the development of the nervous system (Mori et al. 1995). Unlike other EPH 
receptors, it is additionally found in adult epithelial cells, where it regulates cell 
growth, migration and invasion (Lindberg and Hunter 1990). Once stimulated by its 
main ligand Ephrin A1, it binds to SHP-2, SHC, SLAP, GRB2, and PI3K (Kinch 
and Carles-Kinch 2003). Interestingly, the MAPK cascade was either published as 
up- or downregulated, depending on the receptor’s downstream interaction 
partners (Lin et al. 2010). Target proteins of EPHA2 signaling are integrin and 
CLD4, which are involved in cell adhesion, indicating a role for EPHA2 in 
regulating this process (Miao and Wang 2012). Additionally, EPHA2 is 
downregulated by degradation after Ephrin A1 stimulation. As Ephrin A1 is 
localized in the membrane of surrounding cells, an increased cell density results in 
lower amount of EPHA2 on the surface (Walker-Daniels, Riese, and Kinch 2002). 
On the other hand, there are hints that the EPHA2 receptor can be activated in a 
ligand-independent manner, because EPHA2 was shown to also promote cancer 
progression in the absence of Ephrin A1 (Wykosky and Debinski 2008).  
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Interestingly, EPHA2 was phosphorylated at S897 after 20 min HGF stimulation in 
this study, which indicates a downstream role of EPHA2 in Met signaling. As this 
phosphorylation site was already published to affect HGF-induced motility (Miao et 
al. 2009), the role of EPHA2 downstream of Met became especially interesting. In 
order to examine the effect of EPHA2 knockdown on the cellular output of 
HGF/Met signaling, gene expression analyzes were performed.  
Gene arrays concerning the Met pathway have been completed before. In vivo 
approaches include data from Siltanen and co-workers who examined the effect of 
human HGF overexpression in rat myoblasts and Factor et al. who compared the 
transcriptome of murine liver cells with and without Met knockout (Siltanen et al. 
2011; Factor et al. 2010). Additionally, primary hepatocytes were stimulated for 30 
min, as wells as 2, 12, and 24 h with HGF and wildtype cells were compared to 
Met knockout cells (Kaposi-Novak et al. 2006). Two studies performed in the 
canine cell line MDCK illustrated the HGF response after 3 and 24 h and 
influenced by the MAPK inhibitors UO126, PD09859 (Hellman et al. 2008; 
Balkovetz et al. 2004). However, only two arrays were performed so far in human 
cell lines. The first one by Olivero and co-workers stimulated ovarian cancer cells 
(SK-OV-3) for 6 h with HGF. Nevertheless, their results cannot be compared here, 
because the scientists co-treated the cells with cisplatin, a drug usually applied in 
chemotherapy.  
Van Leenders and co-workers recently published an array analysis using prostate 
cancer DU145 cells. They stimulated the cells for 2, 8, and 24 h with HGF and 
analyzed the resulting gene expression compared to the non-stimulated control 
(Van Leenders et al. 2011). Although van Leenders et al. used the same cell line 
their analysis concentrated on the 24 h time point, while the study performed in 
this thesis focused on earlier gene expression. After 1 h of stimulation, the first 
wave of target genes is expressed, while after 4 h first actors of the cellular 
response are induced.  
5.4.1 Early target genes of HGF/Met signaling in DU145 cells 
In the wildtype, microarray results revealed 656 genes as regulated after 1 h and 
1,072 genes after 4 h HGF consistent in the triplicate. Among them, proof-of-
concept data were found that verified the activation of the HGF/Met pathway. 
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Importantly, of 31 known target genes for HGF and Met, 11 were regulated in the 
dataset (see Table 8-5 in the appendix). For example, after 1 h genes of the 
transcription factors FOSB and JUN (Deleu et al. 1999) were upregulated. After 4 
h, genes coding for the integrin ITA2 (Liang and Chen 2001; van Leenders et al. 
2011) and the transcription factor SOX9 (Van Leenders et al. 2011) were affected. 
The latter two were also identified by van Leenders and are described in the 
publication as two stem-cell markers important during prostate development.  
However, about 99% of the regulated genes are not described as transcriptionally 
regulated by HGF/Met, which is consistent with data from other publications. For 
example, Kaposi-Novak identified 730 regulated genes after 0.5, 2, 12, and 24 h 
HGF stimulation, but they name only 5 genes as known HGF/Met targets, and 
Balkovetz et al. found 8 (Kaposi-Novak et al. 2006; Balkovetz et al. 2004). These 
data clearly illustrate the great lack of knowledge of the HGF/Met pathway and 
especially its target genes.  
5.4.2 EPHA2-mediated control of HGF/Met target genes 
In contrast to the above mentioned gene expression arrays addressing the HGF 
response, this work was the first focusing on the effect of the receptor EPHA2 on 
HGF/Met signaling. With this aim, it was also the first study characterizing a 
potential HGF/Met pathway component by RNAi in combination with expression 
analyses.  
In total, 70 genes were affected by EPHA2 knockdown during HGF stimulation 
(see Figure 4-23). The majority of them were upregulated in the EPHA2 
knockdown (91% after 1 h, 74% after 4 h HGF). This means vice versa that 
EPHA2 in vivo predominantly negatively regulates the HGF/Met response.  
In order to clarify the role of EPHA2 in the HGF/Met response, those genes top-
regulated in the wildtype by HGF and those affected by the EPHA2 knockdown 
were matched. After 1 h of HGF stimulation, 7 genes fulfilled these criteria (see 
Figure 4-24 A). All of them were higher upregulated in the EPHA2 knockdown 
compared to the wildtype. Furthermore, all genes were transcription factors and 
so-called immediate-early genes (IEGs). These genes are expressed early after 
growth factor stimulation or other outside signals like stress or injury. The IEGs 
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were examined in detail during neuronal development, where they regulate key 
targets for dramatic phenotypic changes of the cell (Dijkmans et al. 2009). In 
general, IEGs connect late signaling events to gene expression. Therefore, most 
of the IEGs are coding for transcription factors, controlling the expression of 
different sets of target genes. However, cytoplasmic proteins like the phosphatase 
DUS1 and secreted effectors like cytokines belong to that group (Pérez-Cadahía, 
Drobic, and Davie 2011).  
The best-characterized IEG is FOS, which was also identified in this study as 
regulated by EPHA2 knockdown and is a known HGF/Met target (Boccaccio et al. 
1994). Molecular changes of the fos promotor region in response to post-
translational modifications like SUMOylation or phosphorylation cause the 
activation of proteins responsible for fos gene expression. Already 30 to 60 min 
later, the expression is stopped by several feedback mechanisms. This process 
ensures a transient but strong FOS activity (O’Donnell, Odrowaz, and Sharrocks 
2012). Interestingly, Irie and co-workers described the EPHA2 receptor as a target 
of FOS in osteoblasts (Irie et al. 2009). Thus, HGF/Met activates FOS expression 
and this subsequently induces the production of EPHA2. Moreover, this 
mechanism is controlled by EPHA2 itself by negatively affecting FOS expression. 
In this manner, the concentration of EPHA2 in the cell might be regulated by its 
current abundance of the protein.  
Additionally, the egr1-4 genes of the HGF/Met response were strongly affected by 
the EPHA2 knockdown. With a more than 13-fold upregulation in the EPHA2 
knockdown compared to the wildtype after 1 h HGF stimulation, EGR2 was the 
most affected one. In a recent publication by Zaman, egr2 was discovered to be 
regulated by the MK01/MK03 pathway (Zaman et al. 2012). However, no direct 
link between HGF/Met and EGR2 expression is described so far. The same is true 
for egr3 and egr4. Interestingly, EGR1, which was also affected by EPHA2 
knockdown, was found before by Ozen and co-workers to be regulated by HGF in 
hepatocellular carcinoma (HCC). In their publication, the authors describe the 
effect of HGF stimulation on the expression of EGR1 with an egr1 mRNA peak 
after 1 h. Furthermore, they link HGF/Met-induced EGR1 expression to matrix-
metalloproteases (MMPs) activation, followed by induced cancer invasion in HCC 
(Ozen et al. 2012). As Met controls, among others, invasion and migration, the 
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regulation of EGR1 in this study might also affect motility of DU145 cells through 
EPHA2. No effect on the expression of MMPs was detected here. However, Ozen 
and co-workers characterized the effect of MMPs after 24 h; thus, the chosen time 
points 1 and 4 h were probably too early to detect the expression of these 
proteins.  
Taken together, HGF induces the expression of known immediate-early genes 
after 1 h of stimulation, which is negatively controlled by EPHA2 in the wildtype. 
The genes activated by HGF and subsequent expression of this group influence 
motility and development, but also a large number of other cellular effects like 
survival or proliferation (Ozen et al. 2012). Therefore, it is difficult to conclude, 
which Met-induced phenotypes might be controlled by EPHA2 at this time point.  
 
Similar to the 1 h time point, 7 genes were regulated EPHA2-dependently after 4 h 
HGF stimulation (see Figure 4-24 B). However, in this case, 3 were up- and 4 
were downregulated between EPHA2 knockdown and wildtype in response to 
HGF. One of them was egr4 that was already found after 1 h, where it was more 
strongly induced. The lower regulation of EGR4 and the absence of other IEGs 
after 4 h confirm the transient expression of this group of proteins. Furthermore, 
three genes coding for the proteins CL067, CE058, and CN105 were not 
described functionally in the literature. Therefore, they could not be integrated into 
any process. However, the corresponding genes c12orf67, c5orf58, and c14orf105 
were regulated nearly 3-fold between EPHA2 knockdown and wildtype. Thus, it is 
obvious that they play a role in the HGF/Met response, because they are among 
the top-regulated genes by HGF in the wildtype. Interestingly, they are controlled 
by EPHA2, which makes them exciting candidates for further studies of EPHA2-
dependent Met signaling.  
Furthermore, the potassium channel gene kcnk12 is highly upregulated in the 
wildtype, while it is only slightly affected in the EPHA2 knockdown. Thus, EPHA2 
usually promotes the expression of the gene in wildtype cells. However, as this 
protein has not been implicated in growth factor-induced processes so far, it is 
very difficult to speculate about its role in the HGF/Met response. Usually, 
potassium channels play a role in neuronal conduction of stimuli where they create 
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action potentials by translocating K+ ions. However, the protein coded by kcnk12 
has been shown to be expressed in a wide range of cell types (Patel and 
Lazdunski 2004). Besides its pore-forming ability in neuronal cells, it might act as 
plasma membrane-bound component of cell adhesion in epithelial cells, for 
example. Moreover, the gene corresponding to the neuropeptide receptor NPY5R 
was downregulated in the wildtype, but upregulated in the EPHA2 knockdown in 
response to HGF. Therefore, in the wildtype, EPHA2 usually significantly limits the 
expression of NPY5R. The protein was shown to activate the MAP kinases and 
through them, to induce cell growth in BT-549 cells and motility in MDA MB-231 
breast cancer cells (Sheriff et al. 2010). Therefore, the regulation of EPHA2 on 
NPY5R likely is involved in a negative feedback loop downregulating the MAPK-
effect after 4 h HGF. Furthermore, the gene corresponding to SPSB4 was more 
upregulated in wildtype than in the EPHA2 knockdown. It might directly interact 
with the Met receptor, because the protein was co-immunoprecipitated with Met by 
Wang et al. (Wang et al. 2005). However, the effect of the interaction is unknown. 
4 h after HGF stimulation, this ubiquitin E3 ligase (Kamura et al. 2004) might be 
activated in an EPHA2-dependent manner and mediate ubiquitin-associated 
degradation of Met, which is still membrane-localized. The dynamics of Met 
incorporation and degradation after HGF stimulation was investigated by Jeffers 
and co-workers in several cell lines. They showed that degradation of Met starts 
after 1 h, but with a maximum after 8 h (Jeffers et al. 1997). Therefore, it might still 
be early enough for the cell to express SPSB4 after 4 h HGF in order to stop Met 
signaling by receptor endocytosis and degradation (Figure 5-4).  
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Figure 5-4: EPHA2 controls HGF/Met-induced gene expression 
20 min after HGF stimulation, the site pS897 of the receptor EPHA2 is upregulated by the 
known Met pathway member AKT1. Knockdown of EPHA2 revealed an inhibitory role of 
EPHA2 on the expression of HGF/Met target genes. Therefore, it is likely that EPHA2 is 
involved in a negative feedback loop controlling the HGF-induced genetic program. 
 
Taken together, many cellular processes induced by HGF/Met are negatively 
controlled by EPHA2. This is confirmed by the expression of immediate-early 
genes shortly after HGF stimulation, but also by the regulation of effectors of Met 
receptor degradation or phenotypic changes after 4 h. In agreement with Miao et 
al., there is definitely a regulatory role of EPHA2 in growth factor signaling (Miao et 
al. 2009). However, they described the negative effect on cell migration and 
invasion only during co-stimulation with the EPHA2 ligand Ephrin A1 and not in the 
wildtype, as identified here. Nevertheless, the inhibitory effect of EPHA2 on 
migration during Ephrin A1-HGF co-stimulation could not be reproduced in this 
thesis either. The choice of different cell lines might also influence the results. 
While the authors used U373 cells for their migratory experiments, motile cell lines 
DU145, A549, HepG2 and Caco-2 were utilized in this work to reproduce the 
results, but none of them exhibited the effect described by Miao et al..  
M
e
t
M
e
t
HGF
HGF/Met target genes 
E
P
H
A
2
AKT1
pS897
HGF/Met 
signaling
negative 
feedback?
5.4 The EPHA2 receptor regulates HGF/Met gene expression 123 
5.4.3 EPHA2-Met receptor crosstalk 
Results of EPHA2 knockdown on the transcriptional level in this study convincingly 
indicate a regulatory role of the EPHA2 receptor in the HGF/Met response. From 
the point of signal integration, the role of receptor crosstalk is evident. As a cell in 
vivo is usually exposed to a variety of different signals at once, its response has to 
be processed and balanced in order to create the appropriate cellular reaction. 
Furthermore, many different signals may be necessary to produce one particular 
phenotypic change.  
EPHA2 is not the only receptor or transmembrane protein that interferes with Met 
signaling. Other members of the tyrosine kinase receptor family like EGFR, RON 
and RET can also affect a trans-phosphorylation of Met and vice versa. 
Furthermore, GPCRs associated with their ligands may cause phosphorylation of 
Met, as well as CD44 and the integrins α6β1 and α6β4. Likewise, class B plexins 
stimulate Met activation. However, except for RET, which activates Met through 
SRC, all described cross-talking proteins directly interact with the Met receptor 
(Lai, Abella, and Park 2009). In the publication of Miao et al., the authors describe 
AKT1 as the EPHA2-phosphorylating kinase of the site pS897 (Miao et al. 2009). 
Since this phosphorylation site was identified by phosphoproteomics in this work 
as upregulated only after 20 min of HGF stimulation, a direct interaction of EPHA2 
and Met is unlikely. Additionally, no direct interaction, for example by co-
immunoprecipitation has been published so far. Therefore, EPHA2 and RET 
obviously play slightly different roles in Met signaling as they interfere with the 
downstream signaling and not with the receptor itself.  
How cells can realize signal integration was illustrated by preliminary experiments 
after this work. As previously described, the two siRNAs utilized created a 
differently efficient EPHA2 knockdown. While siRNA7 was very effective with a 
reduction of EPHA2 of 70%, the siRNA5 caused a reduction of only 40% in the 
protein level of EPHA2 compared to the wildtype. Interestingly, scatter assays 
performed with these samples after 24 h HGF stimulation indicated that limited 
loss of EPHA2 leads to increased motility, compared with the wildtype. In contrast, 
efficient EPHA2 knockdown seemed to stimulate apoptosis. This hypothesis is 
supported by the gene expression discrepancies between siRNA5 and 7. Efficient 
knockdown of EPHA2 by siRNA7 significantly increased the expression of three 
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genes associated with apoptosis. Their corresponding proteins TNF10, CASP1 
and BMF have been shown to induce programmed cell death (Wiley et al. 1995; 
Alnemri, Fernandes-Alnemri, and Litwack 1995; Puthalakath et al. 2001). Thus, 
the amount of EPHA2 seems to have crucial impact on the regulated genes, as 
well as the phenotypic result. In conclusion, EPHA2 might be a brilliant example 
for signal integration and this should be investigated in further studies.  
Regarding the effect of EPHA2 in Met signaling, EPHA2 has the capacity to limit 
the cellular response. This mechanism makes especially sense when a cell is 
deregulated, for example in the context of cancer. Indeed, HGF/Met signaling is 
upregulated in many types of cancer and supports survival, proliferation, invasion 
and metastasis (Trusolino, Bertotti, and Comoglio 2010; Birchmeier et al. 2003). In 
contrast, the role for EPHA2 in cancer is still unclear. Although it is found 
upregulated in many cancers, it may not necessarily trigger the disease. 
Remarkably, EPHA2 is often regarded even as cancer inhibitor (Pasquale 2010). 
Thus, in the context of this work, EPHA2 might tightly control Met signaling as a 
checkpoint agent that limits the impact of deregulated Met activity. The serum-free 
conditioning combined with the constant stimulation with HGF might create such a 
scenario for the cells.  
5.5 NEK9: never in mitosis, but in migration? 
The kinase NEK9 was first described in the mitotic context. Like other members of 
the Never In Mitosis A-related (NIMA-like) family, it was activated during mitosis. 
Furthermore, it was shown to bind to the highly homologous protein NEK6 and to 
the GTPase Ran. Since overexpression of this protein caused cell cycle arrest, a 
function of NEK9 as mitotic checkpoint was suggested (Roig et al. 2002). 
However, Reinl and co-workers identified a novel phosphorylation site of NEK9 on 
pT333 during stimulation of HeLa S3 cells with the bacterial surface protein InlB of 
L. monocytogenes. This suggested a role for NEK9 as effector during bacterial 
invasion, in addition to its mitotic function (Reinl et al. 2009). Because the 
phosphorylation site was further confirmed in this study during HGF stimulation of 
DU145 cells, the role of NEK9 in Met signaling was characterized.  
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Surprisingly, knockdown of NEK9 did not affect the proliferation rate. However, 
NEK9 knockdown and stimulation with HGF for 14-20 h resulted in a dramatic 
phenotypic change of HeLa S3 cells. While this cell line is usually non-motile and 
responds to HGF with proliferation, the NEK9 knockdown significantly increased 
the motility of HeLa cells in response to HGF. Likewise, cell adhesion was reduced 
and typical HeLa clusters were resolved, while cells moved away from each other. 
The subsequently performed microarray analysis provided evidence for the 
involvment of NEK9 in HGF/Met-induced gene expression causing the discovered 
phenotype (Figure 5-5).  
 
Figure 5-5: NEK9 regulates HGF/Met-induced motility 
The site pT333 of the kinase NEK9 was upregulated in response to HGF stimulation, 
suggesting a role for NEK9 in Met signaling. NEK9 knockdown cells did not proliferate, but 
significantly increased the expression of motility-associated proteins and showed a scatter 
phenotype when stimulated by HGF. Thus, NEK9 seems to be a switch between 
proliferation and motility.  
 
Remarkably, migratory pathways affected by NEK9 knockdown during HGF 
stimulation can be assigned to epithelial-mesenchymal transition (EMT). This 
process is characterized by an increase in motility of usually stationary, tissue-
bound cells and is especially important during embryogenesis and wound healing. 
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Notably, cancer cells exploit EMT to propagate from their area of origin to the 
whole body to create metastases (Figure 5-6). The transition is regulated by 
several signaling pathways that induce the activity of developmental transcriptions 
factors. These in turn induce the expression of proteins that trigger the loss of 
adherence junctions, the degradation of the extracellular matrix, the motility-
associated cytoskeleton, and the resistance to apoptosis. 
 
Figure 5-6: Epithelial-mesenchymal transition during cancer invasion 
Carcinoma cell can undergo EMT, resulting in cells becoming motile are spreading 
through the whole body and invade other tissues. Eventually, mesenchymal-epithelial 
transition (MET) takes place, which allows cells to become adherent again and grow as a 
metastasis. Figure taken from (Thiery 2002). 
 
For example, upregulated extracellular protein PAI1 was shown by Freytag and 
co-workers to trigger TGFβ 1-EGR-induced EMT, monitored by cell invasion into a 
three-dimensional matrix (Freytag et al. 2010). Experiments performed by 
Grotegut et al. investigated the upstream initiation of SNAI1, one major activator of 
EMT, after HGF stimulation. Dominant negative expression of the transcription 
factor EGR1 inhibited SNAl1 expression in HepG2 cells. Furthermore, expression 
of egr1 and snai1 was dependent on the stimulation of the MAPK cascade 
(Grotegut et al. 2006). Therefore, EGR1, in addition to being regulated in the 
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EPHA2 knockdown was also influenced by NEK9 knockdown in this work, was 
revealed as important regulator of HGF/Met-mediated EMT.  
All NEK9-regulated genes involved in the processes necessary for cell migration 
also fit well into the EMT context, where non-motile tissue cells decrease their 
contacts and start to move. These processes include the abrogation of cell-cell 
contacts, the dissolving of the extracellular matrix around the cells, as well as the 
upregulation of components necessary for migration. The latter are cytoskeleton-
associated proteins and those activating the rearrangements of the cytoskeleton. 
Additionally, there is evidence that cells are not able to move and divide in parallel 
(Makagiansar et al. 2007). Accordingly, genes coding for mitotic proteins should 
be downregulated in the NEK9 knockdown. Indeed, the results of the gene 
expression analysis depending on NEK9 and HGF confirmed this assumption.  
FLRT3, which was described by Ogata et al. as a factor abolishing cell adhesion, 
was nearly 8-fold upregulated in response to HGF and NEK9. Loss-of-function 
experiments revealed that FLRT3 causes dynamin-mediated endocytosis of 
cadherin in frog embryos. Thus, the lack of cadherin on the cell surface led to 
increased migration of embryonic cells (Ogata et al. 2007). The two matrix 
metallopeptidases MMP1 and MMP3 were among the top 5 upregulated genes. As 
their names indicate, those proteins degrade the extracellular matrix and provide 
the room for migration of the cells. Interestingly, both proteins are known targets of 
HGF/Met during EMT. Jinnin and co-workers demonstrated that MMP1 is 
regulated via the MK01/MK03 pathway in human fibroblasts (Jinnin et al. 2005). 
Very recently, Lee and co-workers proved the HGF-induced expression of MMP3 
by RT-PCR, but did not characterize the upstream regulatory pathways (Lee, Park, 
and Rah 2011). Upregulation of cytoskeleton modulators SYP2L and PLEK2 and 
small GTPase RAC2 further supported the EMT-inducing effect of NEK9 
knockdown. In contrast, expression of the gene coding for cell adhesion protein 
CLN1 was downregulated, proving the abrogation of cell-cell contacts. 
Additionally, an inhibitor of the cyclin-CDK complex, CDNA1, was upregulated in 
NEK9 knockdown cells, thus verifying the inhibition of mitotic processes during 
EMT.  
Both utilized siRNAs against NEK9 were added in combination and not separately 
to improve the efficiency of the NEK9 knockdown. Therefore, off-target effects of 
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one of the siRNAs cannot be ruled out completely for all experiments. Future 
investigations controlling the monitored motility effect will elucidate whether the 
presented results are due to NEK9-deficiency or are influenced by side effects. 
Nevertheless, if those results confirm the remarkable effects of NEK9 knockdown, 
this would clearly illustrate the importance of Met signaling in regulating crucial 
phenotypic processes.  
Furthermore, the initially apparent discrepancy between the described role of 
NEK9 during cell cycle progression and the novel migratory effect of this protein 
makes sense when considering it more thoroughly. First, motility was observed in 
the NEK9 knockdown, revealing an inhibitory effect of NEK9 on cell motility in the 
wildtype. Second, cells either proliferate or migrate; a mixture of both opposed 
processes in parallel is unlikely (Makagiansar et al. 2007). Therefore, NEK9 
seems to control both, motility-inhibition and cell cycle progression in HeLa cells. 
Which function is activated at a given time point, might be regulated through the 
localization of the protein. As NEK9 was found in the cytoplasm and the nucleus 
(Tan and Lee 2004), spatial distribution of the protein may decide on the protein’s 
effect. Furthermore, NEK9 is phosphorylated on pT210 during mitosis, while it was 
modified at pT333 after HGF stimulation in HeLa cells. These different sites may 
each activate a separate function.  
Taken together, NEK9 was shown to play a central role in regulating HGF/Met-
induced cell migration in HeLa cells. Met signaling balances proliferation and 
motility - as well as survival and apoptosis in healthy cells. In contrast, these 
processes are deregulated in cancer, where Met signaling is permanently 
activated and causes EMT that supports metastasis. Although no studies have 
investigated the expression or activity of NEK9 in cancer compared to healthy cells 
so far, results of this work indicate that NEK9 has to be considered and 
investigated as a tumor suppressor.  
5.6 InlB-induced signaling of Met 
Met-dependent phosphorylation induced by HGF has been characterized in detail 
in the previous chapters. These studies contributed significantly to the current 
knowledge of HGF/Met signaling and its targets, Furthermore, they provided a 
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prerequisite to analyze the impact of a pathogen’s interference with host cell 
signaling. As an example, the invasin InlB of Listeria monocytogenes was used to 
characterize Met-dependent signaling during pathogen infection.  
Importantly, 13 of 28 sites were differentially phosphorylated after InlB stimulation, 
but not affected in the HGF dataset (Figure 5-7 and see Table 4-4). Obviously, 
these candidates seem to be the basic InlB-dependent Met response. However, 
different cell lines and stimulation times were utilized in the two studies. Each 
analysis was performed in the appropriate model cell line, but protein composition 
or phosphorylation responsiveness of the cells might differ. The lack of phospho-
specific antibodies against the identified InlB-specific candidates hampered the 
verification of phosphoproteomic results in different cell lines. Considering the 
different time points used for stimulation with InlB and HGF, it has to be kept in 
mind that these modifications happen fast and are extremely transient. Therefore, 
the one-minute difference between the InlB and HGF datasets may have an 
influence on the phosphorylation pattern. In addition, signaling dynamics induced 
by the two factors might also be different; independent from the same stimulation 
time. Thus, results could vary for this reason as well. Indeed, two publications 
illustrate different phosphorylation kinetics of the two ligands. Shen and co-
workers, who first identified InlB as agonist for Met, observed that tyrosine 
phosphorylation of Met in T47D cells was at least 4 times prolonged after HGF 
stimulation, compared to InlB (Y. Shen et al. 2000). In contrast, InlB caused a 
more intense Ras-MAPK activation than HGF in Vero cells (Copp et al. 2003). 
Both effects were shown to be concentration-independent. As HGF and InlB are 
structurally unrelated and even bind to different sites of the Met receptor, 
discrepancies in signal intensity and kinetics are very likely anyway.  
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Figure 5-7: Comparison of HGF and InlB signaling 
Comparing the regulated phosphorylation sites of the HGF dataset (after 3 and 6 min) with 
those affected by InlB (after 5 min) revealed specific pathway members for each ligand. 
These might cause the known cellular responses proliferation, survival and migration in 
response to HGF, and invasion of the pathogen L. monocytogenes in response to InlB. 
However, 5 sites were significantly regulated similar in both datasets. Further 19 
phosphorylation sites were significantly regulated after HGF stimulation and were also 
affected by InlB, although not significantly. Thus, HGF and InlB share some downstream 
pathway members and might, in part, induce similar cellular responses. 
 
5.6.1 InlB influences immune-associated proteins in its host 
Assuming that the candidates only affected by InlB are validated correctly, the 
InlB-induced signaling involves proteins regulating cellular immunity. TRAD1 
participates in Toll-like receptor (TLR) signaling and Mashima and co-workers 
showed that the protein is part of a negative feedback loop that downregulates 
NFκB signaling. When TLRs are activated following pathogen contact, a 
conserved canonical cascade is induced, which includes the E3 ubiquitin ligase 
TRAF6. This protein activates kinases that finally trigger the transcription factor 
NFκB to relocate into the nucleus, where it activates the transcription of pro-
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inflammatory genes (Lang and Mansell 2007). Mashima et al. showed that TRAD1 
interacts with TRAF6 in HEK-293T cells and that TRAD1, when overexpressed, 
inhibits NFκB-mediated gene expression. However, they did not describe the 
mechanism, which regulates TRAD1-TRAF6 interaction (Mashima et al. 2005). 
Nevertheless, results of this work indicate that TRAD1 activation might be 
controlled by the phosphorylation on pS415 that was downregulated after 5 min of 
InlB stimulation. This phosphorylation site has been identified before, e.g. during 
the stimulation of HeLa cells with the cytokine TNFα (Nabetani et al. 2009). 
However, the function of the site is still unknown. Interestingly, besides TRAD1, 
Nabetani et al. identified two proteins affected by the cytokine that were also 
differentially phosphorylated by InlB in this work. The phosphatase IASPP and 
heat shock protein HSPB1 were regulated by TNFα (Nabetani et al. 2009), and 
also after 5 min of InlB. Furthermore, like TRAD1, they are part of the TRAF6 
network in TLR signaling. While IASPP interacts with the subunit TF65 of NFκB 
and is able to inhibit its transcriptional activity (Yang et al. 1999), HSPB1 interacts 
directly with TRAF6 and supports its ubiquitination. When cytokine-stimulated in 
HeLa cells, HSPB1 is phosphorylated at pS78 and pS82, resulting in the 
dissociation from TRAF6 and subsequently causing decreased TRAF6 
downstream signaling (Wu et al. 2009). Notably, the site pS82 was also 
upregulated after InlB stimulation in this work, proposing a downregulation of 
TRAF6-NFκB signaling in response to contact with the pathogenic protein. The 
second site was not detected here, but might be essential for the inhibitory effect 
(Figure 5-8).  
The identified phosphorylation sites of TRAD1 and IASPP are not characterized 
functionally yet. Thus, direction of regulation does not provide information on the 
proteins’ activity. They may be activated or inhibited by the modification, and 
therefore the immune response might be up- or downregulated. This study only 
proves that the TRAF6-NFκB pathway is influenced by InlB. In fact, InlB was 
already shown by Mansell and co-workers to trigger an NFκB-mediated immune 
response through PI3K in the macrophage-like cell line J774 (Mansell et al. 2000).  
Interestingly, other virulence factors of L. monocytogenes directly affect the 
immune response. Purified extracellular Listeriolysin O stimulates the regulator of 
NFκB and thereby activates this pathway in HEK-293 (Kayal et al. 2002). 
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However, intracellular produced InlC downregulates this pathway through 
interaction with IKK, the regulator of NFκB, in HEK-293 and HeLa cells (Gouin et 
al. 2010). These obvious discrepancies between the activation and the 
downregulation of NFκB signaling by different proteins of L. monocytogenes 
illustrate well the complexity of signaling networks. Perhaps, time-dependent 
activation may explain this problem. For example, InlB effects were investigated 
after minutes, while the downregulation by InlC was monitored only 4 h after 
stimulation. Furthermore, Mansell and colleagues proposed different possibilities 
of the NFκB effect. Firstly, immune response may be upregulated by bacterial 
particles, proving the ability of host cells to defend against pathogens. Secondly, 
Listeria might downregulate NFκB signaling in order to dampen the pro-
inflammatory response. Finally, NFκB signaling can avoid apoptosis of the host 
cell and would therefore support the pathogen’s survival (Mansell et al. 2000). In 
either way, future studies will shed light on these currently still contradictory 
observations. Nevertheless, L. monocytogenes infection clearly affects the NFκB 
pathway through several bacterial proteins. Furthermore, the observed 
upregulation of the site pS82 of HSPB1 might hint at an inhibitory function of InlB in 
this context.  
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Figure 5-8: InlB affects its host's immune response 
The proteins differentially phosphorylated after 5 min InlB (blue rectangles) belong to a 
negative feedback loop that abolishes TRAF6-NFκB signaling. Phosphorylated HSPB1 
and TRAD1 inhibit TRAF6 signal transduction, while the phosphatase IASPP prevents 
transcriptional activity of NFκB (yellow ovals). This cascade is usually stimulated by Toll-
like receptors (TLRs) after pathogenic contact and includes TRAF6 activation and NFκB 
translocation into the nucleus. The latter protein induces the transcription of pro-
inflammatory genes in response to the stimulus. As the monitored phosphorylation sites 
on the three effectors are not characterized, the transcription of pro-inflammatory genes 
might be either up- or downregulated. Furthermore, which proteins are involved in the 
regulation of these sites after InlB stimulation is unknown.  
 
In conclusion, TRAD1, IASPP and HSPB1 belong to a negative feedback loop of 
the TRAF6 network and negatively control the gene expression of pro-
inflammatory genes. Stimulation of cells by InlB might downregulate innate 
immunity and would support Listeria infection. Surprisingly, this was observed in 
epithelial HeLa cells, and not in immune cells that are specialized for TLR 
signaling and the activation of an immune response. Nevertheless, there are hints 
for the involvement of non-immune cells in the activation of the immune system. 
For example, TLRs and other innate pattern recognition receptors (PRRs) are not 
only expressed in immune cells like dendritic cells or macrophages, but also in 
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fibroblasts and epithelial cells like HeLa. Furthermore, even in the non-immune 
cells, the transcription of pro-inflammatory genes is activated in response to 
pathogenic contact (Aoki et al. 2012; Takeuchi and Akira 2010). Therefore, InlB 
stimulation might really affect immunity in HeLa cells via the downregulation of 
TRAF6-mediated signaling. That indicates that L. monocytogenes might promote 
its own survival already at an early stage of infection, when the pathogen is still 
extracellular. At that time point, the bacterium is especially vulnerable, because it 
can be easily detected and eliminated by the immune system. Therefore, it might 
protect itself by downregulating the immune response of all surrounding cells. 
Moreover, InlB has been shown to be not only bound to the bacterial surface, but 
also occurs in a soluble form (Ireton 2007; Trost et al. 2005), which might 
particularly promote the inhibitory effect in a larger expense in the surrounding 
tissues.  
5.6.2 Side effects of L. monocytogenes infection 
The second half of the proteins affected by InlB was comparable to the HGF data 
(see Table 8-6 in the appendix). The large size of this subset supports the theory 
that InlB mainly mimics HGF signaling and not all induced cascades are crucial for 
the invasion of L. monocytogenes. These additional cascades are induced by InlB, 
but might not be an advantage for the pathogen, but rather side effects that at 
least do not hamper invasion and survival of the bacterium. Nevertheless, 
although likely unimportant for the bacterium, many host cell processes are 
deregulated by the induced signaling. As the Met pathway usually regulates a 
great amount of crucial cellular responses, a deregulation might have enormous 
consequences on host cell homeostasis.  
One mechanism induced by Met is apoptosis. However, Listeria needs an intact 
host cell for proliferation, therefore the induction of apoptosis - even by chance - 
would not support the bacterium’s life cycle. In contrast, the opposite signal for 
host cell survival, which is also controlled by Met, maintains the status-quo for the 
pathogen and would support its life in the host. Notably, prolonged host cell 
survival is also one of the characteristics of cancer cells. The question arises 
whether L. monocytogenes infection affects cancer-associated processes. 
Although the ability of L. monocytogenes to trace cancer tissues and to induce 
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inflammatory responses that support cancer therapy was investigated (Guirnalda, 
Wood, and Paterson 2012), there are no hints for a correlation between listeriosis 
and development of cancer yet. However, the causes of cancer induced by viral or 
bacterial infections might be difficult to define due to the long time interval between 
the two diseases. For those infections that are already known to cause cancer, 
patient samples included the pathogens, thus a correlation was more or less 
obvious. Helicobacter pylori infection, for example, was shown in 1984 to be one 
cause of gastric cancer by a screening of gastric biopsy samples (Marshall and 
Warren 1984). Thereby, the virulence factor CagA of H. pylori translocates into the 
host cell upon cellular adhesion. Interestingly, Churin et al. demonstrated that this 
CagA binds and activates the Met receptor intracellularly, causing increased host 
cell motility, which may be associated with cancer development (Churin et al. 
2003). Furthermore, in 1983, the group of zur Hausen identified human papilloma 
virus (HPV) DNA in biopsy samples of invasive cancers, thereby proving that HPV 
infection may induce cervical cancer (Dürst et al. 1983).  
In contrast, most infections with L. monocytogenes in otherwise healthy humans 
mostly cause inconspicuous symptoms like mild diarrhea. Thus, many cases may 
not be diagnosed and therefore complicate the identification of a correlation 
between a Listeria infection and cancer development.  
5.6.3 Does InlB mimic HGF? 
InlB induces many signaling cascades similar to HGF. However, the example of 
the differentially regulated TRAF6-NFκB pathway has demonstrated that InlB 
indeed uses specific signaling molecules to promote its survival in the host. 
Moreover, several hints in the literature show that duration of Met activation is 
different, as well as the strength of induced MAPK signaling (Y. Shen et al. 2000; 
Copp et al. 2003). This is not unexpected as HGF and InlB are structurally 
unrelated and bind to different domains of the Met receptor. Therefore, InlB does 
not mimic HGF, but rather acts like an independent factor that is able to mediate 
specific downstream pathways. Similar signaling pathways downstream of Met 
induced by both ligands might only be side effects of InlB, It is likely that these are 
not essential for the pathogen’s survival, proliferation and spreading in the host, 
but might cause significant attendant symptoms during and after Listeria infection.  
6 Outlook 
As the HGF study was performed in DU145 and InlB in HeLa S3 cells, it is 
necessary that the monitored differences between the regulated phosphorylation 
sites are not cell type-specific. Therefore, all proteins regulated only after HGF or 
InlB stimulation have to be examined via immunoblot against their regulated 
phosphorylation sites. The reason why that was not performed during this work 
was the lack of phospho-specific antibodies against these sites. Thus, it may be 
necessary to produce the required antibodies by immunization of mice or rabbits in 
order to get specific polyclonal antisera. Furthermore, promising candidates should 
also be additionally immunoblotted against the whole protein, to ascertain the 
presence of a constant level of the protein in all samples. In some cases, protein 
degradation might have caused a “downregulation” of the phosphorylation site, 
although the amount of protein had decreased in fact.  
Using phosphoproteomics, this work identified more than 60 proteins downstream 
of Met that were differently phosphorylated in response to HGF or InlB. Through 
their known interaction partners or their involvement in Met-induced processes 
there is evidence that these proteins take part in Met signaling or are substrates of 
involved components. However, only the functional characterization of the 
regulated phosphorylation sites will provide reliable information. Therefore, site-
specific mutagenesis in combination with interaction studies using co-
immunoprecipitation, co-localization, e.g. by fluorescence imaging, and in vitro 
kinase assays are necessary. These experiments will show whether a regulated 
phosphorylation site is functional in response to stimulation or not, and where the 
protein has to be integrated into the Met pathway. Additionally, the TRAF6-NFκB 
network that was influenced by InlB stimulation is worth verification. Also in this 
case, functional characterization of the regulated phosphorylation sites will show, 
through which intermediate proteins InlB regulates modification of these immune 
signaling molecules. Furthermore, in order to answer the question whether InlB 
activates or downregulates the immune response of the host cell, gene expression 
arrays might be performed to investigate the impact of InlB on its host’s genetic 
program. Additionally, InlB-stimulated cells could be screened for the production of 
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pro-inflammatory factors like cytokines. These should be produced, only if InlB 
upregulates the immune response of the cell.  
As InlB has been shown to trigger many side effects that could lead to the 
development of cancer, this correlation might be studied in the future. Therefore, 
extensive epidemiological screens among cancer patients should be performed. 
Additionally, infection studies with mice might also prove if there is a higher 
probability for these animals to develop tumors later on.  
As kinases are still underrepresented in the phosphoproteome after HGF and InlB 
stimulation, further experiments enriching the kinome as realized by Reinl and co-
workers should be performed using the same conditions as in this work (Reinl et 
al. 2009). Kinome and phosphoproteome data integration by systems biology will 
further contribute to the knowledge of the complex regulation of the Met signaling 
networks.  
Although microarrays demonstrated a regulatory role for the EPHA2 receptor in 
HGF/Met-induced gene expression, the molecular mechanism of regulation is still 
unclear. The identified phosphorylation on pS897 should be investigated by site-
specific mutagenesis to verify its participation in controlling the expression of 
target genes. As this site is modified by AKT1, that has several other targets 
besides EPHA2, regulation of this kinase is also worth investigation. Additionally, 
the pathway downstream of EPHA2, which leads to the inhibitory effect on 
HGF/Met-induced gene expression might be studied by phosphoproteomics in 
future. As the amount of EPHA2 in the cell seems to influence the phenotypic 
response as well, signal integration should be considered including protein 
quantity. Most interesting is a comparison of pathways downstream of EPHA2 
induced either indirectly by HGF or directly by its actual extracellular ligand Ephrin 
A1.  
Cell type-specific effects also might have caused the inability to reproduce 
inhibition of scattering by HGF through co-stimulation with Ephrin A1 as described 
in the publication of Miao (Miao et al. 2009). Therefore, the U373 cell line used by 
the authors should be tested as well as their self-made Ephrin A1, which could 
have also prevented the inhibitory phenotype of the co-stimulation. Additionally, 
experiments should be performed, in which the receptor is stimulated by the 
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membrane-bound ligand, because this is its naturally occurring form. Many studies 
done so far used an artificial soluble Ephrin A1, which might not act exactly like the 
bound form.  
Preliminary data of this thesis to elucidate the effect of EPHA2 knockdown on 
HGF-induced scattering of DU145 cells 24 h after stimulation indicated that the 
amount of EPHA2 defines the phenotypic response. Once the effects are 
confirmed, long-term gene expression monitored after 24 h HGF will reveal genes 
responsible for the discovered differential phenotypes of EPHA2 knockdown. As 
epha2 certainly is a target gene of HGF/Met signaling, the knockdown stability 
should be tested by immunoblot over the whole time span. Additionally, EPHA2 
overexpression studies might be performed in order to investigate whether the 
inhibitory effect on HGF-induced gene expression can be increased beyond the 
level observed and a clear dose-response relationship exits.  
NEK9 investigations illustrated that this kinase might regulate HGF/Met-activated 
motility. As all experiments were performed with the two siRNAs in combination, 
off-target effects of one of the siRNAs cannot be excluded. Therefore, data should 
be improved using the siRNAs separately in order to verify the monitored 
impressive effect on cell migration. Once NEK9 is verified as important inhibitor of 
scattering, its cellular protein level should be compared within different cell lines. 
Motile cells like DU145, HepG2, and A549 might contain less NEK9 compared to 
non-motile ones like HeLa or Hep3B. Interestingly, this correlation could also be 
investigated in primary cancer cells. Tissues originating from metastases might 
show lower levels of NEK9 than those of healthy or non-metastatic tissues. In this 
case, NEK9 would be a promising target for cancer therapy. Nevertheless, not 
only the protein level, but also the activity of the NEK9 protein might determine cell 
migration. Therefore, the regulated phosphorylation site pT333 on NEK9 should be 
investigated by site-directed mutagenesis combined with functional studies in 
order to clarify the role of this site in Met signaling. Additionally, overexpression of 
NEK9 should increase its inhibitory effect on cell motility of usually migrating cell 
lines. If this is indeed correct, DU145 cells, for example, will show no response to 
HGF, proving an important role for NEK9 in controlling cellular motility.  
 
7 Summary 
Met is a receptor tyrosine kinase that is located on the surface of vertebrate 
epithelial cells. The main ligand of Met is hepatocyte growth factor (HGF), a 
mesenchymal-derived growth factor, which activates several signaling cascades 
downstream of Met that regulate proliferation, motility as well as apoptosis and 
survival. Therefore, HGF/Met plays an important role during embryogenesis, but 
also during wound healing in adults. However, HGF and Met are deregulated in 
cancer accompanied with poor prognosis and metastasis. Furthermore, the 
pathogenic bacterium Listeria monocytogenes exploits the Met receptor for 
invasion into its host cell through binding with the surface protein internalin B 
(InlB). Infection with the food-borne pathogen might cause meningitis and 
miscarriage in pregnant women. Both Met ligands induce signaling cascades that 
are mediated via phosphorylations, which are transmitted by kinases and are 
removed by phosphatases. Phosphorylation of a protein can affect its activity, 
interaction with other proteins, or even its localization. Therefore, the analysis of 
the phosphorylation pattern after activation of Met by one of its ligands is a 
suitable method to identify novel proteins involved in these signaling cascades. 
The first aim of this work was to characterize the physiological Met signaling in 
DU145 cells. Subsequently, this knowledge was utilized as prerequisite to 
understand the influence of the pathogen L. monocytogenes by stimulation of Met 
with bacterial InlB.  
Phosphoproteomics using Ga-based IMAC phosphopeptide enrichment, followed 
by fractionation via SCX and LC-MS/MS measurement provided access to 7,996 
different phosphopeptides from a triplicate. Quantitative analyses resulted in 95 
phosphopeptides that were significantly regulated in the first 20 min of HGF 
stimulation. This work found 80 proteins that were differentially phosphorylated in 
response to HGF. Although the HGF/Met pathway has been studied for two 
decades, 40 of them are novel pathway components acting downstream of the Met 
receptor. Furthermore, signaling dynamics of all regulated phosphorylation sites 
was characterized.  
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In this study, the function of two novel proteins was studied more detailed to 
determine their roles in HG/Met signaling. Scatter assay and gene expression 
analyses using RNAi revealed the kinase NEK9 as an important regulator of 
cellular motility in response to HGF. Furthermore, knockdown of the receptor 
tyrosine kinase EPHA2 illustrated its role in controlling the HGF/Met-induced target 
gene expression. Thus, besides its receptor function, which is activated by Ephrin 
A proteins, EPHA2 acts as downstream signaling component of HGF/Met. Both 
proteins, NEK9 and EPHA2, could be key components of Met signaling that might 
play an important role as cancer suppressors in healthy tissue.  
When cells were stimulated with the pathogenic InlB and analyzed by 
phosphoproteomics, about 50% of the differentially phosphorylated proteins were 
similar to the physiological signaling induced by HGF. Nevertheless, the other half 
was only regulated after InlB stimulation, indicating crucial components necessary 
for L. monocytogenes infection. Among those were proteins that act as negative 
effectors of cellular immunity, complementing our knowledge how L. 
monocytogenes subverts host cell’s defense during infection.  
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7.1 Zusammenfassung 
Met ist eine membranständige Rezeptor-Tyrosine-Kinase, die sich auf der 
Zelloberfläche von Epithelzellen von Wirbeltieren findet. Der Hauptligand von Met 
ist der Wachstumsfaktor HGF, der den Rezeptor aktiviert und damit mehrere 
Signalkaskaden unterhalb von Met induziert, die Proliferation und Motilität, sowie 
Apoptose und Überleben der Zelle regulieren. Daher spielen HGF und Met eine 
wichtige Rolle in der Embryonalentwicklung, aber auch während der Wundheilung 
bei Erwachsenen. Allerdings sind diese Proteine in Krebs dereguliert, was mit 
einer schlechten Prognose, sowie Metastasierung in Zusammenhang gebracht 
wird. Weiterhin nutzt das pathogene Bakterium Listeria monocytogenes den Met-
Rezeptor als Eintrittspforte in seine Wirtszelle, indem es Met mit dem 
Oberflächenprotein Internalin B (InlB) bindet und aktiviert. Infektion mit diesem 
über kontaminierte Nahrung aufgenommenen Bakterium können zu Meningitis und 
Fehlgeburt führen. Beide Liganden des Met-Rezeptors induzieren 
Signalkaskaden, die durch Phosphorylierung von Kinasen vermittelt, und durch 
Phosphatasen gegenreguliert werden. Phosphorylierung eines Proteins kann 
seine Aktivität, die Interaktion mit anderen Proteinen, als auch seine Lokalisierung 
beeinflussen. Daher ist die Analyse des Phosphorylierungsmusters, welches durch 
einen der beiden Liganden induziert wird, eine geeignete Methode um neue 
Proteine zu identifizieren, die im Met-Signalweg eine Rolle spielen.  
Das erste Ziel dieser Arbeit war es den physiologischen HGF/Met-Signalweg in 
DU145-Zellen zu charakterisieren. Nachfolgend diente dieses Wissen als Basis für 
die Analyse des Einflusses einer Infektion mit L. monocytogenes, welcher nach 
InlB-Stimulation untersucht wurde.  
Phosphoproteomische Analysen mittels Anreicherung der Phosphopeptide durch 
Ga-basiertes IMAC, folgende SCX-Fraktionierung und Messung durch LC-MS/MS 
ermöglichten die Identifizierung von 7.996 verschiedenen Phosphopeptiden aus 
drei Replikaten. Durch quantitativen Vergleich konnten 95 Phosphopeptide 
gefunden werden, die in den ersten 20 min nach HGF-Stimulation signifikant 
reguliert waren. Damit ermöglichte diese Arbeit eine Identifizierung von 80 neuen 
Komponenten stimuliert durch HGF. Obwohl der HGF/Met-Signalweg schon seit 
zwei Dekaden untersucht wird, wurden 40 Proteine gefunden, die unterhalb des 
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Met-Rezeptors agieren. Zudem konnte die Phosphorylierungsdynamik aller 
regulierten Phosphorylierungsstellen innerhalb der ersten 20 min nach Stimulation 
aufgeklärt werden.  
Nachfolgend wurden zwei neue Proteine genauer untersucht, um ihre Rolle im 
Met-Signalweg zu bestimmen. Migrationsstudien und die Analyse der 
Genexpression mit Hilfe der RNAi-Technik ließen eine Funktion der Kinase NEK9 
bei der Inhibition von HGF-induzierter Zellmotilität vermuten. Außerdem zeigte der 
Knockdown von EPHA2, dass dieses Protein die Regulation von HGF/Met-
Zielgenen beeinflusst. Neben seiner Rolle als Rezeptor für Ephrin A-Proteine 
wurde EPHA2 daher als Signalweg-Bestandteile unterhalb von HGF/Met 
identifiziert. Daher können beide Proteine, NEK9 und EPHA2, 
Schlüsselbestandteile des Met-Signalwegs sein, welche im gesunden Gewebe als 
Tumor-Suppressoren wirken.  
Phosphoproteomische Analysen von Zellen, die mit dem pathogenen Protein InlB 
stimuliert wurden, zeigten 50% Ähnlichkeit der regulierten Phosphopeptide, 
verglichen mit dem physiologischen HGF/Met-Signalweg. Hingegen war die 
andere Hälfte nur nach InlB-Stimulation reguliert, was spezifische Signalweg-
Komponenten für InlB vermuten lässt, die die Invasion von L. monocytogenes 
ermöglichen. Unter diesen wurden Proteine gefunden, die innerhalb eines 
Feedback Loops die Immunantwort regulieren. Daher könnte das Pathogen L. 
monocytogenes die Abwehr seines Wirts während der Invasion gezielt 
unterwandern, um sein Überleben zu sichern.  
 
8 Appendix 
8.1 Additional tables 
Table 8-1: List of all 95 HGF-regulated phosphorylation sites 
Significantly regulated phosphorylation sites after 3, 6, or 20 min of HGF stimulation in DU145 cells. Log2 regulation factors of the triplicate E1, E2, 
and E3 are illustrated. Significant RFs possess a pval (p-value) of below 0.05 (marked as bold letters). Proteins that are novel members, but are 
likely involved in Met signaling are marked by ** 
Uniprot ID Protein P-Site E1_3min E2_3min E3_3min E1_6min E2_6min E3_6min E1_20min E2_20min E3_20min pval3 pval6 pval20 
P55196 AFAD** S1799 1.275 1.428 1.648 1.181 1.699 1.664 0.798 1.248 0.887 1.30E-18 6.03E-16 4.94E-07 
P55196 AFAD** S1721 0.076 0.613 -0.122 0.181 0.367 0.214 0.679 1.026 0.867 1 1 6.81E-05 
P52594 AGFG1 T177,S181 -0.508 -0.131 -0.327 -1.182 -0.428 -0.907 -1.63 -0.637 -0.965 1 0.249823418 0.000330069 
Q09666 AHNK** S135 0.343 0.01 -0.414 1.013 0.661 0.748 1.254 0.822 0.819 1 0.00013518 1.93E-07 
Q09666 AHNK** S3426 1.02 0.342 0.375 1.96 0.623 1.051 1.972 0.85 0.938 1 0.000547508 4.64E-08 
Q09666 AHNK** S5099 0.559 1.17 0.26 1.941 1.474 1.122 NA 1.733 1.285 1 2.28E-14 1 
Q9Y2D5 AKAP2** S720 0.17 0.77 -0.04 0.671 0.689 0.656 1.018 0.914 0.556 1 0.00016313 0.005476067 
Q12802 AKP13** S2709 -0.093 0.654 -0.04 0.501 0.717 0.502 1.033 0.878 0.69 1 0.030962004 4.45E-05 
Q96B36 AKTS1** T246 1.227 1.243 1.602 1.22 1.447 1.779 1.055 1.067 1.28 3.16E-17 4.98E-17 1.14E-12 
P25054 APC S2449 -0.093 -0.422 -0.094 -0.344 -0.157 -0.198 -0.638 -0.504 -0.49 1 1 0.043129258 
Q92974 ARHG2** S886 -0.025 0.843 0.038 0.246 0.632 0.848 0.789 0.793 0.873 1 1 7.35E-07 
Q6ZSZ5 ARHGI** S1124 -0.206 0.527 -0.053 0.68 0.402 0.111 0.762 0.514 0.605 1 1 0.020839877 
Q8WWM7 ATX2L S339 -0.079 -0.175 -0.108 -0.299 -0.218 -0.279 -1.209 -0.691 -0.757 1 1 4.28E-05 
Q86UU0 BCL9L S21 -0.301 -0.664 -0.518 -1.299 -0.936 -1.027 -1.155 -0.653 -0.807 1 6.94E-10 0.000182745 
Q13185 CBX3 S95 -0.39 -0.548 -0.108 -0.489 -0.439 -0.095 -0.894 -0.555 -0.514 1 1 0.020839877 
Q9Y5K6 CD2AP** S458 0.644 0.486 0.705 0.532 0.356 0.502 0.451 0.184 0.4 0.048585075 1 1 
Q86WR7 CJ047 S212,S215 0.441 -0.218 0.385 1.134 0.563 0.854 1.04 0.583 0.86 1 0.004342153 0.002221379 
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Q86WR7 CJ047 T214,S215 0.159 -0.378 0.434 1.227 0.511 0.923 1.148 0.325 1 1 0.022825495 1 
Q8IY22 CMIP S343 0.46 0.64 0.314 0.921 0.32 0.452 0.63 0.549 0.497 1 1 0.034980177 
Q8IVT2 CS021 S541 0.124 -0.184 0.228 1.006 0.881 1.089 0.806 0.869 0.621 1 1.06E-08 0.000589022 
Q5VZ89 DEN4C S1089 0.732 0.06 0.563 1.516 0.788 1.229 1.286 0.594 0.847 1 7.67E-07 0.001523204 
Q5VZ89 DEN4C S732,S737 0.8 0.499 0.375 0.573 0.367 0.374 0.995 0.49 0.556 0.98127857 1 0.043129258 
Q16555 DPYL2 T514 -0.402 -0.067 0.012 -0.594 -0.067 0.068 -1.261 -0.564 -0.63 1 1 0.004206287 
P55265 DSRAD T601 0.432 0.418 0.012 0.814 0.308 0.573 1.222 0.617 1.03 1 1 0.000679512 
O75821 EIF3G T41 -0.553 0.367 -0.378 0.22 0.155 0.721 0.669 0.572 0.675 1 1 0.003221361 
Q8WYP5 ELYS** S1232 0.112 -0.251 0 0.458 0.181 0.273 0.85 0.583 0.621 1 1 0.002221379 
P29317 EPHA2** S897 0.193 -0.324 0.1 1.114 0.424 0.923 1.654 0.869 1.105 1 0.278168457 1.89E-08 
P29317 EPHA2** S897,S901 0.248 -0.201 0.25 0.573 0.155 0.263 1.025 0.733 0.84 1 1 7.93E-06 
Q14315 FLNC** S2233 1.546 1.052 1.518 1.744 1.214 1.287 1.383 0.932 0.853 1.36E-12 7.34E-17 4.03E-08 
Q13480 GAB1 Y659 0.644 1.122 1.271 0.553 0.881 1.169 -0.143 0.681 0.644 0.000255336 0.006032746 1 
Q9Y624 JAM1** S284 -0.402 -0.158 -0.194 -0.884 -0.322 -0.42 -0.74 -0.621 -0.55 1 1 0.006661181 
Q9Y4B5 K0802 S609,S613 1.007 1.052 0.088 1.29 1.22 0.347 1.423 1.378 0.88 1 1 1.12E-08 
P05787 K2C8 S330 0.619 0.694 0.293 0.553 0.356 0.51 0.726 0.638 0.683 1 1 0.000318208 
Q14678 KANK1 S325 0.748 0.281 0.453 0.839 0.642 0.699 0.753 0.572 0.548 1 0.000274375 0.007108064 
Q3ZCW2 LEGL S22 -0.192 0.432 0.424 0.181 0.127 0.558 0.659 0.526 0.86 1 1 0.014343647 
Q8WVC0 LEO1 S205 -0.758 -0.362 -0.067 -1.188 -0.253 -0.146 -1.442 -0.504 -0.596 1 1 0.028307432 
Q9UHB6 LIMA1** S686 0.8 0.758 -0.378 0.983 0.889 0.596 1.44 0.773 0.735 1 0.001419435 7.30E-06 
P46821 MAP1B** S1501 0.216 0.855 -0.013 0.583 0.296 0.469 0.979 0.763 0.77 1 1 2.26E-06 
P27816 MAP4** S941 -0.314 -0.575 -0.378 -0.469 -0.344 -0.379 -0.732 -0.597 -0.929 1 1 0.00137291 
P43243 MATR3 S598 -0.287 -0.839 -0.208 -0.449 -0.585 -0.224 -0.879 -0.85 -0.502 1 1 0.030078974 
Q14676 MDC1 S168 -0.012 0.732 0 0.593 0.413 0.641 1.353 0.85 0.506 1 0.372446678 0.026635355 
P55081 MFAP1 S52,S53 0.422 0.38 0.271 0.642 0.501 0.534 0.924 0.365 0.683 1 0.030962004 1 
P28482 MK01 T185,Y187 1.199 1.131 1.486 1.623 1.463 1.71 1.485 0.932 1.493 1.33E-14 1.60E-24 8.52E-10 
P28482 MK01 Y187 0.585 0.77 0.589 0.998 0.632 0.383 0.61 0.284 0.409 0.0020759 0.803345723 1 
P27361 MK03 Y204 1.187 0.866 0.863 1.441 0.744 0.596 1.273 0.325 0.589 2.52E-08 0.001419435 1 
P27361 MK03 T202,Y204 1.136 1.131 1.37 NA 1.578 1.699 1.317 0.743 1.285 1.33E-14 1 5.24E-06 
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O96007 MOC2B S20 0.227 0.513 0.171 0.603 0.344 0.4 1.389 0.692 0.581 1 1 0.002377678 
Q13615 MTMR3** S647 -0.326 1.122 -0.302 -0.041 1.107 0.4 0.65 1.091 0.565 1 1 0.004068994 
Q8NEY1 NAV1 S1000 0 0.145 0.051 0.155 0.39 0.1 0.495 0.594 0.573 1 1 0.037145548 
Q9HCH0 NCK5L S473 1.032 0.499 1.142 0.127 -0.013 -0.035 -0.054 -0.048 0.012 0.032949808 1 1 
Q96PU5 NED4L S448 0.363 0.38 0.205 0.553 0.708 0.542 1.055 0.859 0.756 1 0.008615577 3.04E-06 
Q96TA1 NIBL1 S678,S679 0.515 0.527 0.051 0.881 0.632 0.409 1.468 0.949 1.048 1 0.413596601 3.57E-10 
Q96TA1 NIBL1 S678,S683 0.159 0.499 0.088 0.613 0.689 0.374 1.347 0.967 0.919 1 1 1.64E-09 
Q9Y3T9 NOC2L S672 0.432 0.257 -0.094 0.195 0.014 0.796 0.841 0.526 0.887 1 1 0.014343647 
Q7Z417 NUFP2 T571 1.281 0.667 0.681 1.071 0.49 0.596 1.195 0.365 0.867 0.000107912 0.043071159 1 
Q7Z417 NUFP2 S629 -0.233 0.64 -0.053 0.141 0.642 0.634 0.762 1.075 0.819 1 1 2.36E-06 
Q8N573 OXR1 S202 0.488 0.486 0.063 1.078 0.49 0.392 1.292 0.783 0.506 1 0.64056989 0.026635355 
O00459 P85B S262 -0.012 0.418 0.228 0.332 0.762 0.452 0.948 1.026 1.024 1 1 3.76E-10 
Q8WX93 PALLD S893 -0.149 -0.21 -0.208 0.39 0.332 0.374 0.908 0.941 1.006 1 1 2.84E-09 
P49023 PAXI S137 0.685 0.458 0.293 0.897 0.511 0.699 0.972 0.454 0.906 1 0.022825495 0.122247117 
Q9H4Z3 PCIF1 S143 -0.233 0.189 0.063 0 0.259 0.392 0.59 0.537 0.581 1 1 0.010125514 
Q6Y7W6 PERQ2** T25,S30 0.808 0.599 0.705 1.402 0.542 1.006 1.564 0.514 0.963 0.001281322 0.008615577 0.020839877 
Q6Y7W6 PERQ2** T25,S26 0.373 0.354 0.395 0.873 0.689 0.51 1.113 0.514 0.69 1 0.02353697 0.020839877 
O75151 PHF2 T654 0.373 1.188 0.228 0.913 0.671 0.959 1.6 1.043 1.071 1 9.25E-05 2.25E-12 
Q8WWQ0 PHIP S1315 0.204 0.155 0.025 0.259 0.057 -0.171 0.956 0.763 0.565 1 1 0.004068994 
Q86SQ0 PHLB2 S468 0.628 0.305 0.491 1.568 1.028 1.435 1.241 0.923 0.919 1 5.20E-12 1.64E-09 
Q15149 PLEC** S4386 0.948 0.68 0.96 1.134 0.96 1.239 0.932 0.743 0.887 6.56E-05 2.02E-10 5.24E-06 
Q15149 PLEC** S4386,S4389 0.851 0.556 1.205 1.284 0.983 1.546 1.228 0.949 1.036 0.005478526 6.00E-11 3.57E-10 
Q9NYI0 PSD3** S770 0.17 0.889 -0.194 0.921 1.32 1.006 1.154 1.145 0.799 1 1.48E-09 4.73E-07 
Q05209 PTN12** T587 -0.079 0.667 -0.04 0.447 0.744 0.627 0.995 1.026 1.077 1 0.148482966 3.16E-11 
Q8IY67 RAVR1 T463 -0.093 0.513 -0.067 0.259 0.726 0.338 0.9 1.205 0.763 1 1 2.26E-06 
Q15042 RB3GP** T536 -0.339 0.071 0.038 0.114 0.127 0.469 0.716 0.743 0.873 1 1 1.58E-05 
Q96T37 RBM15 S128 -0.894 -1.355 -1.221 -1.265 -2.087 0.163 -1.437 -1.248 -0.049 5.66E-09 1 1 
Q6GYQ0 RGPA1** S797 0.124 0.68 0.365 0.246 0.897 0.796 0.762 0.923 0.799 1 1 2.36E-06 
Q13017 RHG05** S1124 0.669 0.234 0.545 1.057 0.468 1.057 0.815 0.549 1.065 1 0.081983242 0.006881155 
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Q13017 RHG05 S1195 1.082 0.783 0.334 1.436 0.613 0.329 2.047 0.502 0.573 1 1 0.030078974 
P31350 RIR2** S20 -0.274 0.783 -0.235 0.208 0.583 1.282 0.972 0.896 1.036 1 1 5.13E-09 
Q9NQC3 RTN4 S107 0.653 0.77 1.216 -0.081 -0.081 -0.238 1.317 -0.217 0.445 0.000182827 1 1 
Q96EQ0 SGTB S297 0.076 0.177 0.194 1.028 0.479 0.769 1.055 0.606 0.69 1 0.059586719 0.001002762 
Q9P0V3 SH3B4 S244 1.064 1.102 0.536 1.233 0.717 0.589 1.161 0.802 0.589 0.010458308 0.001807009 0.001809447 
Q16637 SMN T25 0.27 1.122 0.571 0.511 0.49 0.589 0.9 0.793 0.847 1 0.043071159 6.16E-07 
O60749 SNX2 T104 -0.473 0.432 -0.053 0.661 1.155 0.941 0.798 1.248 0.698 1 0.00013518 3.25E-05 
P31948 STIP1 S481 -0.564 -0.508 -0.39 -0.964 -0.119 -0.293 -1.13 -0.645 -0.726 0.675046158 1 0.000245969 
P16949 STMN1** S25 0.302 0.405 0.159 0.652 0.542 0.627 1.365 1.263 1.088 1 0.008615577 1.71E-13 
Q68CZ2 TENS3** S776 1.082 0.585 0.463 1.864 0.68 0.776 1.908 0.56 0.66 0.094777934 6.55E-05 0.004801146 
Q12888 TP53B** S1114 0.343 0.472 0.148 0.402 0.788 0.822 0.85 0.549 0.69 1 0.495999918 0.006881155 
Q12888 TP53B** S1426,S1430 -0.352 0.556 -0.365 -0.397 0.735 1.062 0.569 1.043 0.698 1 1 0.003561541 
Q12888 TP53B** S366 0.506 0.189 0.148 1.314 0.356 0.769 1.891 0.583 1.224 1 1 0.002221379 
P12270 TPR** T2116 0.83 1.082 0.623 1.296 1.419 1.209 1.4 1.115 1.15 0.000548493 1.01E-16 3.47E-14 
Q9C0C9 UBE2O S839 0.469 0.694 0.182 0.071 0.479 0.581 0.64 0.85 0.749 1 1 0.000295707 
Q96JH7 VCIP1 S768 -0.462 -0.362 -0.289 -0.439 -0.194 -0.279 -0.612 -0.539 -0.561 1 1 0.009498571 
O95785 WIZ S1146 0.353 -0.226 0.282 1.078 0.511 0.953 0.875 0.416 0.69 1 0.022825495 0.34459738 
O60293 ZC3H1 S1046 -0.163 0.405 -0.013 0.779 0.762 0.4 1.148 0.949 0.912 1 0.522218676 2.33E-09 
Q6NZY4 ZCHC8 S658 0.124 0.393 -1.122 0.532 0.699 0.329 0.762 0.941 0.637 1 1 0.000330069 
Q15942 ZYX** T306 0.701 0.732 0.545 0.308 0.32 0.1 0.311 0.403 -0.024 0.007836025 1 1 
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Table 8-2: Clusters of HGF-regulated phosphopeptides 
Significantly regulated peptides clustered according to their phosphorylation dynamics over the time course 3, 6, and 20 min. The table lists the 
peptides illustrated in Figure 4-17 as graphs. Due to the triplicate, every peptide occurs three times.  
Figure 4-17A    RHG05_HUMAN@S1195 
Figure 
4-17F   Figure 4-17F   
ord4132 GAB1_HUMAN@Y659 Figure 4-17E   ord1234 K0802_HUMAN@S609.S613 ord1234 NUFP2_HUMAN@S629 
 NCK5L_HUMAN@S473 ord2413 RBM15_HUMAN@S128  K0802_HUMAN@S609.S613  OXR1_HUMAN@S202 
 ZYX_HUMAN@T306 Figure 4-17F    K0802_HUMAN@S609.S613  OXR1_HUMAN@S202 
Figure 4-17B   ord1234 AFAD_HUMAN@S1721  K2C8_HUMAN@S330  OXR1_HUMAN@S202 
ord3142 NCK5L_HUMAN@S473 
 
AHNK_HUMAN@S135  LEGL_HUMAN@S22  P85B_HUMAN@S262 
 RTN4_HUMAN@S107 
 
AHNK_HUMAN@S135  LIMA1_HUMAN@S686  P85B_HUMAN@S262 
Figure 4-17C   
 
AHNK_HUMAN@S3426  MAP1B_HUMAN@S1501  PAXI_HUMAN@S137 
ord4312 NCK5L_HUMAN@S473 
 
AHNK_HUMAN@S3426  MFAP1_HUMAN@S52.S53  PAXI_HUMAN@S137 
 RTN4_HUMAN@S107 
 
AHNK_HUMAN@S5099  MFAP1_HUMAN@S52.S53  PCIF1_HUMAN@S143 
Figure 4-17D   
 
AHNK_HUMAN@S5099  MOC2B_HUMAN@S20  PCIF1_HUMAN@S143 
ord1432 AFAD_HUMAN@S1799 
 
AKAP2_HUMAN@S720  MOC2B_HUMAN@S20  PERQ2_HUMAN@T25.S26 
 AKTS1_HUMAN@T246 
 
AKP13_HUMAN@S2709  NAV1_HUMAN@S1000  PERQ2_HUMAN@T25.S26 
 CD2AP_HUMAN@S458 
 
ARHG2_HUMAN@S886  NAV1_HUMAN@S1000  PERQ2_HUMAN@T25.S30 
 CD2AP_HUMAN@S458 
 
CJ047_HUMAN@S212.S215  NAV1_HUMAN@S1000  PHF2_HUMAN@T654 
 CD2AP_HUMAN@S458 
 
CJ047_HUMAN@T214.S215  NED4L_HUMAN@S448  PHF2_HUMAN@T654 
 FLNC_HUMAN@S2233 
 
CMIP_HUMAN@S343  NED4L_HUMAN@S448  PSD3_HUMAN@S770 
 GAB1_HUMAN@Y659 
 
DSRAD_HUMAN@T601  NED4L_HUMAN@S448  PTN12_HUMAN@T587 
 GAB1_HUMAN@Y659 
 
DSRAD_HUMAN@T601  NIBL1_HUMAN@S678.S679  RAVR1_HUMAN@T463 
 MK01_HUMAN@Y187 
 
ELYS_HUMAN@S1232  NIBL1_HUMAN@S678.S679  RB3GP_HUMAN@T536 
 MK03_HUMAN@Y204 
 
ELYS_HUMAN@S1232  NIBL1_HUMAN@S678.S679  RB3GP_HUMAN@T536 
 MK03_HUMAN@Y204 
 
EPHA2_HUMAN@S897  NIBL1_HUMAN@S678.S683  RGPA1_HUMAN@S797 
 MTMR3_HUMAN@S647 
 
EPHA2_HUMAN@S897  NIBL1_HUMAN@S678.S683  RGPA1_HUMAN@S797 
 NUFP2_HUMAN@T571 
 
EPHA2_HUMAN@S897.S901  NIBL1_HUMAN@S678.S683  RGPA1_HUMAN@S797 
 PERQ2_HUMAN@T25.S30 
 
EPHA2_HUMAN@S897.S901     
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Table 8-3: Clusters HGF-regulated phosphopeptides, continued 
The table lists the peptides illustrated in Figure 4-18 as graphs. 
Figure 4-18A   Figure 4-18A   Figure 4-18B   Figure 4-18D   
 ord1243 AHNK_HUMAN@S3426  ord1243 PLEC_HUMAN@S4386.S4389 ord1423 PAXI_HUMAN@S137 ord1342 ARHGI_HUMAN@S1124 
 
CJ047_HUMAN@S212.S215 
 
PLEC_HUMAN@S4386.S4389 
 
PLEC_HUMAN@S4386 
 
CMIP_HUMAN@S343 
 
CJ047_HUMAN@T214.S215 
 
PSD3_HUMAN@S770 
 
PLEC_HUMAN@S4386 
 
DEN4C_HUMAN@S732.S737 
 
CMIP_HUMAN@S343 
 
RHG05_HUMAN@S1124 
 
PLEC_HUMAN@S4386.S4389 
 
K2C8_HUMAN@S330 
 
CS021_HUMAN@S541 
 
SGTB_HUMAN@S297 
 
TENS3_HUMAN@S776 
 
MAP1B_HUMAN@S1501 
 
CS021_HUMAN@S541 
 
SH3B4_HUMAN@S244 Figure 4-18C   Figure 4-18E   
 
DEN4C_HUMAN@S1089 
 
TENS3_HUMAN@S776 ord2143 AKAP2_HUMAN@S720 ord1324 AFAD_HUMAN@S1721 
 
DEN4C_HUMAN@S1089 
 
TP53B_HUMAN@S1114 
 
CJ047_HUMAN@T214.S215 
 
AKAP2_HUMAN@S720 
 
DEN4C_HUMAN@S1089 
 
TP53B_HUMAN@S1114 
 
CS021_HUMAN@S541 
 
DEN4C_HUMAN@S732.S737 
 
KANK1_HUMAN@S325 
 
TPR_HUMAN@T2116 
 
EIF3G_HUMAN@T41 
 
DEN4C_HUMAN@S732.S737 
 
KANK1_HUMAN@S325 
 
TPR_HUMAN@T2116 
 
PSD3_HUMAN@S770 
 
DSRAD_HUMAN@T601 
 
KANK1_HUMAN@S325 
 
WIZ_HUMAN@S1146 
 
RIR2_HUMAN@S20 
 
EIF3G_HUMAN@T41 
 
LIMA1_HUMAN@S686 
 
WIZ_HUMAN@S1146 
 
SNX2_HUMAN@T104 
 
K2C8_HUMAN@S330 
 
MDC1_HUMAN@S168 Figure 4-18B   
 
TP53B_HUMAN@S1426.S1430 
 
LEGL_HUMAN@S22 
 
MK01_HUMAN@T185.Y187 ord1423 AFAD_HUMAN@S1799 
 
WIZ_HUMAN@S1146 
 
MDC1_HUMAN@S168 
 
MK01_HUMAN@T185.Y187 
 
AFAD_HUMAN@S1799 Figure 4-18D   
 
MOC2B_HUMAN@S20 
 
MK01_HUMAN@Y187 
 
AKTS1_HUMAN@T246 ord1342 SH3B4_HUMAN@S244 
 
NOC2L_HUMAN@S672 
 
MK03_HUMAN@Y204 
 
AKTS1_HUMAN@T246 
 
NUFP2_HUMAN@T571 
 
NOC2L_HUMAN@S672 
 
PERQ2_HUMAN@T25.S26 
 
FLNC_HUMAN@S2233 
 
MK01_HUMAN@Y187 
 
NUFP2_HUMAN@T571 
 
PERQ2_HUMAN@T25.S30 
 
FLNC_HUMAN@S2233 
 
ZYX_HUMAN@T306 
 
PHIP_HUMAN@S1315 
 
PHLB2_HUMAN@S468 
 
MFAP1_HUMAN@S52.S53 
 
ZYX_HUMAN@T306 
 
RHG05_HUMAN@S1195 
 
PHLB2_HUMAN@S468 
 
MK01_HUMAN@T185.Y187 
 
PHF2_HUMAN@T654 
 
RIR2_HUMAN@S20 
 
PHLB2_HUMAN@S468 
 
MK03_HUMAN@T202.Y204 
 
SMN_HUMAN@T25 
 
UBE2O_HUMAN@S839 
 
PLEC_HUMAN@S4386 
 
MK03_HUMAN@T202.Y204 
 
ARHG2_HUMAN@S886 
 
UBE2O_HUMAN@S839 
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Figure 4-18F   
 
ord3124 PHIP_HUMAN@S1315 
 
 
RTN4_HUMAN@S107 
 
Figure 4-18G   
 
 ord4231 APC_HUMAN@S2449 
 
 
CBX3_HUMAN@S95 
 
 
CBX3_HUMAN@S95 
 
 
DPYL2_HUMAN@T514 
 
 
LEO1_HUMAN@S205 
 
 
MAP4_HUMAN@S941 
 
 
MATR3_HUMAN@S598 
 
 
STIP1_HUMAN@S481 
 
 
STIP1_HUMAN@S481 
 
 
VCIP1_HUMAN@S768 
 
 
VCIP1_HUMAN@S768 
 
 
VCIP1_HUMAN@S768 
 
Figure 4-18H   
 
ord3421 BCL9L_HUMAN@S21 
 
 
BCL9L_HUMAN@S21 
 
 
JAM1_HUMAN@S284 
 
Figure 4-18I   
 
ord3241 BCL9L_HUMAN@S21 
 
 
RBM15_HUMAN@S128 
 
Figure 4-18J   
 
ord3214 TP53B_HUMAN@S1426.S1430 
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Table 8-4: List of all 28 InlB-regulated phosphorylation sites 
Significantly regulated phosphorylation sites after 5 min of InlB stimulation in HeLa S3 cells. Log2 regulation factors of the triplicate E1, E2, and E3 
are illustrated. Significant RFs possess a pval (p-value) of below 0.05 (marked as bold letters). 
Uniprot ID Protein P-Site E1_5min E2_5min E3_5min pval_5min 
Q09666 AHNK S135 0.477 1.131 0.977 0.002146028 
Q09666 AHNK S210 0.697 0.644 1.241 2.61E-06 
Q09666 AHNK S511 0.477 0.383 0.707 0.046309956 
Q09666 AHNK T4100 0.879 0.986 0.738 2.89E-08 
Q9H6F5 CCD86 S91 -1.131 -1.906 -0.988 1.35E-14 
P55265 DSRAD T601 1.399 0.795 0.886 1.45E-09 
P00533 EGFR T693 1.642 2.065 2.443 4.28E-39 
P04792 HSPB1 S82 1.049 0.986 0.932 4.93E-13 
Q8WUF5 IASPP S134 -0.666 -0.976 -0.939 9.53E-07 
P78344 IF4G2 T508 -0.782 -0.687 -0.397 0.030247431 
O95239 KIF4A S801 1.526 1.784 1.602 6.71E-34 
P42702 LIFR S1044 0.62 0.586 0.867 3.23E-05 
Q8WWI1 LMO7 S925 -0.703 -1.15 -0.678 5.44E-07 
Q5VZK9 LR16A S1094 0.526 0.721 0.619 0.000354332 
P28482 MK01 T185,Y187 1.216 1.86 0.895 4.77E-12 
P28482 MK01 Y187 0.997 0.903 0.642 2.85E-06 
P27361 MK03 T202,Y204 0.962 1.917 0.941 2.80E-13 
Q9Y6X9 MORC2 S743 -0.674 -1.202 -1.671 6.56E-07 
P18615 NELFE S115 1.091 1.349 0.664 1.05E-06 
Q92882 OSTF1 S213 -1.024 -1.051 -1.059 1.21E-15 
Q16513 PKN2 S583 0.907 0.586 0.829 3.23E-05 
O76021 RL1D1 T358 -0.643 -0.73 -0.617 8.62E-06 
O75396 SC22B S137 0.719 0.805 0.895 7.49E-08 
Q9H788 SH24A S315 0.85 0.977 1.602 6.75E-11 
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P12270 TPR S2155 0.608 0.774 1.226 1.27E-05 
P12270 TPR T2137 0.926 0.855 1.99 5.06E-11 
O14545 TRAD1 S415 -0.802 -1.604 -1.243 9.94E-10 
Q9C0B5 ZDHC5 S406 1.231 1.139 1.496 3.17E-19 
 
 
Table 8-5: Proof-of-concept transcription factors 
The list illustrates 11 of 31 known transcription factors of the HGF/Met response that regulated genes in the DU145 transcriptome in response to 
HGF stimulation. Data were taken from the EPHA2 expression array and compared to known factors involved in HGF/Met-induced gene 
expression in the GeneGo database.  
Uniprot ID  
CEBPA 
CEBPB 
JUN 
MYC 
E2F1 
EGR1 
EGR3 
ETS1 
ETV4 
SOX9 
STAT3 
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Table 8-6: Phosphorylation sites regulated similar in response to HGF and InlB 
All significantly regulated phosphorylation sites identified by phosphoproteomics were compared. 5 sites were significantly regulated in both 
datasets and further 19 sites were significantly regulated in response to HGF and affected by InlB stimulation, although not significantly. 
Uniprot ID Protein P-Site Significantly regulated? 
Q09666 AHNK S135 yes 
P55265 DSRAD T601 yes 
P28482 MK01 T185,Y187 yes 
P28482 MK01 Y187 yes 
P27361 MK03 T202,Y204 yes 
Q09666 AHNK S3426 only in HGF significant 
Q9Y2D5 AKAP2 S720 only in HGF significant 
Q12802 AKP13 S2709 only in HGF significant 
Q96B36 AKTS1 T246 only in HGF significant 
Q6ZSZ5 ARHGI S1124 only in HGF significant 
Q5VZ89 DEN4C S1089 only in HGF significant 
Q8WYP5 ELYS S1232 only in HGF significant 
Q14678 KANK1 S325 only in HGF significant 
P27361 MK03 Y204 only in HGF significant 
O00459 P85B S262 only in HGF significant 
Q8WX93 PALLD S893 only in HGF significant 
P49023 PAXI S137 only in HGF significant 
Q9H4Z3 PCIF1 S143 only in HGF significant 
Q6Y7W6 PERQ2 T25,S26 only in HGF significant 
Q05209 PTN12 T587 only in HGF significant 
Q8IY67 RAVR1 T463 only in HGF significant 
O60749 SNX2 T104 only in HGF significant 
O95785 WIZ S1146 only in HGF significant 
Q15942 ZYX T306 only in HGF significant 
8.2 List of abbreviations 
µM Micromolar 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
cm Centimeter 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial-mesenchmal transition 
EPHA2 Ephrin type-A-receptor 2 
Fe Iron 
Ga Gallium 
GAP GTPase activating protein 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GDT Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GO Gene ontology 
GTP Guanosine diphosphate 
h Hour 
HCl Acetic acid 
HGF Hepatocyte growth factor 
HZI Helmholtz-Center for Infection Research 
IMAC Immobilized metal affinity chromatography 
InlB Internalin B 
iTRAQ Isobaric tags for relative and absolute quantitation 
kDa Kilodalton 
LC-MS/MS Liquid chromatography tandem mass 
spectrometry 
m/z Mass-charge ratio 
MALDI Matrix-assisted laser desorption/ionization 
MAPK Mitogen-activated protein kinase 
mg Milligram 
min Minute 
MK01 Mitogen-activated protein kinase 1 (alias ERK2) 
MK01 Mitogen-activated protein kinase 3 (alias ERK1) 
ml Milliliter 
mM Millimolar 
mRNA Messenger ribonucleic acid 
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MS Mass spectrometry 
MTT Dimethyl thiazolyl diphenyl tetrazolium 
nm Nanometer 
nM Nanomolar 
NS (siRNA) Nonsense (siRNA) 
PBS Phosphate buffered saline 
ppm Parts per million 
pS Phosphoserine 
P-Site Phosphorylation site 
pT Phosphothreonine 
pY Phosphotyrosine 
RF Regulation factor 
RNAi RNA interference 
rpm Rounds per minute 
RT Room temperature 
RTK Receptor tyrosine kinase 
SCX Strong cation exchange chromatography 
SDS Sodium dodecylsulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
sec Second 
si(-RNA) Small interfering RNA 
SILAC stable isotope labeling with amino acids in cell 
culture 
TEMED Tetramethylethylenediamine 
V Volt 
v/v Volume per volume 
w/v Weight per volume 
WT Wildtype 
xg n-fold of standard gravity 
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